
<html lang="en"     class="pb-page"  data-request-id="404cf671-b08b-476b-af4a-ad04fed87e5a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/jm4012388;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2013.56.issue-21;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties" /></meta><meta name="dc.Creator" content="Shilin  Xu" /></meta><meta name="dc.Creator" content="Tianfeng  Xu" /></meta><meta name="dc.Creator" content="Lianwen  Zhang" /></meta><meta name="dc.Creator" content="Zhang  Zhang" /></meta><meta name="dc.Creator" content="Jinfeng  Luo" /></meta><meta name="dc.Creator" content="Yingxue  Liu" /></meta><meta name="dc.Creator" content="Xiaoyun  Lu" /></meta><meta name="dc.Creator" content="Zhengchao  Tu" /></meta><meta name="dc.Creator" content="Xiaomei  Ren" /></meta><meta name="dc.Creator" content="Ke  Ding" /></meta><meta name="dc.Description" content="Structural optimization of a series of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl compounds, potential new irreversible EGFR inhibitors, was performed to improve pharmacokinetic properties of the ..." /></meta><meta name="Description" content="Structural optimization of a series of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl compounds, potential new irreversible EGFR inhibitors, was performed to improve pharmacokinetic properties of the ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 31, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm4012388" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm4012388" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm4012388" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm4012388" /></link>
        
    
    

<title>Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm4012388" /></meta><meta property="og:title" content="Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0007.jpeg" /></meta><meta property="og:description" content="Structural optimization of a series of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl compounds, potential new irreversible EGFR inhibitors, was performed to improve pharmacokinetic properties of the compounds. This led to compound 2v with improved aqueous solubility and good pharmacokinetic properties which at the nanomolar level potently inhibits gefitinib-resistant EGFRL858R/T790M kinase and displays strong antiproliferative activity against H1975 nonsmall cell lung cancer cells. The new inhibitor also shows promising antitumor efficacy in a murine EGFRL858R/T790M-driven H1975 xenograft model without effect on body weight. These studies provide new lead compounds for further development of drugs for treatment of gefitinib-resistant nonsmall cell lung cancer patients." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm4012388"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm4012388">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm4012388&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm4012388&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm4012388&amp;href=/doi/10.1021/jm4012388" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 8803-8813</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm4012356" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm401248x" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shilin++Xu">Shilin Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tianfeng++Xu">Tianfeng Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lianwen++Zhang">Lianwen Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhang++Zhang">Zhang Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jinfeng++Luo">Jinfeng Luo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yingxue++Liu">Yingxue Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoyun++Lu">Xiaoyun Lu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhengchao++Tu">Zhengchao Tu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaomei++Ren">Xiaomei Ren</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ke++Ding">Ke Ding</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Institute of Chemical Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">§</span> <span class="aff-text">University of Chinese Academy of Sciences, #19 Yuquan Road, Beijing 100049, China</span></div><div class="corresp-info"><strong>*</strong>Tel: +86-20-32015276. Fax: +86-20-32015299. E-mail: <a href="/cdn-cgi/l/email-protection#dbbfb2b5bc84b0be9bbcb2b9b3f5bab8f5b8b5"><span class="__cf_email__" data-cfemail="3b5f52555c64505e7b5c525953155a58155855">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm4012388&amp;href=/doi/10.1021%2Fjm4012388" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 8803–8813</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 14, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 August 2013</li><li><span class="item_label"><b>Published</b> online</span>31 October 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 November 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm4012388" title="DOI URL">https://doi.org/10.1021/jm4012388</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8803%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DShilin%2BXu%252C%2BTianfeng%2BXu%252C%2BLianwen%2BZhang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D21%26contentID%3Djm4012388%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2B2-Oxo-3%252C4-dihydropyrimido%255B4%252C5-d%255Dpyrimidinyl%2BDerivatives%2Bas%2BNew%2BIrreversible%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BInhibitors%2Bwith%2BImproved%2BPharmacokinetic%2BProperties%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8813%26publicationDate%3DNovember%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm4012388"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2446</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">20</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm4012388" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Shilin&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Tianfeng&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Lianwen&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Zhang&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Jinfeng&quot;,&quot;last_name&quot;:&quot;Luo&quot;},{&quot;first_name&quot;:&quot;Yingxue&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Xiaoyun&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Zhengchao&quot;,&quot;last_name&quot;:&quot;Tu&quot;},{&quot;first_name&quot;:&quot;Xiaomei&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Ke&quot;,&quot;last_name&quot;:&quot;Ding&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;31&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;8803-8813&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm4012388&quot;},&quot;abstract&quot;:&quot;Structural optimization of a series of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl compounds, potential new irreversible EGFR inhibitors, was performed to improve pharmacokinetic properties of the compounds. This led to compound 2v with improved aqueous solubility and good pharmacokinetic properties which at the nanomolar level potently inhibits gefitinib-resistant EGFRL858R/T790M kinase and displays strong antiproliferative activity against H1975 nonsmall cell lung cancer cells. The new inhibitor also shows promising antitumor efficacy in a murine EGFRL858R/T790M-driven H1975 xenograft model without effect on body weight. These studies provide new lead compounds for further development of drugs for treatment of gefitinib-resistant nonsmall cell lung cancer patients.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4012388&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4012388" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4012388&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4012388" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4012388&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4012388" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm4012388&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4012388&amp;href=/doi/10.1021/jm4012388" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm4012388" /></input><a href="/doi/pdf/10.1021/jm4012388" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm4012388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm4012388%26sid%3Dliteratum%253Aachs%26pmid%3D24124898%26genre%3Darticle%26aulast%3DXu%26date%3D2013%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2B2-Oxo-3%252C4-dihydropyrimido%255B4%252C5-d%255Dpyrimidinyl%2BDerivatives%2Bas%2BNew%2BIrreversible%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BInhibitors%2Bwith%2BImproved%2BPharmacokinetic%2BProperties%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D21%26spage%3D8803%26epage%3D8813%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291411" title="Pharmacokinetics">Pharmacokinetics</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jmcmar.2013.56.issue-21/production/jmcmar.2013.56.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/medium/jm-2013-012388_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012388&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Structural optimization of a series of 2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidinyl compounds, potential new irreversible EGFR inhibitors, was performed to improve pharmacokinetic properties of the compounds. This led to compound <b>2v</b> with improved aqueous solubility and good pharmacokinetic properties which at the nanomolar level potently inhibits gefitinib-resistant EGFR<sup>L858R/T790M</sup> kinase and displays strong antiproliferative activity against H1975 nonsmall cell lung cancer cells. The new inhibitor also shows promising antitumor efficacy in a murine EGFR<sup>L858R/T790M</sup>-driven H1975 xenograft model without effect on body weight. These studies provide new lead compounds for further development of drugs for treatment of gefitinib-resistant nonsmall cell lung cancer patients.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54062" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54062" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Epidermal growth factor receptor kinase (EGFR, ErbB1) is a well-validated target used in anticancer drug discovery.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Several EGFR inhibitors, such as gefitinib<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and erlotinib,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> have achieved significant clinical benefits in the management of nonsmall cell lung cancer (NSCLC) in patients with activating mutations in the EGFR kinase domain, including L858R and delE746-A750).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> However, a secondary threonine<sup>790</sup> → methionine<sup>790</sup> mutation (T790M) in the EGFR catalytic domain is responsible for about 50% of the clinical acquired drug resistance in NSCLC patients.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">Second-generation irreversible EGFR inhibitors have been developed to overcome the EGFR<sup>T790M</sup> mutation-related resistance. CI-1033,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> HKI-272,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and PF-00299804,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> for example, have been advanced into late-stage clinical development.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Most recently, gilotrif (BIBW-2992) was approved by the US FDA for treatment of late-stage NSCLC patients with actively mutated EGFR.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> However, almost all of the molecules lack selectivity between EGFR<sup>T790M</sup> mutants and the wild-type kinase, and this leads to relatively low maximum tolerated dose (MTD) and dosing-limiting toxicity in NSCLC patients.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Only limited clinical efficacy was observed for these inhibitors, and this may be due to the fact that the in vivo concentrations achieved are insufficient to suppress the functions of EGFR<sup>T790M</sup> mutant.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a></div><div class="NLM_p">With respect to the “on-target” toxicity of the current irreversible EGFR inhibitors, a strategy that has become attractive is to develop selective EGFR<sup>T790M</sup> mutant inhibitors capable of overcoming the clinically acquired resistance in NSCLC patients. Recently, WZ4002 was identified to inhibit selectively the proliferation of Ba/F3 cells stably expressing EGFR<sup>T790M</sup> mutation, while displaying relatively low potency with respect to the wild-type kinase.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Another selective inhibitor of the EGFR<sup>T790M</sup> mutant, CO-1686,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> has just advanced into phase I clinical trials (NCT01526928).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p">We have previously reported a number of novel selective EGFR<sup>T790M</sup> mutant inhibitors with different chemical scaffolds.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> 2-Oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidine (<b>1</b>) has been demonstrated to selectively inhibit the proliferation of H1975 NSCLC cells bearing EGFR<sup>T790M</sup> with an IC<sub>50</sub> value of 14 nM, although it was significantly less potent on cancer cells or normal cells with EGFR<sup>WT</sup>.<a onclick="showRef(event, 'cit16a'); return false;" href="javascript:void(0);" class="ref cit16a">(16a)</a> This compound, orally administered, also showed promising antitumor efficacy in a H1975 xenograft mouse model. However, its relatively low aqueous solubility (4.0 μg/mL at pH 6.8) and unsatisfactory pharmacokinetic properties may limit its further development (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">In this paper, we describe further optimization of compound <b>1</b> with the aim of improving its aqueous solubility and oral absorption properties. This has led to the identification of <b>2v</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) which has significantly improved pharmacokinetic properties. It also displays promising antitumor efficacy in the H1975 xenograft mouse model and represents a new attractive lead for further development of compounds that can overcome EGFR<sup>T790M</sup> mutation-induced resistance in NSCLC patients.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/medium/jm-2013-012388_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design of new EGFR<sup>T790M</sup> inhibitors with improved pharmacokinetics.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012388&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11768" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11768" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of compound <b>2</b> is shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Commercially available ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate (<b>3</b>) was reacted with the protected aliphatic amine <b>4</b> to produce the adduct <b>5</b> in high yields. The reduction of <b>5</b> with lithium aluminum hydride gave alcohol <b>6</b>, which was subsequently oxidized with MnO<sub>2</sub> to obtain the aldehyde <b>7</b>. Reductive amination of aldehyde <b>7</b> with diverse amines yielded the corresponding compound <b>8</b>. The key intermediate <b>10</b> was prepared by direct cyclization using triphosgene and subsequent oxidation with <i>m</i>-CPBA. Nucleophilic coupling of intermediates <b>10</b> with different substituted amines followed by treatment with trifluoroacetic acid afforded the key intermediates <b>12</b>, which react with acryloyl chloride to produce the final products, <b>2</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/medium/jm-2013-012388_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0004.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012388&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagent and conditions: (a) K<sub>2</sub>CO<sub>3</sub> (2 equiv), DMF, 60 °C, 85–97%; (b) LiAlH<sub>4</sub> (2 equiv), THF, −40 °C to 0 °C, 40–58%; (c) MnO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 84–93%; (d) R<sub>1</sub>NH<sub>2</sub>, AcOH, NaBH<sub>4</sub>, MeOH, 0 °C to rt, 72–90%; (e) triphosgene (0.34 equiv), Et<sub>3</sub>N (3.0 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 88–96%; (f) 3-chloroperbenzoic acid (3.0 equiv), CH<sub>2</sub>Cl<sub>2</sub>, rt, 80–92%; (g) RNH<sub>2</sub>, (1.2 equiv), trifluoroacetic acid (1.2 equiv), 2-BuOH, 110 °C; (h) trifluoroacetic acid (10 equiv), CH<sub>2</sub>Cl<sub>2</sub>, rt, 38–60% (for two steps); (i) acryloyl chloride (1.2 equiv), DIPEA (2 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 75–90%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01461" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01461" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compound <b>1</b> was identified as a selective EGFR<sup>T790M</sup> inhibitor, which in a FRET-base Z′-Lyte assay potently inhibits EGFR<sup>L858R/T790M</sup> kinase activity with an IC<sub>50</sub> of 0.7 nM. It also displays strong antiproliferative effects (IC<sub>50</sub><i>=</i> 14 nM) on H1975 NSCLC cells harboring EGFR<sup>L858R/T790M</sup>.<a onclick="showRef(event, 'cit16a'); return false;" href="javascript:void(0);" class="ref cit16a">(16a)</a> However, it has relatively low aqueous solubility (4.0 μg/mL at pH 6.8) and generally unsatisfactory pharmacokinetic properties in Sprague–Dawley (SD) rats. Structure feature analysis revealed that compound <b>1</b> is highly planar, and this may greatly contribute to its low aqueous solubility. Disruption of molecular planarity is expected to reduce the crystal-stacking capability of a solid solute in water and becomes an effective strategy to improve the water solubility of a compound.<a onclick="showRef(event, 'cit17a ref18'); return false;" href="javascript:void(0);" class="ref cit17a ref18">(17a, 18)</a></div><div class="NLM_p">Our previous investigations have demonstrated that the “U-shaped” configuration of rings A–D (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), together with the aniline ring (C) bearing a hydrophilic group and the acrylamide moiety, is necessary to maintain the EGFR inhibitory activity.<a onclick="showRef(event, 'cit16a'); return false;" href="javascript:void(0);" class="ref cit16a">(16a)</a> The phenyl ring D functions as a linker suitable for the acrylamide to chelate with Cys797 in EGFR proteins and provides an ideal position at which to reduce the molecular planarity, potentially improving the aqueous solubility (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'cit17a ref18'); return false;" href="javascript:void(0);" class="ref cit17a ref18">(17a, 18)</a> Consequently, we first replaced the phenyl ring D in compound <b>1</b> with a less planar cyclohexyl ring. The resulting compound <b>2a</b> indeed displays an improved aqueous solubility of 18.8 μg/mL (pH 6.8), 4 times that of compound <b>1</b>. However, the introduction of a cyclohexyl group causes a loss of about 1000-fold of potency in both EGFR<sup>L858R/T790M</sup> suppression and H1975 cell growth inhibition assays. For suppression of the enzymatic function of EGFR<sup>L858R/T790M</sup> and inhibition of the proliferation of H1975 NSCLC cells, the corresponding IC<sub>50</sub> values of compound <b>2a</b> are 709 nM and 2.7 μM, respectively (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Other less planar linkers such as 4-piperidinyl (<b>2b</b>), (<i>R</i>)-3-piperidinyl (<b>2c</b>), (<i>S</i>)-3-piperidinyl (<b>2d</b>), (<i>R</i>)-3-pyrrolidinyl (<b>2e</b>), (<i>S</i>)-3-pyrrolidinyl (<b>2f</b>), and 2-aminoethyl moieties (<b>2g</b>) also significantly improve the aqueous solubility of the resulting compounds (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), but these groups have a different impact on the EGFR<sup>L858R/T790M</sup> kinase inhibitory activities. For instance, compound <b>2b</b> has an aqueous solubility of 9.3 μg/mL at pH 6.8, slightly lower than that of <b>2a</b>, but its EGFR<sup>L858R/T790M</sup> inhibitory activity is 5 times greater than that of <b>2a.</b></div><div class="NLM_p">Further investigation revealed that the chirality of the linker could affect the EGFR<sup>L858R/T790M</sup> inhibitory activity of the compounds. Compound <b>2c</b>, with a (<i>R</i>)-3-piperidinyl linker has an IC<sub>50</sub> value of 40.3 nM with EGFR<sup>L858R/T790M</sup>, while the (<i>S</i>)-3-piperidinyl-linked compound <b>2d</b> is 5 times less potent. On the other hand, compound <b>2f</b> containing a (<i>S</i>)-3-pyrrolidinyl moiety was about 12 times as potent as the <i>R-</i>enantiomer <b>2e</b>, which strongly inhibits EGFR<sup>L858R/T790M</sup> with an IC<sub>50</sub> value of 8.8 nM. Compound <b>2f</b> also potently suppresses the proliferation of H1975 NSCLC cells, which possess the EGFR<sup>L858R/T790M</sup>-resistant mutant, with an IC<sub>50</sub> value of 0.28 μM. The aqueous solubility of compound <b>2f</b> is 107.1 μg/mL (pH 6.8), 26 times greater than that of the original compound <b>1.</b> Interestingly, the replacement of pyrrolidinyl ring with an ethenyl chain (<b>2g</b>) almost totally abolishes the kinase inhibitory activity.</div><div class="NLM_p">In view of its promising enzymatic and cellular potencies and aqueous solubility, we further investigated the pharmacokinetic properties of <b>2f</b> in SD rats (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). The compound displays encouraging oral bioavailability (<i>F</i> = 24%) and could serve as a new starting point for further structural optimization. We first studied the impact of the 3-substituent on the biological activity of the compound and showed that when the 3-benzyl group in compound <b>2f</b> was replaced with methyl (<b>2h</b>), isopropyl (<b>2i</b>), cyclopentyl (<b>2j</b>), or cyclohexanyl (<b>2k</b>), the EGFR<sup>L858R/T790M</sup> inhibitory activities decrease between 5- and 100-fold, displaying IC<sub>50</sub> values of 525, 864, 58.7, or 42.9 nM, respectively. When a phenyl group was introduced at the 3-position, however, the resulting compound <b>2l</b> showed inhibitory effect against EGFR<sup>L858R/T790M</sup> enzyme and the proliferation of H1975 NSCLC cells comparable to that of <b>2f</b>, with IC<sub>50</sub> values of 15.2 and 111.0 nM, respectively. Encouragingly, further studies revealed that compound <b>2l</b> displays a 14-fold improvement of aqueous solubility (1535.1 μg/mL at pH 6.8) compared to that of <b>2f</b>. The compound also has greater oral bioavailability than that of <b>2f</b> (<i>F</i> = 44%), higher maximal plasma concentration (<i>C</i><sub>max</sub> = 613 μg/L), and lower clearance rate (Cl = 12 L/h/kg) in SD rats at an oral dose of 25 mg/kg.</div><div class="NLM_p">Structural optimization of phenyl ring C, the (<i>N</i>-methylpiperazinyl)aniline, was also performed to potentially improve the metabolic stability. It was clear that the 2′-methoxy-4-(<i>N</i>-methylpiperazinyl)aniline group possesses high electron density and could be oxidized to a reactive quinone diimine to give rise to idiosyncratic toxicity and impair the oral absorption.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Decreasing the electron density has been proved to be an efficient approach to increase the metabolic stability of aromatics and improve the pharmacokinetic properties of a molecule,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and we first removed the electron-donating 2′-methoxyl and 4-methylpiperazin-1-yl moieties in compound <b>2l</b>. The resulting compound <b>2m</b>, at an oral dose of 25 mg/kg, indeed displayed a higher maximum concentration (<i>C</i><sub>max</sub> = 1673 μg/L) and a lower oral clearance (Cl = 5.7 L/h/kg) in SD rats than that of <b>2l</b>. The investigation also showed that compound <b>2n</b>, formed by removal of the 2′-methoxyl group, appeared to inhibit EGFR kinase somewhat comparably, and deletion of both 2′-methoxyl and 4-methylpiperazin-1-yl moieties, giving <b>2m</b>, caused a 15-fold potency loss, emphasizing the relevance of the hydrophilic group to EGFR kinase inhibition. The compound (<b>2n</b>) lacking a methoxyl group, however, shows no obvious improvement in its pharmacokinetic properties in SD rats. Other modifications, such as switching the 4′-(4-methylpiperazin-1-yl) group in <b>2n</b> to the 3′-position (<b>2o</b>), or replacing the 4′-(4-methylpiperazin-1-yl) group in <b>2n</b> with a 4-(<i>N</i>-methylpiperidinyl) (<b>2p</b>) or a 4-(4-methylpiperazin-1-yl)ethyl moiety (<b>2q</b>), failed to improve the compounds’ pharmacokinetic properties in SD rats or benefit the kinase inhibitory activities.</div><div class="NLM_p">Further investigation revealed that the 3′-methoxylated compound (<b>2r</b>) and the 2′-methoxylated compound (<b>2l</b>) have similar EGFR<sup>L858R/T790M</sup> inhibitory potencies and pharmacokinetic properties. However, in contrast to our previous observation that 2′-fluorine substituents in ring C are detrimental to the kinase inhibitory activity,<a onclick="showRef(event, 'cit16a'); return false;" href="javascript:void(0);" class="ref cit16a">(16a)</a> the 3′-fluorine-substituted compound <b>2s</b> shows similar potency to that of <b>2l</b>. In SD rats, compound <b>2s</b> displays an improved maximum concentration (<i>C</i><sub>max</sub> = 964 μg/L) and lower oral clearance (Cl = 7.3 L/h/kg) than that of <b>2l</b>, which might be due to the strong electron-withdrawing properties of fluorine, decreasing the electron density in the phenyl ring C.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> However, when the 3′-F is replaced with 3′-CF<sub>3</sub> (<b>2t</b>) or 3′-Cl (<b>2u</b>), the resulting compounds are 2–3-fold less potent. When a methyl group is introduced to the 3′-position of phenyl ring C, the resulting compound <b>2v</b> not only displays good biological activities (IC<sub>50</sub> of EGFR<sup>L858R/T790M</sup> = 9.2 nM, and IC<sub>50</sub> of H1975 = 47 nM) but also promising pharmacokinetic properties. The compound displays a reasonable maximum concentration (<i>C</i><sub>max</sub> = 1040 μg/L), acceptable oral clearance rate (Cl = 10 L/h/kg), and oral bioavailability (30%) in SD rats at an oral dose of 25 mg/kg. This might be attributed to the significant improvement of its aqueous solubility (1265 μg/mL at pH 6.8).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro EGFR Inhibition and Antiproliferation Data for Compounds <b>2a</b>–<b>v</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/medium/jm-2013-012388_0005.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/medium/jm-2013-012388_0006.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">EGFR kinase activity assays were performed using the FRET-based Z′-Lyte assay according to the manufacturer’s instructions.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The compounds were incubated with the kinase reaction mixture for 1.5 h before measurement. Reported data are means from two independent experiments.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">The antiproliferative activities of the compounds were evaluated using the MTS assay. The data are means from at least four independent experiments. H1975 is a gefitinib-resistant human lung cancer cell line (EGFR<sup>L858R/T790M</sup>).</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Measured at pH 6.8.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Data from ref <a onclick="showRef(event, 'cit16a'); return false;" href="javascript:void(0);" class="ref cit16a">16a</a>.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Sprague-Dawley Rat PK Parameters for Compounds <b>1</b>,<b> 2f</b>,<b> 2l</b>–<b>s</b>, and <b>2v</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (μg/L)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>(0-∞)</sub> (μg·h/L)</th><th class="colsep0 rowsep0" align="center" char=".">Cl (L/h/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b><a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">4369</td><td class="colsep0 rowsep0" align="char" char=".">1568</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="char" char=".">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2f</b></td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">784</td><td class="colsep0 rowsep0" align="char" char=".">359</td><td class="colsep0 rowsep0" align="char" char=".">14.4</td><td class="colsep0 rowsep0" align="char" char=".">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">102</td><td class="colsep0 rowsep0" align="char" char=".">418</td><td class="colsep0 rowsep0" align="char" char=".">62.6</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2l</b></td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">1789</td><td class="colsep0 rowsep0" align="char" char=".">962</td><td class="colsep0 rowsep0" align="char" char=".">5.2</td><td class="colsep0 rowsep0" align="char" char=".">44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">613</td><td class="colsep0 rowsep0" align="char" char=".">2125</td><td class="colsep0 rowsep0" align="char" char=".">12.0</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2m</b></td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">6544</td><td class="colsep0 rowsep0" align="char" char=".">2034</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">1673</td><td class="colsep0 rowsep0" align="char" char=".">4520</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2n</b></td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">1525</td><td class="colsep0 rowsep0" align="char" char=".">857</td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="char" char=".">54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">783</td><td class="colsep0 rowsep0" align="char" char=".">2312</td><td class="colsep0 rowsep0" align="char" char=".">12.2</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2o</b></td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">1823</td><td class="colsep0 rowsep0" align="char" char=".">746</td><td class="colsep0 rowsep0" align="char" char=".">6.8</td><td class="colsep0 rowsep0" align="char" char=".">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">291</td><td class="colsep0 rowsep0" align="char" char=".">760</td><td class="colsep0 rowsep0" align="char" char=".">33.9</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2p</b></td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">–<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">359</td><td class="colsep0 rowsep0" align="char" char=".">1305</td><td class="colsep0 rowsep0" align="char" char=".">20.1</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2q</b></td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">1413</td><td class="colsep0 rowsep0" align="char" char=".">561</td><td class="colsep0 rowsep0" align="char" char=".">9.2</td><td class="colsep0 rowsep0" align="char" char=".">40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">232</td><td class="colsep0 rowsep0" align="char" char=".">1126</td><td class="colsep0 rowsep0" align="char" char=".">22.9</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2r</b></td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">3408</td><td class="colsep0 rowsep0" align="char" char=".">949</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="char" char=".">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">420</td><td class="colsep0 rowsep0" align="char" char=".">948</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2s</b></td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">3263</td><td class="colsep0 rowsep0" align="char" char=".">2118</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">964</td><td class="colsep0 rowsep0" align="char" char=".">3480</td><td class="colsep0 rowsep0" align="char" char=".">7.3</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2v</b></td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="char" char=".">3975</td><td class="colsep0 rowsep0" align="char" char=".">1640</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char=".">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="char" char=".">1040</td><td class="colsep0 rowsep0" align="char" char=".">2491</td><td class="colsep0 rowsep0" align="char" char=".">10.0</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Compounds were formulated in 2% DMSO, 4% EtOH, 4% castor oil, and 90% H<sub>2</sub>O. The pharmacokinetic parameters were determined after a single oral administration (25 mg/kg, <i>n</i> = 4 rats) and intravenous injection (5 mg/kg, <i>n</i> = 4 rats).</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Compound <b>1</b> was treated as a mesylate salt and was not detected when administrated by oral dosing.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Compound <b>2p</b> was not administrated by intravenous injection due to insolubility in the vehicle.</p></div></div></div><div class="NLM_p">The kinase inhibition of <b>2v</b> was further validated by investigating its suppressive functions on the phosphorylation of EGFR and the downstream signaling proteins in NSCLC H1975 cells harboring EGFR<sup>L858R/T790M</sup>. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>, the treatment of compound <b>2v</b> causes a dose-dependent reduction of the phosphorylation of EGFR in H1975 cells. The protein levels of downstream signals, such as p-AKT and p-ERK, are also clearly inhibited by <b>2v</b> at concentrations of 110 nM and 33 nM, respectively, while the total protein levels of EGFR, AKT, ERK, and GAPDH remain unchanged. Not surprisingly, the phosphorylation of EGFR and the downstream targets are barely affected by gefitinib at the relatively high concentration of 330 nM. Further investigation revealed that compound <b>2v</b> also potently inhibited the kinase activities of EGFR <sup>T790M</sup>, EGFR <sup>L858R</sup>, and EGFR <sup>L851Q</sup> mutants with IC<sub>50</sub> values of 10.0, 3.0, and 3.0 nM, respectively. But its activity against EGFR<sup>WT</sup> is obviously less potent in a Western blot analysis in A431 human epithelial carcinoma cells with overexpressed EGFR<sup>WT</sup> (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div><div class="NLM_p">The selectivity profile of <b>2v</b> against a panel of 456 kinases (including 395 different wild-type kinases) was also investigated by using KINOMEscan platform (Ambit Bioscience, San Diego, CA) at a concentration of 100 nM which was about 70 times of its <i>K</i><sub>d</sub> value on EGFR<sup>L858R/T790M</sup> (<i>K</i><sub>d</sub> = 1.4 nM, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). The results clearly revealed that, in addition to EGFR and the other ERBB family members (ERBB2, ERBB3, and ERBB4), compound <b>2v</b> also exhibited strong binding with Abl1, Blk, Btk, DDR1, Flt3, Kit, Jak3, MEK5, PDGFRβ, RET, Src, and several other kinases, indicating that this compound might be used as a lead compound for treatment of many other types of cancer. However, the potential safety issue of <b>2v</b> related to its relative kinase selectivity requires further investigation.</div><div class="NLM_p">To validate the irreversible inhibition of compound <b>2v</b> against EGFR, an inhibitor washout assay was also performed in HCC827 NSCLC cells with activating EGFR mutation (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). The results clearly showed that the EGFR autophosphorylation in HCC827 cells was obviously recovered soon after the reversible inhibitor was washed out. However, the EGFR phosphorylation recovery could never be observed after <b>2v</b> was removed for 24 h, which strongly suggested that the compound was an irreversible inhibitor of EGFR.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/medium/jm-2013-012388_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. <b>2v</b> dose-dependently decreases the phosphorylation of EGFR, AKT, and ERK. H1975 cells were treated with vehicle (DMSO) or 3 to 330 nM <b>2v</b> for 2 h. The cells were lysed, and the proteins were determined by a Western blot assay. The results are representative of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012388&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The antiproliferative effects of <b>2v</b> against a panel of NSCLC cells with different EGFR status were also investigated (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Compound <b>2v</b> potently inhibits the growth of H1975 NSCLC cells harboring the EGFR<sup>L858R/T790M</sup> mutation and HCC827 cells with EGFR<sup>del E746-A750</sup>, at IC<sub>50</sub> values of 0.047 and 0.005 μM, respectively. However, it is approximately 85–4000-fold less potent to other NSCLC cancer cells with EGFR<sup>WT</sup>. For example, its IC<sub>50</sub> values are 16.0, 4.0, 5.1 and over 20.0 μM against H460, 95D, H1299, and H358 NSCLC cancer cells, respectively. In addition, <b>2v</b> also displayed IC<sub>50</sub> values over 200 times greater on normal human liver than that of H1975, suggesting that its cytotoxic effects are minimal.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Antiproliferative Activities of <b>2v</b> against a Panel of Cells with Wild-Type EGFR</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center">antiproliferation (IC<sub>50</sub>, μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">H460<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">95D<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">H1299<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">H358<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">HL-7702<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">HCC827<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2v</b></td><td class="colsep0 rowsep0" align="left">16.0 ± 8.9</td><td class="colsep0 rowsep0" align="left">4.0 ± 2.4</td><td class="colsep0 rowsep0" align="left">5.1 ± 3.4</td><td class="colsep0 rowsep0" align="left">>20.0</td><td class="colsep0 rowsep0" align="left">>10.0</td><td class="colsep0 rowsep0" align="left">0.005 ± 0.002</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">The antiproliferative activities of compound <b>2v</b> were evaluated using the MTS assay. The data are means from at least three independent experiments.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">H460, 95D, H358, and H1299 are human NSCLC cells harboring wild-type EGFR.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">HL-7702 is a diploid human liver cell line.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">HCC827 is a human NSCLC cell line with EGFR<sup>del E746-A750</sup>.</p></div></div></div><div class="NLM_p">Given its strong inhibition of EGFR<sup>L858R/T790M</sup> kinase and on NSCLC cell growth, together with its promising pharmacokinetic properties, the in vivo antitumor efficacy of <b>2v</b> was evaluated using an EGFR<sup>L858R/T790M</sup>-driven human H1975 xenograft mouse model. Repeated oral administration of <b>2v</b> (qd) for 14 days displays dose-dependent inhibition of tumor growth. The tumor growth inhibition (TGI) values are 35.4% and 56.8% at dosages of 10 and 30 mg/kg/day, respectively (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A). In addition, all doses of <b>2v</b> are well-tolerated, with no mortality or significant loss of body weight (<5% relative to the vehicle-matched controls) observed during treatment (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/medium/jm-2013-012388_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. In vivo effect of compound <b>2v</b> on tumor volume and body weight in xenograft model of H1975. (A) Antitumor efficacy of compound <b>2v</b> in a human NSCLC (H1975) xenograft nude mouse model. (B) Body weight of mice during treatment with <b>2v</b> for 2 weeks. Mice were orally dosed once daily (qd) for 14 days at 10 mg/kg or 30 mg/kg, and were monitored for signs of morbidity. Tumors and body weight were measured every other day (*<i>p</i> < 0.05, **<i>p</i> < 0.01).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012388&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Summary</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08460" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08460" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have described structural optimization aimed at improving the aqueous solubility and pharmacokinetic properties of a series of irreversible EGFR inhibitors based on a 2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidinyl analogue. One of the most promising compounds, <b>2v</b>, displays an aqueous solubility of 1265 μg/mL, some 300-fold greater than that of the original lead compound <b>1</b> (4.0 μg/mL). Compound <b>2v</b> potently inhibits the enzymatic function of EGFR<sup>L858R/T790M</sup> with an IC<sub>50</sub> value of 9.2 nM and suppresses proliferation of gefitinib-resistant H1975 human NSCLC cells with an IC<sub>50</sub> value of 47 nM. The compound also exhibits good pharmacokinetic properties with oral bioavailability of 30%. Furthermore, it displayed promising antitumor efficacy in vivo in an EGFR<sup>L858R/T790M</sup>-driven human H1975 xenograft mouse model without obvious toxic signs during the treatment. Our studies provide a new lead compound with improved pharmacokinetic properties and acceptable in vivo antitumor activity for further development of the drug for treatment of gefitinib-resistant NSCLC. Further investigation on the compound is in progress and will be reported in due course.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12135" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12135" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> General Methods for Chemistry</h3><div class="NLM_p last">All reagents and solvents were used as purchased from commercial sources. Flash chromatography was performed using 300 mesh silica gel. All reactions were monitored by TLC, using silica gel plates with fluorescence F<sub>254</sub> and UV light visualization. <sup>1</sup>H NMR spectra was recorded on a Bruker AV-400 spectrometer at 400 MHz or a Bruker AV-500 spectrometer at 500 MHz. <sup>13</sup>C NMR spectra was recorded on a Bruker AV-500 spectrometer at 125 MHz. Coupling constants (<i>J</i>) are expressed in hertz (Hz). Chemical shifts (δ) of NMR are reported in parts per million (ppm) units relative to an internal standard (TMS). Low resolution ESI-MS were recorded on an Agilent 1200 HPLC-MSD mass spectrometer and high resolution ESI-MS on an Applied Biosystems Q-STAR Elite ESI-LC-MS/MS mass spectrometer. Purity of compounds was determined by reverse-phase high performance liquid chromatography (HPLC) analysis to be >95%. HPLC instrument: Dionex Summit HPLC (Column: Diamonsil C18, 5.0 μm, 4.6 × 250 mm (Dikma Technologies); detector: PDA-100 photodiode array; injector: ASI-100 autoinjector; pump: p-680A). A flow rate of 1.0 mL/min was used with mobile phase of MeOH in H<sub>2</sub>O with 0.1% modifier (ammonia, v/v).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Ethyl 4-(4-(<i>tert</i>-Butoxycarbonylamino)cyclohexylamino)-2-(methylthio)pyrimidine-5-carboxylate (<b>5a</b>)</h3><div class="NLM_p last">General procedure for syntheses of <b>5a</b>–<b>v</b>. Compound <b>4a</b> (6.63 g, 30.94 mmol) and potassium carbonate (7.1 g, 51.56 mmol) were added to a solution of <b>3</b> (6 g, 25.78 mmol) in DMF (50 mL). The resulting solution was stirred at 60 °C overnight. After cooling to room temperature, ice–water (500 mL) was added to the reaction mixture. The precipitate was filtered, and the filter cake was rinsed with additional cool water and then dried in a vacuum oven to give <b>5a</b> (9.21 g, yield 87%), which was used without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.62 (s, 1H), 8.22 (d, <i>J</i> = 6.0 Hz, 1H), 4.40 (s, 1H), 4.31 (q, <i>J</i> = 7.2 Hz, 2H), 4.08–3.99 (m, 1H), 3.47 (s, 1H), 2.52 (s, 3H), 2.14–2.07 (m, 4H), 1.45 (s, 9H), 1.41–1.40 (m, 2H), 1.36 (t, <i>J</i> = 7.2 Hz, 3H), 1.31–1.22 (m, 2H). MS (ESI) <i>m</i>/<i>z</i> 411.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> <i>tert</i>-Butyl 4-(5-(Hydroxymethyl)-2-(methylthio)pyrimidin-4-ylamino)cyclohexylcarbamate (<b>6a</b>)</h3><div class="NLM_p last">General procedure for syntheses of <b>6a</b>–<b>v</b>. A suspension of LiAlH<sub>4</sub> (1.7 g, 44.82 mmol) in anhydrous THF (50 mL) was added dropwise to a solution of <b>5a</b> (9.2 g, 22.41 mmol) in anhydrous THF (200 mL) under stirring for 0.5 h at −40 °C. The reaction mixture was stirred until the temperature was warmed to 0 °C, and then it was treated with 2 mL of H<sub>2</sub>O to decompose unreacted LiAlH<sub>4</sub>. Then, a further 6 mL of H<sub>2</sub>O was added to the reaction mixture followed by 15% aqueous NaOH (2 mL). The resulting mixture was stirred for 10 min at room temperature and filtered through a pad of Celite. The Celite was washed with THF, and the washes were combined and then concentrated in vacuo. The concentrated mixture was poured into H<sub>2</sub>O and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was separated, washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The resultant crude material was purified by column chromatography (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/MeOH stepwise elution, 40:1 to 20:1) to give <b>6a</b> (4.25 g, yield 51%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.63 (s, 1H), 5.86 (d, <i>J</i> = 7.2 Hz, 1H), 4.46 (s, 2H), 4.45 (s, 1H), 4.00–3.93 (m, 1H), 3.41 (s, 1H), 2.83 (s, 1H), 2.47 (s, 3H), 2.13–2.03 (m, 4H), 1.43 (s, 9H), 1.35–1.26 (m, 4H). MS (ESI) <i>m</i>/<i>z</i> 369.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> <i>tert</i>-Butyl 4-(5-Formyl-2-(methylthio)pyrimidin-4-ylamino)cyclohexylcarbamate (<b>7a</b>)</h3><div class="NLM_p last">General procedure for syntheses of <b>7a</b>–<b>v</b>. MnO<sub>2</sub> (3g, 34.59 mmol) was added to a solution of <b>6a</b> (4.25 g, 11.53 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL). The resulting solution was stirred at room temperature overnight, and then the reaction mixture was filtered through a pad of Celite. Filtration and removal of the solvent gave an oily crude product that was subjected to flash column chromatography (SiO<sub>2</sub>, petroleum ether/EtOAc stepwise elution, 3:1 to 1:1) to give <b>7a</b> (3.8 g, yield 90%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.68 (s, 1H), 8.54 (s, 1H), 8.31 (s, 1H), 4.40 (s, 1H), 4.11–4.04 (m, 1H), 3.48 (s, 1H), 2.54 (s, 3H), 2.14–2.09 (m, 4H), 1.45 (s, 9H), 1.41–1.22 (m, 4H). MS (ESI) <i>m</i>/<i>z</i> 367.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> <i>tert</i>-Butyl 4-(5-((Benzylamino)methyl)-2-(methylthio)pyrimidin-4-ylamino)cyclohexylcarbamate (<b>8a</b>)</h3><div class="NLM_p last">General procedure for syntheses of <b>8a</b>–<b>v</b>. Benzylamine (1 g, 9.25 mmol) and AcOH (0.1 mL) were added at room temperature to a solution of <b>7a</b> (2.26 g, 6.17 mmol) in MeOH (50 mL). After the amine was converted completely to the imine, NaBH<sub>4</sub> (469 mg, 12.34 mmol) was added to the reaction mixture at 0 °C. The resulting mixture was concentrated in vacuo, partitioned between CH<sub>2</sub>Cl<sub>2</sub> and saturated NaHCO<sub>3</sub>, and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was separated, washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The resulting crude material was subjected to flash column chromatography (SiO<sub>2</sub>, petroleum ether/EtOAc, 3:1) to give <b>8a</b> (2.46 g, yield 87%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.71 (s, 1H), 7.36–7.33 (m, 2H), 7.30–7.28 (m, 2H), 7.25 (s, 1H), 4.42 (s, 1H), 3.94–3.92 (m, 1H), 3.70 (s, 2H), 3.65 (s, 2H), 3.47 (s, 1H), 2.48 (s, 3H), 2.12–2.06 (m, 4H), 1.77 (br, 2H), 1.45 (s, 9H), 1.31–1.24 (m, 4H). MS (ESI) <i>m</i>/<i>z</i> 458.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> <i>tert</i>-Butyl 4-(3-Benzyl-7-(methylthio)-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)cyclohexylcarbamate (<b>9a</b>)</h3><div class="NLM_p last">General procedure for syntheses of <b>9a</b>–<b>v</b>. <i>N</i>,<i>N</i>-Diisopropylethylamine (2.8 mL, 16.14 mmol) and triphosgene (0.58 g, 2 mmol) were added to a solution of <b>8a</b> (2.46 g, 5.38 mmol) in CH<sub>2</sub>Cl<sub>2</sub> at 0 °C. The mixture was poured into a solution of 10% aqueous NaHCO<sub>3</sub> and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was separated, washed with 10% aqueous NaHCO<sub>3</sub> and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give <b>9a</b> (2.50 g, yield 96%), which was used without further purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.94 (s, 1H), 7.36–7.33 (m, 2H), 7.32–7.28 (m, 3H), 4.73–4.68 (m, 1H), 4.63 (s, 2H), 4.40 (s, 1H), 4.12 (s, 2H), 3.52 (s, 1H), 2.55 (s, 3H), 2.14 (d, <i>J</i> = 8.8 Hz, 2H), 1.76 (d, <i>J</i> = 8.8 Hz, 2H), 1.45 (s, 9H), 1.31–1.22 (m, 4H). MS (ESI) <i>m</i>/<i>z</i> 484.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> <i>tert</i>-Butyl 4-(3-Benzyl-7-(methylsulfonyl)-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)cyclohexylcarbamate (<b>10a</b>)</h3><div class="NLM_p last">General procedure for syntheses of <b>10a</b>–<b>v</b>. <i>m</i>-CPBA (75%) (2.4 g, 10.34 mmol) was added to a solution of <b>9a</b> (2.5 g, 5.17 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (50 mL) at 0 °C under argon. The reaction mixture was allowed to warm to room temperature and then stirred for 4 h. The solution was diluted with CH<sub>2</sub>Cl<sub>2</sub> and then treated with 50% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>/NaHCO<sub>3</sub> solution. The organic layer was separated, washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The resulting crude material was subjected to flash column chromatography (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/MeOH stepwise elution, 40:1 to 20:1) to give <b>10a</b> (2.4 g, yield 90%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.26 (s, 1H), 7.39–7.33 (m, 3H), 7.32–7.29 (m, 2H), 4.77–4.71 (m, 1H), 4.66 (s, 2H), 4.40 (s, 1H), 4.27 (s, 2H), 3.53 (s, 1H), 3.31 (s, 3H), 2.71–2.64 (m, 2H), 2.16 (d, <i>J</i> = 8.4 Hz, 2H), 1.78 (d, <i>J</i> = 9.2 Hz, 2H), 1.60 (s, 9H), 1.34–1.27 (m, 2H).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> 1-(4-Aminocyclohexyl)-3-benzyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>12a</b>)</h3><div class="NLM_p last">General procedure for syntheses of <b>12a</b>–<b>v</b>. 2-Methoxy-4-(4-methylpiperazin-1-yl)aniline (464 mg, 2.10 mmol) was added to a solution of <b>10a</b> (0.9 g, 1.75 mmol), in 2-butyl alcohol (5 mL), followed by trifluoroacetic acid (157 μL, 2.10 mmol). The reaction mixture was stirred for 18 h at 110 °C in a sealed tube. The reaction mixture was cooled to room temperature and concentrated in vacuo to give crude product <b>11a</b> which was used in the next step without characterization. Then trifluoroacetic acid (0.5 mL) was added to a solution of <b>11a</b> in CH<sub>2</sub>Cl<sub>2</sub> (5 mL), and the resulting mixture was stirred at room temperature for 4 h. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub>, basified with saturated aqueous NaHCO<sub>3</sub> to pH = 9, and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was separated, washed with 10% aqueous NaHCO<sub>3</sub> and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The resultant crude material was purified by column chromatography (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH, 40:1:0.4) to give <b>12a</b> (485 mg, yield 50% for two steps). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.07–8.06 (m, 1H), 7.82 (s, 1H), 7.34–7.32 (m, 2H), 7.29–7.26 (m, 4H), 6.55–6.54 (m, 2H), 4.73–4.66 (m, 1H), 4.61 (s, 2H), 4.06 (s, 2H), 3.86 (s, 3H), 3.18 (t, <i>J</i> = 4.0 Hz, 4H), 2.81–2.76 (m, 1H), 2.64–2.57 (m, 6H), 2.35 (s, 3H), 1.98 (d, <i>J</i> = 9.2 Hz, 2H), 1.75 (d, <i>J</i> = 8.8 Hz, 2H), 1.32–1.23 (m, 2H). MS (ESI) <i>m</i>/<i>z</i> 557.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> <i>N</i>-(4-(3-Benzyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)cyclohexyl)acrylamide (<b>2a</b>)</h3><div class="NLM_p last">General procedure for syntheses of <b>2a</b>–<b>v</b>. <i>N</i>,<i>N</i>-Diisopropylethylamine (300 μL, 1.742 mmol) and acryloyl chloride (85 μL, 1.045 mmol) were added to a solution of <b>12a</b> (485 mg, 0.871 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (10 mL) with stirring at 0 °C. The reaction was allowed to warm to room temperature, and then, after stirring for 4 h, the reaction mixture was poured into a solution of 10% aqueous NaHCO<sub>3</sub> and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was separated, washed with 10% aqueous NaHCO<sub>3</sub> and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The resultant crude material was purified by column chromatography (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH, 40:1:0.4) to give <b>2a</b> (425 mg, yield 80%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.07 (d, <i>J</i> = 8.5 Hz, 1H), 7.84 (s, 1H), 7.36–7.29 (m, 5H), 7.24 (s, 1H), 6.70 (d, <i>J</i> = 8.5 Hz, 1H), 6.29 (d, <i>J</i> = 17.0 Hz, 1H), 6.08 (dd, <i>J</i> = 10.0, 17.0 Hz, 1H), 5.64 (d, <i>J</i> = 10.0 Hz, 1H), 5.42 (d, <i>J</i> = 7.5 Hz, 1H), 4.71 (t, <i>J</i> = 12.0 Hz, 1H), 4.63 (s, 2H), 4.08 (s, 2H), 4.04–3.97 (m, 1H), 3.89 (s, 3H), 3.21 (s, 4H), 2.78 (q, <i>J</i> = 12.0 Hz, 2H), 2.61 (s, 4H), 2.37 (s, 3H), 2.16 (d, <i>J</i> = 12.0 Hz, 2H), 1.78 (s, 2H), 1.34 (q, <i>J</i> = 12.0 Hz, 2H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 164.6, 159.4, 157.7, 154.2, 153.1, 149.7, 147.6, 136.4, 131.2, 128.7, 128.1, 127.7, 126.1, 121.8, 120.9, 108.3, 102.5, 100.4, 55.6, 55.2, 54.2, 51.5, 49.9, 48.0, 46.0, 43.8, 33.0, 27.6. HRMS (ESI) for C<sub>34</sub>H<sub>42</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 611.3453, found: 611.3440. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 7.68 min, 99.58% purity.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 1-(1-Acryloylpiperidin-4-yl)-3-benzyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2b</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.08 (d, <i>J</i> = 8.8 Hz, 1H), 7.87 (s, 1H), 7.37–7.33 (m, 3H), 7.31–7.28 (m, 3H), 6.63 (dd, <i>J</i> = 10.8, 16.8 Hz, 1H), 6.54 (d, <i>J</i> = 2.4 Hz, 1H), 6.49 (dd, <i>J</i> = 2.4, 8.8 Hz, 1H), 6.29 (dd, <i>J</i> = 2.0, 16.8 Hz, 1H), 5.69 (dd, <i>J</i> = 2.0, 10.4 Hz, 1H), 5.01–4.95 (m, 1H), 4.89–4.87 (m, 1H), 4.62 (s, 2H), 4.16–4.12 (m, 1H), 4.10 (s, 2H), 3.88 (s, 3H), 3.17 (t, <i>J</i> = 4.8 Hz, 4H), 3.13–3.10 (m, 1H), 2.86–2.71 (m, 3H), 2.59 (t, <i>J</i> = 4.8 Hz, 4H), 2.35 (s, 3H), 1.85–1.79 (m, 2H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 165.5, 159.1, 157.4, 153.9, 153.4, 149.2, 147.4, 136.3, 128.8, 128.1, 127.8, 127.4, 121.8, 119.8, 107.9, 102.2, 100.3, 55.6, 55.2, 53.0, 51.4, 49.9, 46.2, 46.1, 43.8, 42.5, 29.3, 28.5. HRMS (ESI) for C<sub>33</sub>H<sub>40</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 597.3296, found: 597.3297. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 7.96 min, 97.18% purity.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> (<i>R</i>)-1-(1-Acryloylpiperidin-3-yl)-3-benzyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2c</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> +123.337 (<i>c</i> 0.154, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 7.99 (d, <i>J</i> = 8.4 Hz, 1H), 7.89 (s, 0.6H), 7.86 (s, 0.4H), 7.37–7.25 (m, 6H), 6.67–6.60 (m, 1H), 6.53–6.46 (m, 2H), 6.30 (t, <i>J</i> = 16.0 Hz, 1H), 5.72–5.61 (m, 1H), 4.82–4.76 (m, 1H), 4.72–4.64 (m, 2H), 4.62–4.55 (m, 1H), 4.15–4.13 (m, 0.4H), 4.11 (s, 2H), 4.00–3.97 (m, 1H), 3.87 (s, 3H), 3.82–3.77 (m, 0.6H), 3.18–3.14 (m, 4H), 3.09–2.63 (m, 2H), 2.60–2.58 (m, 4H), 2.35 (s, 3H), 1.98–1.86 (m, 2H), 1.63–1.55 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 165.6, 165.1, 159.4, 157.3, 153.8, 153.5, 149.8, 149.6, 147.7, 147.6, 136.2, 136.1, 128.8, 128.0, 127.8, 127.7, 127.3, 121.9, 121.5, 121.1, 120.6, 108.0, 102.1, 102.0, 100.6, 100.3, 55.6, 55.1, 52.5, 51.3, 50.1, 49.9, 48.2, 46.1, 44.4, 43.8, 43.7, 42.3, 27.5, 27.3, 26.5, 25.4. HRMS (ESI) for C<sub>33</sub>H<sub>40</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 597.3296, found: 597.3292. HPLC analysis: MeOH–H<sub>2</sub>O (78:22), 12.63 min, 97.39% purity.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> (<i>S</i>)-1-(1-Acryloylpiperidin-3-yl)-3-benzyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2d</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> −124.090 (<i>c</i> 0.137, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.00 (d, <i>J</i> = 8.8 Hz, 1H), 7.89 (s, 0.6H), 7.86 (s, 0.4H), 7.37–7.29 (m, 6H), 6.67–6.60 (m, 1H), 6.53–6.47 (m, 2H), 6.30 (t, <i>J</i> = 16.4 Hz, 1H), 5.72–5.61 (m, 1H), 4.83–4.77 (m, 1H), 4.72–4.55 (m, 3H), 4.18–4.15 (m, 0.5H), 4.11 (s, 2H) 4.00–3.97 (m, 1H), 3.87 (s, 3H), 3.83–3.77 (m, 0.5H), 3.18–3.16 (m, 4H), 3.10–2.67(m, 2H), 2.62–2.60 (m, 4H), 2.37 (s, 3H), 1.98–1.86 (m, 2H), 1.63–1.60 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 165.6, 165.1, 159.3, 157.3, 153.7, 153.5, 149.8, 149.6, 147.7, 147.6, 136.2, 136.1, 128.8, 128.0, 127.8, 127.7, 127.3, 121.9, 121.5, 121.1, 120.7, 108.0, 102.2, 102.0, 100.6, 100.3, 55.6, 55.1, 52.5, 51.3, 50.1, 49.9, 48.2, 46.1, 44.4, 43.7, 42.3, 27.5, 27.3, 26.5, 25.4. HRMS (ESI) for C<sub>33</sub>H<sub>40</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 597.3296, found: 597.3291. HPLC analysis: MeOH–H<sub>2</sub>O (78:22), 12.63 min, 98.5% purity.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (<i>R</i>)-1-(1-Acryloylpyrrolidin-3-yl)-3-benzyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2e</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> +1.075 (<i>c</i> 0.186, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 7.95 (d, <i>J</i> = 8.4 Hz, 1H), 7.90 (s, 0.6H), 7.89 (s, 0.4H), 7.38–7.23 (m, 6H), 6.58–6.38 (m, 4H), 5.72–5.55 (m, 2H), 4.72–4.56 (m, 2H), 4.31–4.27 (m, 0.6H), 4.13 (s, 1.2H), 4.12 (s, 0.8H), 4.10–3.89 (m, 1.7H), 3.87 (s, 1.8H), 3.86 (s, 1.2H), 3.85–3.80 (m, 0.7H), 3.67–3.51 (m, 1H), 3.20–3.15 (m, 4H), 2.99–2.85 (m, 1H), 2.62–2.59 (m, 4H), 2.37 (s, 3H), 2.28–2.08 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 164.6, 164.3, 159.2, 157.1, 157.0, 153.7, 153.6, 153.5, 149.7, 149.5, 147.7, 136.1, 136.0, 128.8, 128.3, 128.1, 127.9, 127.8, 127.4, 127.3, 121.6, 121.3, 120.7, 120.3, 107.9, 107.8, 102.2, 100.4, 100.1, 55.6, 55.1, 52.4, 51.6, 51.4, 50.8, 50.0, 49.7, 46.9, 46.7, 46.1, 45.7, 44.4, 43.8, 28.2, 25.8. HRMS (ESI) for C<sub>32</sub>H<sub>38</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 583.3140, found: 583.3138. HPLC analysis: MeOH–H<sub>2</sub>O (78:22), 11.28 min, 98.5% purity.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> (<i>S</i>)-1-(1-Acryloylpyrrolidin-3-yl)-3-benzyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2f</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> −1.105 (<i>c</i> 0.181, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 7.95 (d, <i>J</i> = 8.8 Hz, 1H), 7.90 (s, 0.6H), 7.89 (s, 0.4H), 7.38–7.23 (m, 6H), 6.58–6.44 (m, 3H), 6.40–6.38 (m, 1H), 5.72–5.55 (m, 2H), 4.72–4.56 (m, 2H), 4.31–4.26 (m, 0.6H), 4.13 (s, 1.2H), 4.12 (s, 0.8H), 4.10–3.89 (m, 1.7H), 3.87 (s, 1.8H), 3.86 (s, 1.2H), 3.85–3.80 (m, 0.7H), 3.67–3.51 (m, 1H), 3.20–3.15 (m, 4H), 2.99–2.85 (m, 1H), 2.62–2.58 (m, 4H), 2.37 (s, 3H), 2.28–2.08 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 164.6, 164.3, 159.2, 159.1, 157.1, 157.0, 153.7, 153.6, 153.5, 149.7, 149.5, 147.7, 136.1, 136.0, 128.8, 128.3, 128.1, 128.0, 127.8, 127.3, 121.5, 121.3, 120.7, 120.3, 107.8, 107.7, 102.2, 100.4, 100.1, 55.6, 55.1, 52.4, 51.5, 51.4, 50.7, 49.9, 49.7, 46.9, 46.7, 46.1, 45.7, 44.4, 43.7, 28.2, 25.8. HRMS (ESI) for C<sub>32</sub>H<sub>38</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 583.3140, found: 583.3135. HPLC analysis: MeOH–H<sub>2</sub>O (78:22), 11.31 min, 97.8% purity.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>N</i>-(2-(3-Benzyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)ethyl)acrylamide (<b>2g</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) 8.09 (d, <i>J</i> = 8.5 Hz, 1H), 7.90 (s, 1H), 7.38–7.28 (m, 7H), 7.02 (s, 1H), 6.59–6.56 (m, 2H), 6.21–6.17 (m, 2H), 5.98 (dd, <i>J</i> = 10.5, 17.0 Hz, 1H), 5.56 (d, <i>J</i> = 10.5 Hz, 1H), 4.68 (s, 2H), 4.37–4.35 (m, 2H), 4.24 (s, 2H), 3.90 (s, 3H), 3.72–3.71 (m, 2H), 3.27 (s, 4H), 2.75 (s, 4H), 2.47 (s, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 165.8, 159.1, 156.3, 154.5, 153.6, 149.3, 147.4, 135.8, 131.1, 128.8, 128.0, 127.8, 125.5, 121.7, 120.2, 108.1, 100.9, 100.4, 55.6, 55.0, 51.6, 49.9, 46.0, 44.0, 40.3. HRMS (ESI) for C<sub>30</sub>H<sub>36</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 557.2983, found: 557.2987. HPLC analysis: MeOH–H<sub>2</sub>O (82:18), 7.59 min, 97.01% purity.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (<i>S</i>)-1-(1-Acryloylpyrrolidin-3-yl)-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2h</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> −4.000 (<i>c</i> 0.100, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 7.96 (s, 0.6H), 7.95 (s, 0.4H), 7.93 (d, <i>J</i> = 8.8 Hz, 1H), 7.31 (s, 0.6H), 7.22 (s, 0.4H), 6.55–6.42 (m, 3H), 6.38–6.35 (m, 1H), 5.71–5.51 (m, 2H), 4.28–4.21 (m, 0.6H), 4.24 (s, 2H), 4.04–3.91 (m, 1.7H), 3.86 (s, 2H), 3.85 (s, 1H), 3.78–3.74 (m, 0.7H), 3.64–3.48 (m, 1H), 3.18–3.14 (m, 4H), 3.03 (s, 1.8H), 3.02 (s, 1.2H), 2.93–2.79 (m, 1H), 2.60–2.58 (m, 4H), 2.35 (s, 3H), 2.22–2.02 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 164.6, 164.3, 159.2, 157.2, 157.1, 153.7, 153.6, 153.4, 149.8, 149.5, 147.6, 128.8, 128.3, 127.3, 121.6, 121.4, 120.7, 120.3, 107.9, 107.8, 102.1, 100.4, 100.2, 55.6, 55.1, 50.5, 49.9, 49.7, 46.8, 46.6, 46.4, 46.1, 46.0, 45.7, 44.4, 35.7, 35.6, 28.2, 25.8. HRMS (ESI) for C<sub>26</sub>H<sub>34</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 507.2827, found: 507.2822. HPLC analysis: MeOH–H<sub>2</sub>O (78:22), 6.66 min, 97.09% purity.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (<i>S</i>)-1-(1-Acryloylpyrrolidin-3-yl)-3-isopropyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2i</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> +9.589 (<i>c</i> 0.146, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.00 (s, 0.6H), 7.99 (s, 0.4H), 7.98–7.94 (m, 1H), 7.32 (s, 0.7H), 7.23 (s, 0.3H), 6.57–6.36 (m, 4H), 5.71–5.61 (m, 1H), 5.55–5.43 (m, 1H), 4.75–4.67 (m, 1H), 4.28–4.23 (m, 0.6H), 4.10 (s, 1.2H), 4.09 (s, 0.8H), 4.05–3.89 (m, 1.7H), 3.87 (s, 1.8H), 3.86 (s, 1.2H), 3.83–3.78 (m, 0.7H), 3.65–3.49 (m, 1H), 3.21–3.16 (m, 4H), 2.97–2.83 (m, 1H), 2.65–2.61 (m, 4H), 2.39 (s, 1.8H), 2.38 (s, 1.2H), 2.26–2.05 (m, 1H), 1.22–1.18 (m, 6H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 164.6, 159.2, 157.4, 157.3, 153.4, 153.3, 153.2, 149.7, 149.4, 147.6, 128.8, 128.3, 127.3, 121.7, 121.5, 120.6, 120.3, 107.9, 107.8, 102.8, 102.7, 100.4, 100.2, 55.6, 55.1, 52.5, 50.9, 49.9, 49.7, 47.0, 46.7, 46.1, 46.0, 45.9, 45.7, 44.4, 37.3, 28.2, 25.7, 19.2. HRMS (ESI) for C<sub>28</sub>H<sub>38</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 535.3140, found: 535.3138. HPLC analysis: MeOH–H<sub>2</sub>O (78:22), 8.34 min, 98.42% purity.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (<i>S</i>)-1-(1-Acryloylpyrrolidin-3-yl)-3-cyclopentyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2j</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> +6.667 (<i>c</i> 0.120, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.00 (s, 0.7H), 7.98 (s, 0.3H), 7.97–7.94 (m, 1H), 7.32 (s, 0.6H), 7.24 (s, 0.4H), 6.56–6.33 (m, 4H), 5.71–5.61 (m, 1H), 5.52–5.43 (m, 1H), 4.85–4.79 (m, 1H), 4.27–4.20 (m, 0.6H), 4.11 (s, 1.2H), 4.10 (s, 0.8H), 4.06–3.89 (m, 1.7H), 3.82–3.77 (m, 0.7H), 3.87 (s, 3H), 3.65–3.48 (m, 1H), 3.25–3.22 (m, 4H), 2.95–2.83 (m, 1H), 2.72–2.69 (m, 4H), 2.45 (s, 1.8H), 2.43 (s, 1.2H), 2.26–2.06 (m, 1H), 1.91–1.85 (m, 2H), 1.76–1.72 (m, 2H), 1.66–1.55 (m, 4H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 164.5, 164.2, 159.2, 159.1, 157.4, 157.3, 153.7, 153.5, 153.2, 153.0, 149.6, 149.3, 147.5, 147.4, 128.8, 128.3, 127.2, 121.7, 121.4, 120.5, 120.2, 107.8, 107.7, 102.8, 100.3, 100.1, 56.0, 55.8, 55.5, 55.0, 52.5, 50.9, 49.8, 49.6, 46.9, 46.6, 46.0, 45.9, 45.6, 44.3, 38.6, 28.2, 27.9, 27.8, 25.7, 24.1, 24.0. HRMS (ESI) for C<sub>30</sub>H<sub>40</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 561.3296, found: 561.3290. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 7.21 min, 99.51% purity.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (<i>S</i>)-1-(1-Acryloylpyrrolidin-3-yl)-3-cyclohexyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2k</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> +5.085 (<i>c</i> 0.118, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.02–7.95 (m, 2H), 7.32 (s, 0.6H), 7.25 (s, 0.4H), 6.55–6.47 (m, 2H), 6.42–6.33 (m, 2H), 5.72–5.61 (m, 1H), 5.54–5.45 (m, 1H), 4.30–4.27 (m, 1H), 4.25–4.22 (m, 0.6H), 4.13 (s, 2H), 4.02–3.94 (m, 1.7H), 3.87 (s, 3H), 3.83–3.77 (m, 0.7H), 3.67–3.49 (m, 1H), 3.25–3.22 (m, 4H), 2.96–2.81 (m, 1H), 2.73–2.70 (m, 4H), 2.46 (s, 1.6H), 2.44 (s, 1.4H), 2.24–2.05 (m, 1H), 1.86–1.68 (m, 5H), 1.52–1.36 (m, 4H), 1.15–1.07 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 164.6, 164.2, 159.2, 157.4, 157.3, 153.5, 153.3, 153.2, 153.1, 149.6, 149.3, 147.4, 128.8, 128.3, 127.3, 121.8, 121.6, 120.5, 120.1, 107.9, 102.9, 100.4, 100.1, 55.6, 55.1, 55.0, 54.3, 54.1, 52.5, 50.9, 49.9, 49.6, 47.0, 46.7, 46.0, 45.9, 45.7, 44.4, 38.6, 29.7, 28.3, 25.8, 25.6, 25.5. HRMS (ESI) for C<sub>31</sub>H<sub>42</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 575.3453, found: 575.3446. HPLC analysis: MeOH–H<sub>2</sub>O (82:18), 10.51 min, 98.94% purity.</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>S</i>)-1-(1-Acryloylpyrrolidin-3-yl)-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-phenyl-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2l</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> −8.421 (<i>c</i> 0.095, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.02–7.99 (m, 2H), 7.44–7.39 (m, 3H), 7.32–7.28 (m, 3H), 6.54–6.37 (m, 4H), 5.70–5.61 (m, 1H), 5.59–5.51 (m, 1H), 4.68–4.58 (m, 2H), 4.31–4.27 (m, 0.8H), 4.07–3.91 (m, 1.5H), 3.89 (s, 1.7H), 3.88 (s, 1.3H), 3.86–3.80 (m, 0.7H), 3.66–3.52 (m, 1H), 3.22–3.18 (m, 4H), 2.98–2.82 (m, 1H), 2.65–2.61 (m, 4H), 2.39 (s, 3H), 2.33–2.12 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 164.6, 164.2, 159.4, 159.3, 157.3, 157.2, 153.5, 153.4, 153.3, 153.2, 149.7, 149.5, 147.7, 142.0, 141.9, 129.2, 129.1, 128.8, 128.3, 127.3, 126.8, 126.7, 125.3, 125.2, 121.5, 121.3, 120.7, 120.3, 107.9, 107.8, 102.8, 100.4, 100.1, 55.6, 55.1, 52.7, 51.0, 49.9, 49.7, 47.2, 47.1, 47.0, 46.7, 46.1, 45.7, 44.4, 28.4, 25.8. HRMS (ESI) for C<sub>31</sub>H<sub>36</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 569.2983, found: 569.2980. HPLC analysis: MeOH–H<sub>2</sub>O (78:22), 8.79 min, 96.98% purity.</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (<i>S</i>)-1-(1-Acryloylpyrrolidin-3-yl)-3-phenyl-7-(phenylamino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2m</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> −2.564 (<i>c</i> 0.078, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.05 (s, 0.6H), 8.03 (s, 0.4H), 7.57–7.51 (m, 2H), 7.48–7.41 (m, 3H), 7.34–7.28 (m, 5H), 7.08–7.05 (m, 1H), 6.52–6.38 (m, 2H), 5.72–5.63 (m, 1H), 5.61–5.49 (m, 1H), 4.70–4.62 (m, 2H), 4.22–4.18 (m, 0.6H), 4.09–3.99 (m, 1.4H), 3.90–3.84 (m, 1H), 3.63–3.58 (m, 0.4H), 3.54–3.48 (m, 0.6H), 2.86–2.75 (m, 1H), 2.32–2.17 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 165.1, 164.4, 159.1, 157.5, 157.1, 153.3, 153.2, 153.0, 141.9, 139.0, 138.9, 129.2, 128.9, 128.8, 128.1, 127.6, 127.5, 126.9, 126.8, 125.3, 125.2, 123.2, 123.1, 120.2, 119.7, 103.9, 52.9, 51.2, 47.7, 47.1, 47.0, 45.7, 44.7, 28.4, 26.3. HRMS (ESI) for C<sub>25</sub>H<sub>24</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 441.2034, found: 441.2030. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 4.73 min, 99.24% purity.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>S</i>)-1-(1-Acryloylpyrrolidin-3-yl)-7-(4-(4-methylpiperazin-1-yl)phenylamino)-3-phenyl-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2n</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> +1.770 (<i>c</i> 0.113, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.01 (s, 0.6H), 8.00 (s, 0.4H), 7.44–7.36 (m, 4H), 7.32–7.27 (m, 3H), 7.09 (s, 0.6H), 6.92–6.88 (m, 2.4H), 6.52–6.33 (m, 2H), 5.70–5.63 (m, 1H), 5.57–5.47 (m, 1H), 4.67–4.58 (m, 2H), 4.23–4.20 (m, 0.6H), 4.09–3.98 (m, 1.4H), 3.87–3.83 (m, 1H), 3.62–3.57 (m, 0.4H), 3.52–3.46 (m, 0.6H), 3.24–3.20 (m, 4H), 2.85–2.77 (m, 1H), 2.69–2.65 (m, 4H), 2.42 (s, 1.8H), 2.41 (s, 1.2H), 2.29–2.14 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 164.7, 164.2, 159.6, 159.5, 157.3, 157.0, 153.4, 153.3, 147.5, 141.9, 131.3, 129.1, 128.7, 128.2, 127.4, 126.7, 126.6, 125.2, 125.1, 122.1, 121.6, 116.5, 102.8, 55.0, 54.9, 52.7, 51.0, 49.4, 49.2, 47.2, 46.9, 46.0, 45.9, 45.6, 44.5, 28.2, 26.0. HRMS (ESI) for C<sub>30</sub>H<sub>34</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 539.2878, found: 539.2872. HPLC analysis: MeOH–H<sub>2</sub>O (81:19), 5.74 min, 98.71% purity.</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (<i>S</i>)-1-(1-Acryloylpyrrolidin-3-yl)-7-(3-(4-methylpiperazin-1-yl)phenylamino)-3-phenyl-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2o</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20 </sup> −5.825 (<i>c</i> 0.103, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.05 (s, 0.6H), 8.04 (s, 0.4H), 7.44–7.40 (m, 2H), 7.32–7.25 (m, 4H), 7.23–7.04 (m, 3H), 6.65–6.63 (m, 1H), 6.52–6.34 (m, 2H), 5.71–5.53 (m, 2H), 4.70–4.60 (m, 2H), 4.19 −4.16 (m, 0.6H), 4.12–4.03 (m, 1.3H), 3.94–3.84 (m, 1.1H), 3.65–3.60 (m, 0.4H), 3.53–3.47 (m, 0.6H), 3.30–3.29 (m, 4H), 2.83–2.76 (m, 1H), 2.75–2.65 (m, 4H), 2.45 (s, 1.2H), 2.43 (s, 1.8H), 2.34–2.18 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 165.0, 164.2, 159.3, 159.2, 157.4, 157.0, 153.4, 153.3, 153.2, 152.9, 151.9, 141.9, 140.0, 139.9, 129.5, 129.4, 129.2, 128.8, 128.2, 127.5, 127.4, 126.8, 126.7, 125.2, 111.6, 111.2, 110.9, 107.8, 107.4, 103.4, 54.9, 54.9, 52.8, 51.0, 48.8, 47.9, 47.2, 47.0, 45.9, 45.7, 44.7, 28.6, 26.4. HRMS (ESI) for C<sub>30</sub>H<sub>34</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 539.2878, found: 539.2872. HPLC analysis: MeOH–H<sub>2</sub>O (75:25), 9.27 min, 99.87% purity.</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (<i>S</i>)-1-(1-Acryloylpyrrolidin-3-yl)-7-(4-(1-methylpiperidin-4-yl)phenylamino)-3-phenyl-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2p</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> −28.000 (<i>c</i> 0.100, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.04 (s, 0.6H), 8.03 (s, 0.4H), 7.50–7.40 (m, 4H), 7.32–7.29 (m, 3H), 7.21–7.18 (m, 2.6H), 7.02 (s, 0.4H), 6.55–5.37 (m, 2H), 5.72–5.63 (m, 1H), 5.61–5.51 (m, 1H), 4.69–4.60 (m, 2H), 4.23–4.19 (m, 0.6H), 4.11–3.99 (m, 1.4H), 3.95–3.85 (m, 1H), 3.66–3.60 (m, 0.4H), 3.54–3.46 (m, 0.6H), 3.14–3.10 (m, 2H), 2.89–2.74 (m, 1H), 2.55–2.50 (m, 1H), 2.45 (s, 1.7H), 2.43 (s, 1.3H), 2.33–2.29 (m, 1H), 2.26–2.17 (m, 2H), 2.02–1.92 (m, 4H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 165.0, 164.3, 159.3, 159.2, 157.4, 157.0, 153.4, 153.3, 153.1, 141.9, 141.1, 141.0, 137.0, 129.2, 128.8, 128.2, 127.6, 127.2, 126.8, 126.7, 125.3, 125.2, 120.2, 120.0, 103.5, 103.4, 56.3, 56.2, 52.8, 51.2, 47.6, 47.1, 47.0, 46.3, 45.7, 44.6, 41.3, 41.2, 33.4, 33.3, 28.4, 26.2. HRMS (ESI) for C<sub>31</sub>H<sub>35</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 538.2925, found: 538.2921. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 10.26 min, 99.75% purity.</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (<i>S</i>)-1-(1-Acryloylpyrrolidin-3-yl)-7-(4-(2-(4-methylpiperazin-1-yl)ethyl)phenylamino)-3-phenyl-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2q</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> −5.455 (<i>c</i> 0.110, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.04 (s, 0.6H), 8.02 (s, 0.4H), 7.48–7.40 (m, 4H), 7.32–7.27 (m, 3H), 7.23 (s, 0.6H), 7.15 (d, <i>J</i> = 8.0 Hz, 2H), 7.03 (s, 0.4H), 6.54–6.37 (m, 2H), 5.72–5.62 (m, 1H), 5.60–5.49 (m, 1H), 4.69–4.59 (m, 2H), 4.22–4.18 (m, 0.6H), 4.11–3.99 (m, 1.4H), 3.93–3.85 (m, 1H), 3.65–3.59 (m, 0.4H), 3.54–3.47 (m, 0.6H), 2.88–2.83 (m, 1H), 2.81–2.77 (m, 2H), 2.73–2.66 (m, 2H), 2.64–2.47 (m, 8H), 2.35 (s, 3H), 2.31–2.16 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 164.9, 164.3, 159.3, 159.2, 157.4, 157.0, 153.4, 153.3, 153.1, 141.9, 137.1, 137.0, 135.1, 135.0, 129.1, 129.0, 128.7, 128.1, 127.5, 126.8, 126.7, 125.2, 120.2, 120.0, 103.4, 60.3, 55.0, 53.0, 52.8, 51.1, 47.6, 47.1, 47.0, 45.9, 45.7, 44.6, 32.8, 32.7, 28.4, 26.3. HRMS (ESI) for C<sub>32</sub>H<sub>38</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 567.3191, found: 567.3185. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 6.29 min, 99.55% purity.</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (<i>S</i>)-1-(1-Acryloylpyrrolidin-3-yl)-7-(3-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-phenyl-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2r</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> −25.263 (<i>c</i> 0.095, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.04 (s, 0.7H), 8.02 (s, 0.3H), 7.44–7.40 (m, 2H), 7.32–7.28 (m, 3H), 7.22–6.89 (m, 4H), 6.53–6.35 (m, 2H), 5.72–5.51 (m, 2H), 4.69–4.60 (m, 2H), 4.18–4.15 (m, 0.6H), 4.10–3.99 (m, 1.4H), 3.94–3.89 (m, 1H), 3.87 (s, 1.8H), 3.86 (s, 1.2H), 3.64–3.59 (m, 0.4H), 3.51–3.46 (m, 0.6H), 3.19 (s, 4H), 2.87–2.77 (m, 4H), 2.75–2.69 (m, 1H), 2.50 (s, 3H), 2.32–2.18 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 165.0, 164.3, 159.3, 159.2, 157.4, 157.0, 153.4, 153.3, 153.0, 152.5, 141.9, 137.0, 136.8, 134.7, 134.5, 129.2, 128.7, 128.1, 127.6, 127.5, 126.8, 126.7, 125.2, 118.4, 112.6, 112.1, 104.8, 104.3, 103.3, 55.5, 55.4, 55.2, 52.7, 51.0, 50.6, 50.5, 48.0, 47.1, 47.0, 45.9, 45.7, 44.7, 28.5, 26.5. HRMS (ESI) for C<sub>31</sub>H<sub>36</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 569.2983, found: 569.2975. HPLC analysis: MeOH–H<sub>2</sub>O (75:25), 8.83 min, 99.39% purity.</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (<i>S</i>)-1-(1-Acryloylpyrrolidin-3-yl)-7-(3-fluoro-4-(4-methylpiperazin-1-yl)phenylamino)-3-phenyl-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2s</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> −1.538 (<i>c</i> 0.130, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.04 (s, 0.6H), 8.03 (s, 0.4H), 7.56–7.49 (m, 1H), 7.44–7.40 (m, 2H), 7.32–7.28 (m, 4H), 7.16–7.08 (m, 1H), 6.93–6.89 (m, 1H), 6.53–6.33 (m, 2H), 5.71–5.48 (m, 2H), 4.69–4.61 (m, 2H), 4.18–4.08 (m, 1.5H), 4.01–3.87 (m, 1.5H), 3.66–3.61 (m, 0.4H), 3.53–3.47 (m, 0.6H), 3.18–3.17 (m, 4H), 2.88–2.82 (m, 1H), 2.78–2.67 (m, 4H), 2.47 (s, 1.8H), 2.46 (s, 1.2H), 2.36–2.21 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 165.1, 164.4, 158.9, 157.5, 157.0, 156.4, 154.5, 153.3, 153.0, 141.9, 135.2, 134.4, 129.2, 128.8, 128.3, 127.6, 127.5, 126.9, 126.8, 125.2, 119.2, 115.5, 115.4, 108.7, 108.6, 108.4, 103.7, 55.0, 52.9, 51.3, 50.5, 50.4, 48.1, 47.0, 45.9, 45.7, 44.8, 28.5, 26.6. HRMS (ESI) for C<sub>30</sub>H<sub>33</sub>FN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 557.2783, found: 557.2775. HPLC analysis: MeOH–H<sub>2</sub>O (75:25), 10.74 min, 99.9% purity.</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (<i>S</i>)-1-(1-Acryloylpyrrolidin-3-yl)-7-(4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenylamino)-3-phenyl-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2t</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> −36.190 (<i>c</i> 0.105, CHCl<sub>3</sub>).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.08–7.99 (m, 2H), 7.74–7.60 (m, 2H), 7.46–7.42 (m, 3H), 7.32–7.29 (m, 3H), 6.56–6.37 (m, 2H), 5.75–5.52 (m, 2H), 4.79–4.64 (m, 2H), 4.20–3.88 (m, 3H), 3.69–3.62 (m, 1H), 3.52–3.44 (m, 4H), 3.07 (s, 4H), 2.84 (s, 3H), 2.68–2.60 (m, 1H), 2.36–2.26 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 165.2, 164.4, 158.8, 157.6, 157.2, 153.4, 153.1, 152.8, 146.6, 141.8, 136.5, 136.4, 129.3, 129.2, 128.8, 128.2, 128.0, 127.7, 127.6, 126.9, 125.3, 125.0, 124.9, 123.4, 122.7, 118.1, 118.0, 104.29, 55.3, 53.0, 52.8, 51.4, 48.5, 47.2, 47.0, 45.7, 44.9, 28.6, 26.9. HRMS (ESI) for C<sub>31</sub>H<sub>33</sub>F<sub>3</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 607.2751, found: 607.2750. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 8.56 min, 99.62% purity.</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (<i>S</i>)-1-(1-Acryloylpyrrolidin-3-yl)-7-(3-chloro-4-(4-methylpiperazin-1-yl)phenylamino)-3-phenyl-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2u</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> −23.704 (<i>c</i> 0.135, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.05 (s, 0.6H), 8.04 (s, 0.4H), 7.87 (s, 0.6H), 7.79 (s, 0.4H), 7.44–7.40 (m, 2H), 7.36–7.28 (m, 5H), 7.07–7.02 (m, 1H), 6.53–6.33 (m, 2H), 5.71–5.50 (m, 2H), 4.77–4.62 (m, 2H), 4.18–3.89 (m, 3H), 3.68–3.63 (m, 0.4H), 3.54–3.48 (m, 0.6H), 3.18 (s, 4H), 2.86–2.82 (m, 4H), 2.75–2.71 (m, 1H), 2.53 (s, 3H), 2.38–2.22 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 165.0, 164.3, 159.0, 158.9, 157.5, 157.1, 153.3, 153.1, 152.9, 144.4, 141.8, 135.1, 129.1, 128.9, 128.8, 128.1, 127.5, 126.8, 126.7, 125.2, 122.1, 121.9, 120.5, 120.4, 119.0, 118.8, 103.7, 55.2, 52.9, 51.3, 51.2, 51.1, 47.9, 47.0, 46.9, 45.9, 45.7, 44.7, 28.5, 26.5. HRMS (ESI) for C<sub>30</sub>H<sub>33</sub>ClN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 573.2488, found: 573.2483. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 7.52 min, 98.38% purity.</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (<i>S</i>)-1-(1-Acryloylpyrrolidin-3-yl)-7-(3-methyl-4-(4-methylpiperazin-1-yl)phenylamino)-3-phenyl-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>2v</b>)</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> −42.478 (<i>c</i> 0.113, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.03 (s, 0.6H), 8.02 (s, 0.4H), 7.42–7.40 (m, 3H), 7.35–7.29 (m, 4H), 7.14–6.96 (m, 2H), 6.54–6.33 (m, 2H), 5.73–5.51 (m, 2H), 4.68–4.59 (m, 2H), 4.19–3.85 (m, 3H), 3.67–3.61 (m, 0.4H), 3.52–3.47 (m, 0.6H), 3.13 (s, 4H), 2.96 (s, 4H), 2.87–2.77 (m, 1H), 2.62 (s, 3H), 2.28 (s, 3H), 2.24–2.19 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 164.9, 164.3, 159.4, 159.3, 157.5, 157.1, 153.5, 153.4, 153.3, 153.0, 146.8, 141.9, 134.5, 133.4, 129.2, 128.8, 128.2, 127.6, 126.8, 126.7, 125.3, 125.2, 123.0, 119.7, 118.5, 118.4, 103.2, 55.4, 52.8, 51.4, 51.3, 51.2, 47.7, 47.2, 47.0, 45.7, 44.7, 28.5, 26.4, 17.9. HRMS (ESI) for C<sub>31</sub>H<sub>36</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 553.3034, found: 553.3032. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 7.09 min, 99.95% purity.</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Cell Lines and Reagents</h3><div class="NLM_p last">Cell lines H1975 (NSCLC, EGFR<sup>L858R/T790M</sup>) were obtained from ATCC. The cells were maintained at 37 °C in 5% CO<sub>2</sub> incubator in RPMI 1460 (Gibco, Invitrogen) containing 10% fetal bovine serum (Gibco, Invitrogen). H460 (NSCLC, EGFR<sup>WT</sup>), 95D (NSCLC, EGFR<sup>WT</sup>), H358 (NSCLC, EGFR<sup>WT</sup>), H1299 (NSCLC, EGFR<sup>WT</sup>), and HL-7702 (diploid human liver cell, EGFR<sup>WT</sup>) were gifts from Prof. Duanqing Pei. The EGFR gene of every cell line was sequenced before use. Gefitinib was synthesized in our chemistry laboratory.</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> In Vitro Kinase Enzyme Assay</h3><div class="NLM_p last">EGFR (L858R/T790M) mutant and the Z′-Lyte Kinase Assay Kit were purchased from Invitrogen. The concentration gradients from 5.1 × 10<sup>–11</sup> to 1.0 × 10<sup>–6</sup> mol/L were used for all the test compounds. The experiments were performed according to the instructions of the manufacturer.</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Cell Proliferation and Growth Inhibition Assay</h3><div class="NLM_p last">Cell proliferation was assessed by MTS assay. Cells were exposed to treatment for 72 h, and the number of cells used per experiment for each cell line was adjusted to obtain an absorbance of 0.5 to 1.2 at 570 nm. Compounds were tested at six concentrations (0.1 nM to 10 μM), with each concentration duplicated six times. All experiments were repeated at least four times. The data were calculated using GraphPad Prism version 4.0. Dose–response curves were fitted using a nonlinear regression model with a sigmoidal dose–response.</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Antibodies and Western Blot Assay</h3><div class="NLM_p last">H1975 cells were plated in 6-cm dishes. After 24 h of growth, the cells were treated with the compounds at the indicated concentrations for 2 h. Cell lysates were collected with 1 × lysis buffer (CST) and were briefly sonicated. Western blot analyses were conducted after separation by SDS/PAGE electrophoresis and transfer to PVDF membranes. Membranes were blocked in 5% bovine serum albumin/TBST and probed with the indicated antibodies, followed by a peroxidase-conjugated antimouse or rabbit secondary antibody (Thermo). Antiphospho Akt (Ser 173), antitotal Akt, anti-EGFR, antiphospho specific EGFR (pY1068), antitotal Erk1/2, and antiphospho Erk1/2 (pT202/pY204) antibodies were obtained from Cell Signaling Technology Inc.</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Determination of Pharmacokinetic Parameters in Rats</h3><div class="NLM_p last">Male Sprague–Dawley rats (180–220 g) were dosed with the test compounds intravenously (iv) at 5 mg/kg and by oral gavage (po) at 25 mg/kg. The compound was dissolved in a vehicle of 2% DMSO, 4% EtOH, 4% castor oil, and 90% H<sub>2</sub>O. Blood samples (0.3 mL) were then obtained via orbital sinus puncture at 2 min, 10 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 21 h, 24 h, 30 h, 36 h, 48 h, and 72 h time points and collected into heparinized tubes. Blood samples were centrifuged for cell removal, and the plasma supernatant was then transferred to a clean vial and subsequently stored in 4 °C prior to analysis. Test sample concentrations were determined by LC/MS using propranolol as an internal standard. Pharmacokinetic parameters were calculated using DAS 2.0 software.</div></div><div id="sec5_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Mouse Tumor Xenograft Efficacy Study</h3><div class="NLM_p last">The efficacy study was conducted in accordance with the guidelines for the Care and Use of Laboratory Animals in Guangzhou Institute of Biomedicine and Health (GIBH, CAS). Six week old SCID mice were inoculated subcutaneously with H1975 NSCLC cells (2 × 10<sup>6</sup>/mouse) in the right flank. Upon attaining an average tumor volume of 200–300 mm<sup>3</sup> (10–12 days post implantation), animals were randomized into treatment groups (<i>n</i> = 5 per group). Each group was dosed orally for 14 days with either vehicle only or with compound <b>2v</b> at 10 or 30 mg/kg daily (qd). Final concentration of vehicle was 1% DMSO, 5% EtOH, 15% castor oil, and 79% H<sub>2</sub>O. The doses were 0.1 mL/20 g of the animal body weight. The length (<i>L</i>) and width (<i>W</i>) of the tumor mass were measured, and the tumor volume (TV) was calculated as: TV = <i>W</i><sup>2</sup>(<i>L</i>/2). Tumor growth inhibition (TGI) was calculated using the following formula: TGI = [1 – (<i>T</i> – <i>T</i><sub>0</sub>)/(<i>C</i> – <i>C</i><sub>0</sub>)] × 100, where <i>T</i> and <i>T</i><sub>0</sub> are the mean tumor volumes on a specific experimental day and on the first day of treatment, respectively, for the experimental groups, and likewise where<i> C</i> and <i>C</i><sub>0</sub> are the mean tumor volumes for the control group.</div></div><div id="sec5_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Thermodynamic Aqueous Solubility</h3><div class="NLM_p last">Each compound was added to 1 mL of phosphate buffer (PBS, pH 6.8) to obtain saturated solution. The resulting mixture was then shaken at ambient temperature for 24 h. The concentration of compounds was determined by HPLC.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47"><a href="/doi/suppl/10.1021/jm4012388">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53357" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53357" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last"><sup>1</sup>H NMR, <sup>13</sup>C NMR, and purity determination for compounds <b>2a</b>–<b>v</b>, and biological assay details and results. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm4012388/suppl_file/jm4012388_si_001.pdf">jm4012388_si_001.pdf (14.13 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm4012388" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87856" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87856" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ke Ding</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemical Biology, Guangzhou Institutes
of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#bedad7d0d9e1d5dbfed9d7dcd690dfdd90ddd0"><span class="__cf_email__" data-cfemail="b8dcd1d6dfe7d3ddf8dfd1dad096d9db96dbd6">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shilin Xu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemical Biology, Guangzhou Institutes
of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span>; 
    <span class="hlFld-Affiliation affiliation">University of Chinese
Academy of Sciences, #19 Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tianfeng Xu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemical Biology, Guangzhou Institutes
of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span>; 
    <span class="hlFld-Affiliation affiliation">University of Chinese
Academy of Sciences, #19 Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lianwen Zhang</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemical Biology, Guangzhou Institutes
of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhang Zhang</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemical Biology, Guangzhou Institutes
of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinfeng Luo</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemical Biology, Guangzhou Institutes
of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingxue Liu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemical Biology, Guangzhou Institutes
of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoyun Lu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemical Biology, Guangzhou Institutes
of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhengchao Tu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemical Biology, Guangzhou Institutes
of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaomei Ren</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemical Biology, Guangzhou Institutes
of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d2707e3674-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35755" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35755" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank National Basic Research Program of China (no. 2010CB529706, 2009CB940904), National Natural Science Foundation (no. 21072192), Key Project on Innovative Drug of Guangdong Province (no. 2011A080501013), Strategic Collaborative project of Guangdong Province and Chinese Academy of Sciences, and Key Project on Innovative Drug of Guangzhou City (grant no. 2009Z1-E911, 2010J-E551) for their financial support.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i49" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i49"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i50" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i50"> Abbreviations Used</h2><tr><td class="NLM_term">T</td><td class="NLM_def"><p class="first last">threonine</p></td></tr><tr><td class="NLM_term">M</td><td class="NLM_def"><p class="first last">methionine</p></td></tr><tr><td class="NLM_term">L</td><td class="NLM_def"><p class="first last">leucine</p></td></tr><tr><td class="NLM_term">R</td><td class="NLM_def"><p class="first last">arginine</p></td></tr><tr><td class="NLM_term">E</td><td class="NLM_def"><p class="first last">glutamic acid</p></td></tr><tr><td class="NLM_term">A</td><td class="NLM_def"><p class="first last">alanine</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall cell lung cancer</p></td></tr><tr><td class="NLM_term">MTD</td><td class="NLM_def"><p class="first last">maximum tolerated dose</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">Sprague–Dawley</p></td></tr><tr><td class="NLM_term">F</td><td class="NLM_def"><p class="first last">oral bioavailability</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term">Cl</td><td class="NLM_def"><p class="first last">clearance rate</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under curve</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild-type</p></td></tr><tr><td class="NLM_term"><i>m</i>-CPBA</td><td class="NLM_def"><p class="first last">3-chloroperbenzoic acid</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinases</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">ABL1</td><td class="NLM_def"><p class="first last">abelson murine leukemia viral oncogene homologue 1</p></td></tr><tr><td class="NLM_term">Blk</td><td class="NLM_def"><p class="first last">B lymphocyte kinase</p></td></tr><tr><td class="NLM_term">Btk</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">DDR1</td><td class="NLM_def"><p class="first last">discoidin domain receptor 1</p></td></tr><tr><td class="NLM_term">Flt3</td><td class="NLM_def"><p class="first last">FMS-like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">Kit</td><td class="NLM_def"><p class="first last">mast/stem cell growth factor receptor</p></td></tr><tr><td class="NLM_term">Jak3</td><td class="NLM_def"><p class="first last">Janus kinase 3</p></td></tr><tr><td class="NLM_term">MEK5</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase 5</p></td></tr><tr><td class="NLM_term">PDGFRβ</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptors β</p></td></tr><tr><td class="NLM_term">RET</td><td class="NLM_def"><p class="first last">rearranged during transfection kinase</p></td></tr><tr><td class="NLM_term">Src</td><td class="NLM_def"><p class="first last">Rous sarcoma oncogene cellular homologue</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75411" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75411" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 22 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yarden, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Untangling the ErbB Signalling Network</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1038%2F35052073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=11252954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=127-137&author=Y.+Yardenauthor=M.+X.+Sliwkowski&title=Untangling+the+ErbB+Signalling+Network"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Untangling the ErbB signalling network</span></div><div class="casAuthors">Yarden, Yosef; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-137</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 112 refs.  When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signaling pathways, culminating in responses ranging from cell division to death, motility to adhesion.  The network is often dysregulated in cancer and lends credence to the mantra that mol. understanding yields clin. benefit: over 25,000 women with breast cancer have now been treated with Herceptin, a recombinant antibody designed to block the receptor ErbB2.  Likewise, small-mol. enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clin. testing.  What can this pathway teach us about translating basic science into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhWL1HObvNrVg90H21EOLACvtfcHk0ljipm7qQEECEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D&md5=1561a9666f77fce888be821399870cd6</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2F35052073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35052073%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DUntangling%2520the%2520ErbB%2520Signalling%2520Network%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D127%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hynes, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span> </span><span class="NLM_article-title">ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&author=N.+E.+Hynesauthor=H.+A.+Lane&title=ERBB+Receptors+and+Cancer%3A+The+Complexity+of+Targeted+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0ljipm7qQEECEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DERBB%2520Receptors%2520and%2520Cancer%253A%2520The%2520Complexity%2520of%2520Targeted%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D341%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Cell Signaling by Receptor Tyrosine Kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1016%2FS0092-8674%2800%2900114-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=11057895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=211-225&author=J.+Schlessinger&title=Cell+Signaling+by+Receptor+Tyrosine+Kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-225</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review, with 109 refs.  The purpose of this review is to describe general concepts underlying the mechanism of action of RTKs and the signaling pathways that they regulate, while attempting to shed light on the question of how specificity is defined by the action of RTKs, and how a specific biol. response can be generated by the diverse array of signaling pathways activated by all RTKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0AvjN2PpaVbVg90H21EOLACvtfcHk0lhYTbRk_AoOAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D&md5=7b4cacd2513290f3b3e6120b58647654</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900114-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900114-8%26sid%3Dliteratum%253Aachs%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520Signaling%2520by%2520Receptor%2520Tyrosine%2520Kinases%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D211%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Blume-Jensen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span> </span><span class="NLM_article-title">Oncogenic Kinase Signalling</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">411</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1038%2F35077225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=11357143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktVSjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=411&publication_year=2001&pages=355-365&author=P.+Blume-Jensenauthor=T.+Hunter&title=Oncogenic+Kinase+Signalling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1dR"><div class="casContent"><span class="casTitleNuber">1d</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic kinase signaling</span></div><div class="casAuthors">Blume-Jensen, Peter; Hunter, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">411</span>
        (<span class="NLM_cas:issue">6835</span>),
    <span class="NLM_cas:pages">355-365</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 93 refs.  Protein-tyrosine kinases (PTKs) are important regulators of intracellular signal-transduction pathways mediating development and multicellular communication in metazoans.  Their activity is normally tightly controlled and regulated.  Perturbation of PTK signaling by mutations and other genetic alterations results in deregulated kinase activity and malignant transformation.  The lipid kinase phosphoinositide 3-OH kinase (PI(3)K) and some of its downstream targets, such as the protein-serine/threonine kinases Akt and p70 S6 kinase (p70S6K), are crucial effectors in oncogenic PTK signaling.  This review emphasizes how oncogenic conversion of protein kinases results from perturbation of the normal autoinhibitory constraints on kinase activity and provides an update on our knowledge about the role of deregulated PI(3)K/Akt and mammalian target of rapamycin/p70S6K signaling in human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJiBzQk4vjZbVg90H21EOLACvtfcHk0lhYTbRk_AoOAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktVSjsr0%253D&md5=cd1bce803c2daadb98cbdba8550be43b</span></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.1038%2F35077225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35077225%26sid%3Dliteratum%253Aachs%26aulast%3DBlume-Jensen%26aufirst%3DP.%26aulast%3DHunter%26aufirst%3DT.%26atitle%3DOncogenic%2520Kinase%2520Signalling%26jtitle%3DNature%26date%3D2001%26volume%3D411%26spage%3D355%26epage%3D365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henthorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, L.</span><span> </span><span class="NLM_article-title">Studies Leading to the Identification of ZD1839 (Iressa): An Orally Active, Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Targeted to the Treatment of Cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1016%2FS0960-894X%2801%2900344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=11459659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1911-1914&author=A.+J.+Barkerauthor=K.+H.+Gibsonauthor=W.+Grundyauthor=A.+A.+Godfreyauthor=J.+J.+Barlowauthor=M.+P.+Healyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=L.+Scarlettauthor=L.+Henthornauthor=L.+Richards&title=Studies+Leading+to+the+Identification+of+ZD1839+%28Iressa%29%3A+An+Orally+Active%2C+Selective+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitor+Targeted+to+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span></div><div class="casAuthors">Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1914</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compds.  ZD1839 has suitable properties for use as a clin. effective drug and shows activity against human tumors.  In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvsJ1FTqEwvbVg90H21EOLACvtfcHk0lhYTbRk_AoOAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D&md5=ebb210453ade246e43de9fd07ae1d581</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900344-4%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26aulast%3DGrundy%26aufirst%3DW.%26aulast%3DGodfrey%26aufirst%3DA.%2BA.%26aulast%3DBarlow%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DScarlett%26aufirst%3DL.%26aulast%3DHenthorn%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DL.%26atitle%3DStudies%2520Leading%2520to%2520the%2520Identification%2520of%2520ZD1839%2520%2528Iressa%2529%253A%2520An%2520Orally%2520Active%252C%2520Selective%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitor%2520Targeted%2520to%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1911%26epage%3D1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacci, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiOrio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neveu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollack, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnik, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theleman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, P.</span><span> </span><span class="NLM_article-title">Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4838</span><span class="NLM_x">–</span> <span class="NLM_lpage">4848</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=9354447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADyaK2sXnt12nsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=4838-4848&author=J.+D.+Moyerauthor=E.+G.+Barbacciauthor=K.+K.+Iwataauthor=L.+Arnoldauthor=B.+Bomanauthor=A.+Cunninghamauthor=C.+DiOrioauthor=J.+Dotyauthor=M.+J.+Morinauthor=M.+P.+Moyerauthor=M.+Neveuauthor=V.+A.+Pollackauthor=L.+R.+Pustilnikauthor=M.+M.+Reynoldsauthor=D.+Sloanauthor=A.+Thelemanauthor=P.+Miller&title=Induction+of+Apoptosis+and+Cell+Cycle+Arrest+by+CP-358%2C774%2C+an+Inhibitor+of+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase</span></div><div class="casAuthors">Moyer, James D.; Barbacci, Elsa G.; Iwata, Kenneth K.; Arnold, Lee; Boman, Bruce; Cunningham, Ann; Diorio, Catherine; Doty, Jonathan; Morin, Michael J.; Moyer, Mikel P.; Neveu, Mark; Pollack, Vincent A.; Pustilnik, Leslie R.; Reynolds, Margaret M.; Sloan, Don; Theleman, April; Miller, Penny</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4838-4848</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of carcinomas and contributes to the malignant phenotype.  CP-358774 is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM and reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM.  This inhibition is selective for EGFR tyrosine kinase relative to other tyrosine kinases we have examd., both in assays of isolated kinases and whole cells.  At doses of 100 mg/kg, CP-358774 completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice.  CP-358774 inhibits the proliferation of DiFi human colon tumor cells at submicromolar concns. in cell culture and blocks cell cycle progression at the G1 phase.  This inhibitor produces a marked accumulation of retinoblastoma protein in its underphosphorylated form and accumulation of p27KIP1 in DiFi cells, which may contribute to the cell cycle block.  Inhibition of the EGFR also triggers apoptosis in these cells as detd. by formation of DNA fragments and other criteria.  These results indicate that CP-358774 has potential for the treatment of tumors that are dependent on the EGFR pathway for proliferation or survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpghArQOnGlkbVg90H21EOLACvtfcHk0lgfEV32l6o0sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt12nsr4%253D&md5=0a6e9697bf290d8e7c44cbe2a125e0b1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DBarbacci%26aufirst%3DE.%2BG.%26aulast%3DIwata%26aufirst%3DK.%2BK.%26aulast%3DArnold%26aufirst%3DL.%26aulast%3DBoman%26aufirst%3DB.%26aulast%3DCunningham%26aufirst%3DA.%26aulast%3DDiOrio%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%26aulast%3DMorin%26aufirst%3DM.%2BJ.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DNeveu%26aufirst%3DM.%26aulast%3DPollack%26aufirst%3DV.%2BA.%26aulast%3DPustilnik%26aufirst%3DL.%2BR.%26aulast%3DReynolds%26aufirst%3DM.%2BM.%26aulast%3DSloan%26aufirst%3DD.%26aulast%3DTheleman%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DP.%26atitle%3DInduction%2520of%2520Apoptosis%2520and%2520Cell%2520Cycle%2520Arrest%2520by%2520CP-358%252C774%252C%2520an%2520Inhibitor%2520of%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D4838%26epage%3D4848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Chan, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullick, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, M. E.</span><span> </span><span class="NLM_article-title">Mutations of the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer – Search and Destroy</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=17-23&author=S.+K.+Chanauthor=W.+J.+Gullickauthor=M.+E.+Hill&title=Mutations+of+the+Epidermal+Growth+Factor+Receptor+in+Non-Small+Cell+Lung+Cancer+%E2%80%93+Search+and+Destroy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DS.%2BK.%26aulast%3DGullick%26aufirst%3DW.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BE.%26atitle%3DMutations%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520%25E2%2580%2593%2520Search%2520and%2520Destroy%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2006%26volume%3D42%26spage%3D17%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.-H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+Lung+Cancer-Derived+EGFR+Mutants+and+Inhibitor+Complexes%3A+Mechanism+of+Activation+and+Insights+into+Differential+Inhibitor+Sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lgfEV32l6o0sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520Lung%2520Cancer-Derived%2520EGFR%2520Mutants%2520and%2520Inhibitor%2520Complexes%253A%2520Mechanism%2520of%2520Activation%2520and%2520Insights%2520into%2520Differential%2520Inhibitor%2520Sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">235</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=225-235&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+Resistance+of+Lung+Adenocarcinomas+to+Gefitinib+or+Erlotinib+Is+Associated+with+a+Second+Mutation+in+the+EGFR+Kinase+Domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520Resistance%2520of%2520Lung%2520Adenocarcinomas%2520to%2520Gefitinib%2520or%2520Erlotinib%2520Is%2520Associated%2520with%2520a%2520Second%2520Mutation%2520in%2520the%2520EGFR%2520Kinase%2520Domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3D225%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib</span> <span class="citation_source-journal">New Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+J%C3%A4nneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+Mutation+and+Resistance+of+Non-Small-Cell+Lung+Cancer+to+Gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0ljDAAyPVr2G6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520Mutation%2520and%2520Resistance%2520of%2520Non-Small-Cell%2520Lung%2520Cancer%2520to%2520Gefitinib%26jtitle%3DNew%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer</span> <span class="citation_source-journal">Clin. Cancer. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2895</span><span class="NLM_x">–</span> <span class="NLM_lpage">2899</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1158%2F1078-0432.CCR-07-2248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=18483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A280%3ADC%252BD1czitVKjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=2895-2899&author=J.+A.+Engelmanauthor=P.+A.+J%C3%A4nne&title=Mechanisms+of+Acquired+Resistance+to+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitors+in+Non%E2%80%93Small+Cell+Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5dR"><div class="casContent"><span class="casTitleNuber">5d</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer</span></div><div class="casAuthors">Engelman Jeffrey A; Janne Pasi A</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2895-9</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective therapies for non-small cell lung cancer patients whose tumors harbor somatic mutations in EGFR.  All patients, however, ultimately develop resistance to these agents.  Thus, there is a great need to understand how patients become resistant to develop effective therapies for these cancers.  Studies over the last few years have identified two different EGFR tyrosine kinase inhibitor resistance mechanisms, a secondary mutation in EGFR, EGFR 790M, and amplification of the MET oncogene.  These findings have led to clinical trials using newly designed targeted therapies that can overcome these resistance mechanisms and have shown promise in laboratory studies.  Ongoing research efforts will likely continue to identify additional resistance mechanisms, and these findings will hopefully translate into effective therapies for non-small cell lung cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSwZmvJ4PNLtd-cVm4E2RlLfW6udTcc2eYMAplYrMec2Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czitVKjug%253D%253D&md5=a3ecf68a85a0ae413c451cf8f756a976</span></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-2248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-2248%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DMechanisms%2520of%2520Acquired%2520Resistance%2520to%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitors%2520in%2520Non%25E2%2580%2593Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer.%2520Res.%26date%3D2008%26volume%3D14%26spage%3D2895%26epage%3D2899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M Mutation in EGFR Kinase Causes Drug Resistance by Increasing the Affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+Mutation+in+EGFR+Kinase+Causes+Drug+Resistance+by+Increasing+the+Affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5eR"><div class="casContent"><span class="casTitleNuber">5e</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0ljDAAyPVr2G6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit5e&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520Mutation%2520in%2520EGFR%2520Kinase%2520Causes%2520Drug%2520Resistance%2520by%2520Increasing%2520the%2520Affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Slichenmyer, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">CI-1033, a Pan-erbB Tyrosine Kinase Inhibitor</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1016%2FS0093-7754%2801%2990285-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=11706399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1Wgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2001&pages=80-85&author=W.+J.+Slichenmyerauthor=W.+L.+Elliottauthor=D.+W.+Fry&title=CI-1033%2C+a+Pan-erbB+Tyrosine+Kinase+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">CI-1033, a pan-erbB tyrosine kinase inhibitor</span></div><div class="casAuthors">Slichenmyer, William J.; Elliott, William L.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5, Suppl. 16</span>),
    <span class="NLM_cas:pages">80-85</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  Overexpression of the erbB family of receptor tyrosine kinases has been implicated in a variety of tumors including breast, lung, prostate, and brain.  Most solid tumors express one or more of these receptors, which can often be related to tumor aggressiveness and poor patient prognosis.  CI-1033, a pan-erbB tyrosine kinase inhibitor, is a clin. promising agent that is active against all four members of the erbB receptor tyrosine kinase family.  In vitro studies of human cancer cell lines indicate that CI-1033 results in prompt, potent, and sustained inhibition of tyrosine kinase activity.  This inhibition is highly selective for erbBI (epidermal growth factor receptor), erbB2, erbB3, and erbB4 without inhibiting tyrosine kinase activity of receptors such as platelet-derived growth factor receptor, fibroblast growth factor receptor, and insulin receptor, even at high concns.  Treatment of athymic nude mice bearing xenografts of human A431 epidermoid carcinoma, H125 non-small cell lung carcinoma, and SF-767 glioblastoma results in highly significant suppression of tumor growth.  The major toxicity in animals is diarrhea, which is more severe at higher doses.  In animal models, all side effects are reversible on cessation of treatment.  Thus, CI-1033, which is currently undergoing phase I clin. trials, holds significant potential for use in a broad range of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWblWCZGMLQLVg90H21EOLACvtfcHk0livqmhs1pBhxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1Wgu7c%253D&md5=cc0507480a4182c3e52314750347b4c2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0093-7754%2801%2990285-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0093-7754%252801%252990285-4%26sid%3Dliteratum%253Aachs%26aulast%3DSlichenmyer%26aufirst%3DW.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DCI-1033%252C%2520a%2520Pan-erbB%2520Tyrosine%2520Kinase%2520Inhibitor%26jtitle%3DSemin.%2520Oncol.%26date%3D2001%26volume%3D28%26spage%3D80%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">3958</span><span class="NLM_x">–</span> <span class="NLM_lpage">3965</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1158%2F0008-5472.CAN-03-2868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=15173008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=3958-3965&author=S.+K.+Rabindranauthor=C.+M.+Discafaniauthor=E.+C.+Rosfjordauthor=M.+Baxterauthor=M.+B.+Floydauthor=J.+Golasauthor=W.+A.+Hallettauthor=B.+D.+Johnsonauthor=R.+Nilakantanauthor=E.+Overbeekauthor=M.+F.+Reichauthor=R.+Shenauthor=X.+Shiauthor=H.-R.+Tsouauthor=Y.-F.+Wangauthor=A.+Wissner&title=Antitumor+Activity+of+HKI-272%2C+an+Orally+Active%2C+Irreversible+Inhibitor+of+the+HER-2+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase</span></div><div class="casAuthors">Rabindran, Sridhar K.; Discafani, Carolyn M.; Rosfjord, Edward C.; Baxter, Michelle; Floyd, M. Brawner; Golas, Jonathan; Hallett, William A.; Johnson, Bernard D.; Nilakantan, Ramaswamy; Overbeek, Elsebe; Reich, Marvin F.; Shen, Ru; Shi, Xiaoqing; Tsou, Hwei-Ru; Wang, Yu-Fen; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3958-3965</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER-2 belongs to the ErbB family of receptor tyrosine kinases, which has been implicated in a variety of cancers.  Overexpression of HER-2 is seen in 25-30% of breast cancer patients and predicts a poor outcome in patients with primary disease.  Trastuzumab (Herceptin), a monoclonal antibody to HER-2, is specifically approved for HER-2-pos. breast cancer but is active only in a subset of these tumors.  Blocking HER-2 function by a small mol. kinase inhibitor, therefore, represents an attractive alternate strategy to inhibit the growth of HER-2-pos. tumors.  HKI-272 is a potent inhibitor of HER-2 and is highly active against HER-2-overexpressing human breast cancer cell lines in vitro.  It also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.  HKI-272 reduces HER-2 receptor autophosphorylation in cells at doses consistent with inhibition of cell proliferation and functions as an irreversible binding inhibitor, most likely by targeting a cysteine residue in the ATP-binding pocket of the receptor.  In agreement with the predicted effects of HER-2 inactivation, HKI-272 treatment of cells results in inhibition of downstream signal transduction events and cell cycle regulatory pathways.  This leads to arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle, ultimately resulting in decreased cell proliferation.  In vivo, HKI-272 is active in HER-2- and EGFR-dependent tumor xenograft models when dosed orally on a once daily schedule.  On the basis of its favorable preclin. pharmacol. profile, HKI-272 has been selected as a candidate for addnl. development as an antitumor agent in breast and other HER-2-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2xeLXlAwWvbVg90H21EOLACvtfcHk0livqmhs1pBhxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D&md5=60accd0599b7c489e4c3753d4f39cab4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-2868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-2868%26sid%3Dliteratum%253Aachs%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DBaxter%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DAntitumor%2520Activity%2520of%2520HKI-272%252C%2520an%2520Orally%2520Active%252C%2520Irreversible%2520Inhibitor%2520of%2520the%2520HER-2%2520Tyrosine%2520Kinase%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D3958%26epage%3D3965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations That Are Resistant to Gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">11924</span><span class="NLM_x">–</span> <span class="NLM_lpage">11932</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-11932&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=C.-M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.-K.+Wongauthor=P.+A.+J%C3%A4nne&title=PF00299804%2C+an+Irreversible+Pan-ERBB+Inhibitor%2C+Is+Effective+in+Lung+Cancer+Models+with+EGFR+and+ERBB2+Mutations+That+Are+Resistant+to+Gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DGale%26aufirst%3DC.-M.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPF00299804%252C%2520an%2520Irreversible%2520Pan-ERBB%2520Inhibitor%252C%2520Is%2520Effective%2520in%2520Lung%2520Cancer%2520Models%2520with%2520EGFR%2520and%2520ERBB2%2520Mutations%2520That%2520Are%2520Resistant%2520to%2520Gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11924%26epage%3D11932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Barf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span> </span><span class="NLM_article-title">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6243</span><span class="NLM_x">–</span> <span class="NLM_lpage">6262</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+Protein+Kinase+Inhibitors%3A+Balancing+the+Benefits+and+Risks"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0lgC8kT6kFmhUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520Protein%2520Kinase%2520Inhibitors%253A%2520Balancing%2520the%2520Benefits%2520and%2520Risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6243%26epage%3D6262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm360499.htm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm360499.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm360499.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacharchuk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freyman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ananthakrishnan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J.-C.</span><span> </span><span class="NLM_article-title">Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients with Advanced Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">3076</span><span class="NLM_x">–</span> <span class="NLM_lpage">3083</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1200%2FJCO.2009.27.9414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=20479403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=3076-3083&author=L.+V.+Sequistauthor=B.+Besseauthor=T.+J.+Lynchauthor=V.+A.+Millerauthor=K.+K.+Wongauthor=B.+Gitlitzauthor=K.+Eatonauthor=C.+Zacharchukauthor=A.+Freymanauthor=C.+Powellauthor=R.+Ananthakrishnanauthor=S.+Quinnauthor=J.-C.+Soria&title=Neratinib%2C+an+Irreversible+Pan-ErbB+Receptor+Tyrosine+Kinase+Inhibitor%3A+Results+of+a+Phase+II+Trial+in+Patients+with+Advanced+Non-Small-Cell+Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Neratinib, an irreversible Pan-ErbB, receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Sequist, Lecia V.; Besse, Benjamin; Lynch, Thomas J.; Miller, Vincent A.; Wong, Kwok K.; Gitlitz, Barbara; Eaton, Keith; Zacharchuk, Charles; Freyman, Amy; Powell, Christine; Ananthakrishnan, Revathi; Quinn, Susan; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3076-3083</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non-small-cell lung cancer (NSCLC) outcomes, particularly for patients with EGFR mutations.  Resistance emerges after 9 to 12 mo, primarily mediated by the T790M resistance mutation.  We studied neratinib, an irreversible pan-ErbB TKI that may overcome T790M.  Patients with advanced NSCLC underwent EGFR sequencing of available tumor tissue at enrollment.  Those with ≥ 12 wk of prior TKI therapy were placed in arm A if they were EGFR mutation pos. or arm B if they were wild-type.  Arm C included TKI-naive patients with adenocarcinoma and light smoking histories (≤ 20 pack-years).  All patients received daily oral neratinib, initially at 320 mg but subsequently reduced to 240 mg because of excessive diarrhea.  The primary end point was objective response rate (RR).  167 Patients were treated: 91 in arm A, 48 in arm B, and 28 in arm C.  Diarrhea was the most common toxicity; grade 3 incidence was 50% at 320 mg but improved to 25% after dose redn.  The RR was 3% in arm A and zero in arms B and C.  No patients with known T790M responded.  Notably, three of four patients with an exon 18 G719X EGFR mutation had a partial response and the fourth had stable disease lasting 40 wk.  Neratinib had low activity in patients with prior benefit from TKIs and in TKI-naive patients, potentially because of insufficient bioavailability from diarrhea-imposed dose limitation.  Responses were seen in patients with the rare G719X EGFR mutation, highlighting the importance of obtaining comprehensive genetic information on trials of targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Z3gsvbWbOrVg90H21EOLACvtfcHk0lgC8kT6kFmhUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D&md5=460e088e58919bbfcf8c153772f157b0</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.27.9414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.27.9414%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DGitlitz%26aufirst%3DB.%26aulast%3DEaton%26aufirst%3DK.%26aulast%3DZacharchuk%26aufirst%3DC.%26aulast%3DFreyman%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DC.%26aulast%3DAnanthakrishnan%26aufirst%3DR.%26aulast%3DQuinn%26aufirst%3DS.%26aulast%3DSoria%26aufirst%3DJ.-C.%26atitle%3DNeratinib%252C%2520an%2520Irreversible%2520Pan-ErbB%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitor%253A%2520Results%2520of%2520a%2520Phase%2520II%2520Trial%2520in%2520Patients%2520with%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D3076%26epage%3D3083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddigkeit, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">868</span><span class="NLM_x">–</span> <span class="NLM_lpage">874</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1158%2F0008-5472.CAN-09-3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=20103621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=868-874&author=M.+L.+Sosauthor=H.+B.+Rodeauthor=S.+Heynckauthor=M.+Peiferauthor=F.+Fischerauthor=S.+Kl%C3%BCterauthor=V.+G.+Pawarauthor=C.+Reuterauthor=J.+M.+Heuckmannauthor=J.+Weissauthor=L.+Ruddigkeitauthor=M.+Rabillerauthor=M.+Kokerauthor=J.+R.+Simardauthor=M.+Getlikauthor=Y.+Yuzaauthor=T.-H.+Chenauthor=H.+Greulichauthor=R.+K.+Thomasauthor=D.+Rauh&title=Chemogenomic+Profiling+Provides+Insights+into+the+Limited+Activity+of+Irreversible+EGFR+Inhibitors+in+Tumor+Cells+Expressing+the+T790M+EGFR+Resistance+Mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span></div><div class="casAuthors">Sos, Martin L.; Rode, Haridas B.; Heynck, Stefanie; Peifer, Martin; Fischer, Florian; Klueter, Sabine; Pawar, Vijaykumar G.; Reuter, Cecile; Heuckmann, Johannes M.; Weiss, Jonathan; Ruddigkeit, Lars; Rabiller, Matthias; Koker, Mirjam; Simard, Jeffrey R.; Getlik, Matthaeus; Yuza, Yuki; Chen, Tzu-Hsiu; Greulich, Heidi; Thomas, Roman K.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">868-874</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small mols. to improve progression-free survival of patients with EGFR-mutated lung cancers.  Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clin. activity in patients with T790M-mutant tumors.  In this study, we systematically analyzed the determinants of the activity and selectivity of the second-generation EGFR inhibitors.  A focused library of irreversible as well as structurally corresponding reversible EGFR-inhibitors was synthesized for chemogenomic profiling involving over 79 genetically defined NSCLC and 19 EGFR-dependent cell lines.  Overall, our results show that the growth-inhibitory potency of all irreversible inhibitors against the EGFRT790M resistance mutation was limited by reduced target inhibition, linked to decreased binding velocity to the mutant kinase.  Combined treatment of T790M-mutant tumor cells with BIBW-2992 and the phosphoinositide-3-kinase/mammalian target of rapamycin inhibitor PI-103 led to synergistic induction of apoptosis.  Our findings offer a mechanistic explanation for the limited efficacy of irreversible EGFR inhibitors in EGFRT790M gatekeeper-mutant tumors, and they prompt combination treatment strategies involving inhibitors that target signaling downstream of the EGFR.  Cancer Res; 70(3); 868-74.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjzYq32JnJ7Vg90H21EOLACvtfcHk0lgC8kT6kFmhUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D&md5=db40fb75245450e8f79fca7e37bad588</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3106%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DPawar%26aufirst%3DV.%2BG.%26aulast%3DReuter%26aufirst%3DC.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DRuddigkeit%26aufirst%3DL.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.-H.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DChemogenomic%2520Profiling%2520Provides%2520Insights%2520into%2520the%2520Limited%2520Activity%2520of%2520Irreversible%2520EGFR%2520Inhibitors%2520in%2520Tumor%2520Cells%2520Expressing%2520the%2520T790M%2520EGFR%2520Resistance%2520Mutation%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D868%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulkus, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheswaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">The T790M “Gatekeeper” Mutation in EGFR Mediates Resistance to Low Concentrations of an Irreversible EGFR Inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">874</span><span class="NLM_x">–</span> <span class="NLM_lpage">879</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1158%2F1535-7163.MCT-07-2387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=18413800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1GmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=874-879&author=N.+Godin-Heymannauthor=L.+Ulkusauthor=B.+W.+Branniganauthor=U.+McDermottauthor=J.+Lambauthor=S.+Maheswaranauthor=J.+Settlemanauthor=D.+A.+Haber&title=The+T790M+%E2%80%9CGatekeeper%E2%80%9D+Mutation+in+EGFR+Mediates+Resistance+to+Low+Concentrations+of+an+Irreversible+EGFR+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor</span></div><div class="casAuthors">Godin-Heymann, Nadia; Ulkus, Lindsey; Brannigan, Brian W.; McDermott, Ultan; Lamb, Jennifer; Maheswaran, Shyamala; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">874-879</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal growth factor receptor (EGFR) kinase domain tend to respond well to the tyrosine kinase inhibitors, gefitinib and erlotinib.  However, following clin. response, these patients typically relapse within a year of treatment.  In many cases, resistance is caused by an acquired secondary EGFR kinase domain mutation, T790M.  In vitro studies have shown that a new class of EGFR-irreversible inhibitors could overcome the resistance conferred by T790M.  Clin. trials are under way to examine the efficacy of one of these inhibitors, HKI-272, in patients with NSCLC who initially responded to gefitinib/erlotinib and subsequently relapsed.  To anticipate the possibility that patients who respond to irreversible inhibitors will develop secondary resistance to such inhibitors, as has been seen in other similar settings, we modeled acquired resistance to the dual EGFR/HER2-irreversible tyrosine kinase inhibitor HKI-272 in a NSCLC cell culture model.  We found that HKI-272-resistant clones fall into two biochem. groups based on the retention of EGFR phosphorylation in the presence of the drug.  Cells that retain phosphorylated EGFR have acquired the secondary mutation T790M.  Moreover, HKI-272 can overcome T790M resistance only at suprapharmacol. concns.  We further model mutations at EGFR C797 as a mechanism of resistance to irreversible EGFR inhibitors and show that although these mutants are resistant to the irreversible inhibitor, they retain erlotinib sensitivity.  Our findings suggest that HKI-272 treatment at maximally tolerated dosing may lead to the emergence of T790M-mediated resistance, whereas treatment with a more potent irreversible inhibitor could yield a resistance mutation at EGFR C797.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra5FtRNHnlNLVg90H21EOLACvtfcHk0lhVdF5HOlvyaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1GmsLo%253D&md5=f71cd83bfabef2d7b2c5d8b6e5cfac6a</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2387%26sid%3Dliteratum%253Aachs%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DUlkus%26aufirst%3DL.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DThe%2520T790M%2520%25E2%2580%259CGatekeeper%25E2%2580%259D%2520Mutation%2520in%2520EGFR%2520Mediates%2520Resistance%2520to%2520Low%2520Concentrations%2520of%2520an%2520Irreversible%2520EGFR%2520Inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D874%26epage%3D879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel Mutant-Selective EGFR Kinase Inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">4</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-4&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+Mutant-Selective+EGFR+Kinase+Inhibitors+against+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lhVdF5HOlvyaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520Mutant-Selective%2520EGFR%2520Kinase%2520Inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of Selective Irreversible Inhibitors for EGFR-T790M</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">638</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1016%2Fj.bmcl.2010.12.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=21208802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=638-643&author=W.+Zhouauthor=D.+Ercanauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Discovery+of+Selective+Irreversible+Inhibitors+for+EGFR-T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for EGFR-T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">638-643</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer.  A series of novel covalent EGFR kinase inhibitors with selectivity for the clin. relevant T790M gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening.  A representative compd. 3i (I) was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB2Qq3f78-wLVg90H21EOLACvtfcHk0lhVdF5HOlvyaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D&md5=c19f3f288ab99aaaab0a23bcf5273daf</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520Selective%2520Irreversible%2520Inhibitors%2520for%2520EGFR-T790M%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D638%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tjin Tham Sjin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T.,  St</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kalken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-mediated Resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=A.+O.+Walterauthor=R.+Tjin+Tham+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+Mutant-Selective+Covalent+Inhibitor+of+EGFR+That+Overcomes+T790M-mediated+Resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DTjin%2BTham%2BSjin%26aufirst%3DR.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520Mutant-Selective%2520Covalent%2520Inhibitor%2520of%2520EGFR%2520That%2520Overcomes%2520T790M-mediated%2520Resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span>Clinical Trials. <a href="http://clinicaltrials.gov/" class="extLink">http://clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+Trials.+http%3A%2F%2Fclinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine<sup>790</sup> → Methionine<sup>790</sup> Mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2711</span><span class="NLM_x">–</span> <span class="NLM_lpage">2723</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Novel+Conformationally+Constrained+Inhibitors+Targeting+Epidermal+Growth+Factor+Receptor+Threonine790+%E2%86%92+Methionine790+Mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Novel%2520Conformationally%2520Constrained%2520Inhibitors%2520Targeting%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Threonine790%2520%25E2%2586%2592%2520Methionine790%2520Mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2711%26epage%3D2723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of New Molecules Inhibiting Epidermal Growth Factor Receptor Threonine<sup>790</sup> → Methionine<sup>790</sup> Mutant</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1155</span><span class="NLM_x">–</span> <span class="NLM_lpage">1159</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1155-1159&author=S.+Xuauthor=L.+Zhangauthor=S.+Changauthor=J.+Luoauthor=X.+Luauthor=Z.+Tuauthor=Y.+Liuauthor=Z.+zhangauthor=Y.+Xuauthor=X.+Renauthor=K.+Ding&title=Design%2C+Synthesis+and+Biological+Evaluation+of+New+Molecules+Inhibiting+Epidermal+Growth+Factor+Receptor+Threonine790+%E2%86%92+Methionine790+Mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3Dzhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520New%2520Molecules%2520Inhibiting%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Threonine790%2520%25E2%2586%2592%2520Methionine790%2520Mutant%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D1155%26epage%3D1159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Pyrimido[4,5-<i>d</i>]pyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine<sup>790</sup> to Methionine<sup>790</sup> (T790M) Mutants</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">8387</span><span class="NLM_x">–</span> <span class="NLM_lpage">8390</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=8387-8390&author=T.+Xuauthor=L.+Zhangauthor=S.+Xuauthor=C.-Y.+Yangauthor=J.+Luoauthor=F.+Dingauthor=X.+Luauthor=Y.+Liuauthor=Z.+Tuauthor=S.+Liauthor=D.+Peiauthor=Q.+Caiauthor=H.+Liauthor=X.+Renauthor=S.+Wangauthor=K.+Ding&title=Pyrimido%5B4%2C5-d%5Dpyrimidin-4%281H%29-one+Derivatives+as+Selective+Inhibitors+of+EGFR+Threonine790+to+Methionine790+%28T790M%29+Mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DPyrimido%255B4%252C5-d%255Dpyrimidin-4%25281H%2529-one%2520Derivatives%2520as%2520Selective%2520Inhibitors%2520of%2520EGFR%2520Threonine790%2520to%2520Methionine790%2520%2528T790M%2529%2520Mutants%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D8387%26epage%3D8390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ishikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, Y.</span><span> </span><span class="NLM_article-title">Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1539</span><span class="NLM_x">–</span> <span class="NLM_lpage">1554</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101356p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1539-1554&author=M.+Ishikawaauthor=Y.+Hashimoto&title=Improvement+in+Aqueous+Solubility+in+Small+Molecule+Drug+Discovery+Programs+by+Disruption+of+Molecular+Planarity+and+Symmetry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry</span></div><div class="casAuthors">Ishikawa, Minoru; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1539-1554</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKbtbfvqKZjrVg90H21EOLACvtfcHk0lgC1VhOSJj8dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D&md5=a88804b3850625ef9c3f7424366acb91</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1021%2Fjm101356p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101356p%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DImprovement%2520in%2520Aqueous%2520Solubility%2520in%2520Small%2520Molecule%2520Drug%2520Discovery%2520Programs%2520by%2520Disruption%2520of%2520Molecular%2520Planarity%2520and%2520Symmetry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1539%26epage%3D1554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kerns, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span> </span><span class="NLM_article-title">Pharmaceutical Profiling in Drug Discovery</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">323</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1016%2FS1359-6446%2803%2902649-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=12654544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1Kls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=316-323&author=E.+H.+Kernsauthor=L.+Di&title=Pharmaceutical+Profiling+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmaceutical profiling in drug discovery</span></div><div class="casAuthors">Kerns, Edward H.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">316-323</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug discovery research organizations are building capability for measuring an ensemble of crucial drug-like' properties.  These structure-property relationship (SPR) data complement current SAR information.  This pharmaceutical profiling strategy enables research teams to better plan and interpret discovery expts., be alerted to potential 'show stoppers', improve property liabilities, and select the best candidates for advancement.  High throughput property assays for physicochem. properties - soly., permeability, lipophilicity, stability, and pKa - in vitro ADME - metab., transporters, protein binding and CYP inhibition - and in vivo PK/exposure provide a wealth of data for teams to make informed decisions.  The measurement of crucial 'druglike' properties involves correlating SAR and SPR data and enables research teams to better plan and interpret drug discovery expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbKmN9rLPo3bVg90H21EOLACvtfcHk0lgC1VhOSJj8dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1Kls7g%253D&md5=4260212023cf21edd518ae9ceea601b0</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2803%2902649-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252803%252902649-7%26sid%3Dliteratum%253Aachs%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DPharmaceutical%2520Profiling%2520in%2520Drug%2520Discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2003%26volume%3D8%26spage%3D316%26epage%3D323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Vignaroli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamperini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreassi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelucci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanita, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crespan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kissova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maga, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schenone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musumeci, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, M.</span><span> </span><span class="NLM_article-title">Pyrazolo[3,4-<i>d</i>]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">622</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml4000782" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=622-626&author=G.+Vignaroliauthor=C.+Zamperiniauthor=E.+Dreassiauthor=M.+Radiauthor=A.+Angelucciauthor=P.+Sanitaauthor=E.+Crespanauthor=M.+Kissovaauthor=G.+Magaauthor=S.+Schenoneauthor=F.+Musumeciauthor=M.+Botta&title=Pyrazolo%5B3%2C4-d%5Dpyrimidine+Prodrugs%3A+Strategic+Optimization+of+the+Aqueous+Solubility+of+Dual+Src%2FAbl+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1021%2Fml4000782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4000782%26sid%3Dliteratum%253Aachs%26aulast%3DVignaroli%26aufirst%3DG.%26aulast%3DZamperini%26aufirst%3DC.%26aulast%3DDreassi%26aufirst%3DE.%26aulast%3DRadi%26aufirst%3DM.%26aulast%3DAngelucci%26aufirst%3DA.%26aulast%3DSanita%26aufirst%3DP.%26aulast%3DCrespan%26aufirst%3DE.%26aulast%3DKissova%26aufirst%3DM.%26aulast%3DMaga%26aufirst%3DG.%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DPyrazolo%255B3%252C4-d%255Dpyrimidine%2520Prodrugs%253A%2520Strategic%2520Optimization%2520of%2520the%2520Aqueous%2520Solubility%2520of%2520Dual%2520Src%252FAbl%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D622%26epage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Press, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fullerton, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tranter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denholm, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haberthuer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatto, J. D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keenan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercer, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oakman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahri, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuffnell, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tweed, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyler, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fozard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trifilieff, A.</span><span> </span><span class="NLM_article-title">Solubility-Driven Optimization of Phosphodiesterase-4 Inhibitors Leading to a Clinical Candidate</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7472</span><span class="NLM_x">–</span> <span class="NLM_lpage">7479</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300459a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOrurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7472-7479&author=N.+J.+Pressauthor=R.+J.+Taylorauthor=J.+D.+Fullertonauthor=P.+Tranterauthor=C.+McCarthyauthor=T.+H.+Kellerauthor=N.+Arnoldauthor=D.+Beerauthor=L.+Brownauthor=R.+Cheungauthor=J.+Christieauthor=A.+Denholmauthor=S.+Haberthuerauthor=J.+D.+I.+Hattoauthor=M.+Keenanauthor=M.+K.+Mercerauthor=H.+Oakmanauthor=H.+Sahriauthor=A.+R.+Tuffnellauthor=M.+Tweedauthor=J.+W.+Tylerauthor=T.+Wagnerauthor=J.+R.+Fozardauthor=A.+Trifilieff&title=Solubility-Driven+Optimization+of+Phosphodiesterase-4+Inhibitors+Leading+to+a+Clinical+Candidate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Solubility-Driven Optimization of Phosphodiesterase-4 Inhibitors Leading to a Clinical Candidate</span></div><div class="casAuthors">Press, Neil J.; Taylor, Roger J.; Fullerton, Joseph D.; Tranter, Pamela; McCarthy, Clive; Keller, Thomas H.; Arnold, Nicola; Beer, David; Brown, Lyndon; Cheung, Robert; Christie, Julie; Denholm, Alastair; Haberthuer, Sandra; Hatto, Julia D. I.; Keenan, Mark; Mercer, Mark K.; Oakman, Helen; Sahri, Helene; Tuffnell, Andrew R.; Tweed, Morris; Tyler, John W.; Wagner, Trixie; Fozard, John R.; Trifilieff, Alexandre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7472-7479</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The soly.-driven optimization of a series of 1,7-naphthyridine phosphodiesterase-4 inhibitors is described.  Directed structural changes resulted in increased aq. soly., enabling superior pharmacokinetic properties with retention of PDE4 inhibition.  A range of potent and orally bioavailable compds. with good in vivo efficacy in animal models of inflammation and reduced emetic potential compared to previously described drugs were synthesized.  Compd. 2d (I) was taken forward as a clin. candidate for the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL0BzBNQVqnrVg90H21EOLACvtfcHk0lgC1VhOSJj8dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOrurnO&md5=deee9ca074de0b531a130d9a6ce530b2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm300459a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300459a%26sid%3Dliteratum%253Aachs%26aulast%3DPress%26aufirst%3DN.%2BJ.%26aulast%3DTaylor%26aufirst%3DR.%2BJ.%26aulast%3DFullerton%26aufirst%3DJ.%2BD.%26aulast%3DTranter%26aufirst%3DP.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DArnold%26aufirst%3DN.%26aulast%3DBeer%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DL.%26aulast%3DCheung%26aufirst%3DR.%26aulast%3DChristie%26aufirst%3DJ.%26aulast%3DDenholm%26aufirst%3DA.%26aulast%3DHaberthuer%26aufirst%3DS.%26aulast%3DHatto%26aufirst%3DJ.%2BD.%2BI.%26aulast%3DKeenan%26aufirst%3DM.%26aulast%3DMercer%26aufirst%3DM.%2BK.%26aulast%3DOakman%26aufirst%3DH.%26aulast%3DSahri%26aufirst%3DH.%26aulast%3DTuffnell%26aufirst%3DA.%2BR.%26aulast%3DTweed%26aufirst%3DM.%26aulast%3DTyler%26aufirst%3DJ.%2BW.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DFozard%26aufirst%3DJ.%2BR.%26aulast%3DTrifilieff%26aufirst%3DA.%26atitle%3DSolubility-Driven%2520Optimization%2520of%2520Phosphodiesterase-4%2520Inhibitors%2520Leading%2520to%2520a%2520Clinical%2520Candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7472%26epage%3D7479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Wells-Knecht, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesaros, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yazdanian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeigler, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">2,7-Disubstituted-Pyrrolotriazine Kinase Inhibitors with an Unusually High Degree of Reactive Metabolite Formation</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1994</span><span class="NLM_x">–</span> <span class="NLM_lpage">2003</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx200304r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1994-2003&author=K.+J.+Wells-Knechtauthor=G.+R.+Ottauthor=M.+Chengauthor=G.+J.+Wellsauthor=H.+J.+Breslinauthor=D.+E.+Gingrichauthor=L.+Weinbergauthor=E.+F.+Mesarosauthor=Z.+Huangauthor=M.+Yazdanianauthor=M.+A.+Atorauthor=L.+D.+Aimoneauthor=K.+Zeiglerauthor=B.+D.+Dorsey&title=2%2C7-Disubstituted-Pyrrolotriazine+Kinase+Inhibitors+with+an+Unusually+High+Degree+of+Reactive+Metabolite+Formation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Ftx200304r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200304r%26sid%3Dliteratum%253Aachs%26aulast%3DWells-Knecht%26aufirst%3DK.%2BJ.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DWells%26aufirst%3DG.%2BJ.%26aulast%3DBreslin%26aufirst%3DH.%2BJ.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DWeinberg%26aufirst%3DL.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DYazdanian%26aufirst%3DM.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DZeigler%26aufirst%3DK.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3D2%252C7-Disubstituted-Pyrrolotriazine%2520Kinase%2520Inhibitors%2520with%2520an%2520Unusually%2520High%2520Degree%2520of%2520Reactive%2520Metabolite%2520Formation%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1994%26epage%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mesaros, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thieu, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zificsak, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diebold, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wohler, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells-Knecht, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Strategies to Mitigate the Bioactivation of 2-Anilino-7-arylpyrrolo[2,1-<i>f</i>][1,2,4]triazines: Identification of Orally Bioavailable, Efficacious ALK Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=115-125&author=E.+F.+Mesarosauthor=T.+V.+Thieuauthor=G.+J.+Wellsauthor=C.+A.+Zificsakauthor=J.+C.+Wagnerauthor=H.+J.+Breslinauthor=R.+Tripathyauthor=J.+L.+Dieboldauthor=R.+J.+McHughauthor=A.+T.+Wohlerauthor=M.+R.+Quailauthor=W.+Wanauthor=L.+Luauthor=Z.+Huangauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=K.+J.+Wells-Knechtauthor=L.+D.+Aimoneauthor=M.+Chengauthor=M.+A.+Atorauthor=G.+R.+Ottauthor=B.+D.+Dorsey&title=Strategies+to+Mitigate+the+Bioactivation+of+2-Anilino-7-arylpyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazines%3A+Identification+of+Orally+Bioavailable%2C+Efficacious+ALK+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DThieu%26aufirst%3DT.%2BV.%26aulast%3DWells%26aufirst%3DG.%2BJ.%26aulast%3DZificsak%26aufirst%3DC.%2BA.%26aulast%3DWagner%26aufirst%3DJ.%2BC.%26aulast%3DBreslin%26aufirst%3DH.%2BJ.%26aulast%3DTripathy%26aufirst%3DR.%26aulast%3DDiebold%26aufirst%3DJ.%2BL.%26aulast%3DMcHugh%26aufirst%3DR.%2BJ.%26aulast%3DWohler%26aufirst%3DA.%2BT.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DWells-Knecht%26aufirst%3DK.%2BJ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DStrategies%2520to%2520Mitigate%2520the%2520Bioactivation%2520of%25202-Anilino-7-arylpyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazines%253A%2520Identification%2520of%2520Orally%2520Bioavailable%252C%2520Efficacious%2520ALK%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D55%26spage%3D115%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Huang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutta, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rinker, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donatelli, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurkow, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span> </span><span class="NLM_article-title">Pyrido[2,3-<i>d</i>]pyrimidin-5-ones: A Novel Class of Antiinflammatory Macrophage Colony-Stimulating Factor-1 Receptor Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1081</span><span class="NLM_x">–</span> <span class="NLM_lpage">1099</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801406h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1081-1099&author=H.+Huangauthor=D.+A.+Huttaauthor=J.+M.+Rinkerauthor=H.+Huauthor=W.+H.+Parsonsauthor=C.+Schubertauthor=R.+L.+DesJarlaisauthor=C.+S.+Cryslerauthor=M.+A.+Chaikinauthor=R.+R.+Donatelliauthor=Y.+Chenauthor=D.+Chengauthor=Z.+Zhouauthor=E.+Yurkowauthor=C.+L.+Mantheyauthor=M.+R.+Player&title=Pyrido%5B2%2C3-d%5Dpyrimidin-5-ones%3A+A+Novel+Class+of+Antiinflammatory+Macrophage+Colony-Stimulating+Factor-1+Receptor+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1021%2Fjm801406h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801406h%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHutta%26aufirst%3DD.%2BA.%26aulast%3DRinker%26aufirst%3DJ.%2BM.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DParsons%26aufirst%3DW.%2BH.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DCrysler%26aufirst%3DC.%2BS.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DDonatelli%26aufirst%3DR.%2BR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DYurkow%26aufirst%3DE.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26atitle%3DPyrido%255B2%252C3-d%255Dpyrimidin-5-ones%253A%2520A%2520Novel%2520Class%2520of%2520Antiinflammatory%2520Macrophage%2520Colony-Stimulating%2520Factor-1%2520Receptor%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1081%26epage%3D1099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hagmann, W. K.</span><span> </span><span class="NLM_article-title">The Many Roles for Fluorine in Medicinal Chemistry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4359</span><span class="NLM_x">–</span> <span class="NLM_lpage">4369</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800219f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1WjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4359-4369&author=W.+K.+Hagmann&title=The+Many+Roles+for+Fluorine+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">The Many Roles for Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Hagmann, William K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4359-4369</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkZV7sio8RhbVg90H21EOLACvtfcHk0lgRYTBcaHsXqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1WjtLo%253D&md5=821f8076bb0f632f687b1c90b05dd382</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1021%2Fjm800219f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800219f%26sid%3Dliteratum%253Aachs%26aulast%3DHagmann%26aufirst%3DW.%2BK.%26atitle%3DThe%2520Many%2520Roles%2520for%2520Fluorine%2520in%2520Medicinal%2520Chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4359%26epage%3D4369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2529</span><span class="NLM_x">–</span> <span class="NLM_lpage">2591</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+Some+Recent+Tactical+Application+of+Bioisosteres+in+Drug+Design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0lim0ScHXv0lEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520Some%2520Recent%2520Tactical%2520Application%2520of%2520Bioisosteres%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Jares-Erijman, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jovin, T. M.</span><span> </span><span class="NLM_article-title">FRET Imaging</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1387</span><span class="NLM_x">–</span> <span class="NLM_lpage">1395</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1038%2Fnbt896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=14595367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosFOksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=1387-1395&author=E.+A.+Jares-Erijmanauthor=T.+M.+Jovin&title=FRET+Imaging"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">FRET imaging</span></div><div class="casAuthors">Jares-Erijman, Elizabeth A.; Jovin, Thomas M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1387-1395</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Foerster (or Fluorescence) Resonance Energy Transfer (FRET) is unique in generating fluorescence signals sensitive to mol. conformation, assocn., and sepn. in the 1-10 nm range.  We introduce a revised photophys. framework for the phenomenon and provide a systematic catalog of FRET techniques adapted to imaging systems, including new approaches proposed as suitable prospects for implementation.  Applications extending from a single mol. to live cells will benefit from multidimensional microscopy techniques, particularly those adapted for optical sectioning and incorporating new algorithms for resolving the component contributions to images of complex mol. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTN4i2irXbCLVg90H21EOLACvtfcHk0lim0ScHXv0lEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosFOksbo%253D&md5=01814592b10786fdb8f660c4a23dfa78</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnbt896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt896%26sid%3Dliteratum%253Aachs%26aulast%3DJares-Erijman%26aufirst%3DE.%2BA.%26aulast%3DJovin%26aufirst%3DT.%2BM.%26atitle%3DFRET%2520Imaging%26jtitle%3DNat.%2520Biotechnol.%26date%3D2003%26volume%3D21%26spage%3D1387%26epage%3D1395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c','cit1d'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5a','cit5b','cit5c','cit5d','cit5e'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12a','cit12b'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16a','cit16b','cit16c'],'ref17':['cit17a','cit17b','cit17c'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20a','cit20b'],'ref21':['cit21a','cit21b'],'ref22':['cit22']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 20 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyun Lu, Tao Zhang, Su-Jie Zhu, Qiuju Xun, Lingjiang Tong, Xianglong Hu, Yan Li, Shingpan Chan, Yi Su, Yiming Sun, Yi Chen, Jian Ding, Cai-Hong Yun, Hua Xie, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (11)
                                     , 1123-1127. <a href="https://doi.org/10.1021/acsmedchemlett.8b00373" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00373%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BJND3229%252Bas%252Ba%252BNew%252BEGFRC797S%252BMutant%252BInhibitor%252Bwith%252BIn%252BVivo%252BMonodrug%252BEfficacy%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D15082018%26date%3D08102018%26date%3D10102018%26date%3D08102018%26volume%3D9%26issue%3D11%26spage%3D1123%26epage%3D1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yongjia Hao, Jiankun Lyu, Rong Qu, Yi Tong, Deheng Sun, Fang Feng, Linjiang Tong, Tingyuan Yang, Zhenjiang Zhao, Lili Zhu, Jian Ding, Yufang Xu, Hua Xie, <span class="NLM_string-name hlFld-ContribAuthor">Honglin Li</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (13)
                                     , 5609-5622. <a href="https://doi.org/10.1021/acs.jmedchem.8b00346" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00346</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00346%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BPyrimido%25255B4%25252C5-d%25255Dpyrimidine-2%25252C4%2525281H%25252C3H%252529-diones%252Bas%252BPotent%252Band%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%252Bagainst%252BL858R%25252FT790M%252BResistance%252BMutation%26aulast%3DHao%26aufirst%3DYongjia%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D04032018%26date%3D25062018%26date%3D15062018%26volume%3D61%26issue%3D13%26spage%3D5609%26epage%3D5622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qiuju Xun, Zhang Zhang, Jinfeng Luo, Linjiang Tong, Minhao Huang, Zhen Wang, Jian Zou, Yingqiang Liu, Yong Xu, Hua Xie, Zheng-Chao Tu, Xiaoyun Lu, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Structure–Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (6)
                                     , 2353-2371. <a href="https://doi.org/10.1021/acs.jmedchem.7b01612" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01612</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01612%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationship%252BStudy%252Bof%252B2-Oxo-3%25252C4-dihydropyrimido%25255B4%25252C5-d%25255Dpyrimidines%252Bas%252BNew%252BColony%252BStimulating%252BFactor%252B1%252BReceptor%252B%252528CSF1R%252529%252BKinase%252BInhibitors%26aulast%3DXun%26aufirst%3DQiuju%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D01112017%26date%3D13032018%26date%3D02032018%26volume%3D61%26issue%3D6%26spage%3D2353%26epage%3D2371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yongjia  Hao</span>, <span class="hlFld-ContribAuthor ">Xia  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Deheng  Sun</span>, <span class="hlFld-ContribAuthor ">Yi  Tong</span>, <span class="hlFld-ContribAuthor ">Yuqiong  Xu</span>, <span class="hlFld-ContribAuthor ">Haiyang  Chen</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Lili  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhenjiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhuo  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Yufang  Xu</span>, and <span class="hlFld-ContribAuthor ">Honglin  Li</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (15)
                                     , 7111-7124. <a href="https://doi.org/10.1021/acs.jmedchem.6b00403" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00403</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00403%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BStructural%252BOptimization%252Bof%252BN5-Substituted%252B6%25252C7-Dioxo-6%25252C7-dihydropteridines%252Bas%252BPotent%252Band%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%252Bagainst%252BL858R%25252FT790M%252BResistance%252BMutation%26aulast%3DHao%26aufirst%3DYongjia%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D26032016%26date%3D21072016%26date%3D11082016%26date%3D11072016%26volume%3D59%26issue%3D15%26spage%3D7111%26epage%3D7124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhendong  Song</span>, <span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Shanshan  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Youwen  Zhou</span>, and <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>  . </span><span class="cited-content_cbyCitation_article-title">Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (14)
                                     , 6580-6594. <a href="https://doi.org/10.1021/acs.jmedchem.5b00840" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00840%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DChallenges%252Band%252BPerspectives%252Bon%252Bthe%252BDevelopment%252Bof%252BSmall-Molecule%252BEGFR%252BInhibitors%252Bagainst%252BT790M-Mediated%252BResistance%252Bin%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DSong%26aufirst%3DZhendong%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D02062015%26date%3D26022016%26date%3D28072016%26date%3D16022016%26volume%3D59%26issue%3D14%26spage%3D6580%26epage%3D6594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hengmiao  Cheng</span>, <span class="hlFld-ContribAuthor ">Sajiv K.  Nair</span>, <span class="hlFld-ContribAuthor ">Brion W.  Murray</span>, <span class="hlFld-ContribAuthor ">Chau  Almaden</span>, <span class="hlFld-ContribAuthor ">Simon  Bailey</span>, <span class="hlFld-ContribAuthor ">Sangita  Baxi</span>, <span class="hlFld-ContribAuthor ">Doug  Behenna</span>, <span class="hlFld-ContribAuthor ">Sujin  Cho-Schultz</span>, <span class="hlFld-ContribAuthor ">Deepak  Dalvie</span>, <span class="hlFld-ContribAuthor ">Dac M.  Dinh</span>, <span class="hlFld-ContribAuthor ">Martin P.  Edwards</span>, <span class="hlFld-ContribAuthor ">Jun Li  Feng</span>, <span class="hlFld-ContribAuthor ">Rose Ann  Ferre</span>, <span class="hlFld-ContribAuthor ">Ketan S.  Gajiwala</span>, <span class="hlFld-ContribAuthor ">Michelle D.  Hemkens</span>, <span class="hlFld-ContribAuthor ">Amy  Jackson-Fisher</span>, <span class="hlFld-ContribAuthor ">Mehran  Jalaie</span>, <span class="hlFld-ContribAuthor ">Ted O.  Johnson</span>, <span class="hlFld-ContribAuthor ">Robert S.  Kania</span>, <span class="hlFld-ContribAuthor ">Susan  Kephart</span>, <span class="hlFld-ContribAuthor ">Jennifer  Lafontaine</span>, <span class="hlFld-ContribAuthor ">Beth  Lunney</span>, <span class="hlFld-ContribAuthor ">Kevin K.-C.  Liu</span>, <span class="hlFld-ContribAuthor ">Zhengyu  Liu</span>, <span class="hlFld-ContribAuthor ">Jean  Matthews</span>, <span class="hlFld-ContribAuthor ">Asako  Nagata</span>, <span class="hlFld-ContribAuthor ">Sherry  Niessen</span>, <span class="hlFld-ContribAuthor ">Martha A.  Ornelas</span>, <span class="hlFld-ContribAuthor ">Suvi T. M.  Orr</span>, <span class="hlFld-ContribAuthor ">Mason  Pairish</span>, <span class="hlFld-ContribAuthor ">Simon  Planken</span>, <span class="hlFld-ContribAuthor ">Shijian  Ren</span>, <span class="hlFld-ContribAuthor ">Daniel  Richter</span>, <span class="hlFld-ContribAuthor ">Kevin  Ryan</span>, <span class="hlFld-ContribAuthor ">Neal  Sach</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Tod  Smeal</span>, <span class="hlFld-ContribAuthor ">Jim  Solowiej</span>, <span class="hlFld-ContribAuthor ">Scott  Sutton</span>, <span class="hlFld-ContribAuthor ">Khanh  Tran</span>, <span class="hlFld-ContribAuthor ">Elaine  Tseng</span>, <span class="hlFld-ContribAuthor ">William  Vernier</span>, <span class="hlFld-ContribAuthor ">Marlena  Walls</span>, <span class="hlFld-ContribAuthor ">Shuiwang  Wang</span>, <span class="hlFld-ContribAuthor ">Scott L.  Weinrich</span>, <span class="hlFld-ContribAuthor ">Shuibo  Xin</span>, <span class="hlFld-ContribAuthor ">Haiwei  Xu</span>, <span class="hlFld-ContribAuthor ">Min-Jean  Yin</span>, <span class="hlFld-ContribAuthor ">Michael  Zientek</span>, <span class="hlFld-ContribAuthor ">Ru  Zhou</span>, and <span class="hlFld-ContribAuthor ">John C.  Kath</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (5)
                                     , 2005-2024. <a href="https://doi.org/10.1021/acs.jmedchem.5b01633" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01633</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01633%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B1-%25257B%2525283R%25252C4R%252529-3-%25255B%252528%25257B5-Chloro-2-%25255B%2525281-methyl-1H-pyrazol-4-yl%252529amino%25255D-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-yl%25257Doxy%252529methyl%25255D-4-methoxypyrrolidin-1-yl%25257Dprop-2-en-1-one%252B%252528PF-06459988%252529%25252C%252Ba%252BPotent%25252C%252BWT%252BSparing%25252C%252BIrreversible%252BInhibitor%252Bof%252BT790M-Containing%252BEGFR%252BMutants%26aulast%3DCheng%26aufirst%3DHengmiao%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D17102015%26date%3D28012016%26date%3D10032016%26date%3D12012016%26volume%3D59%26issue%3D5%26spage%3D2005%26epage%3D2024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan P.  Wurz</span>, <span class="hlFld-ContribAuthor ">Liping H.  Pettus</span>, <span class="hlFld-ContribAuthor ">Kate  Ashton</span>, <span class="hlFld-ContribAuthor ">James  Brown</span>, <span class="hlFld-ContribAuthor ">Jian Jeffrey  Chen</span>, <span class="hlFld-ContribAuthor ">Brad  Herberich</span>, <span class="hlFld-ContribAuthor ">Fang-Tsao  Hong</span>, <span class="hlFld-ContribAuthor ">Essa  Hu-Harrington</span>, <span class="hlFld-ContribAuthor ">Tom  Nguyen</span>, <span class="hlFld-ContribAuthor ">David J.  St. Jean, Jr.</span>, <span class="hlFld-ContribAuthor ">Seifu  Tadesse</span>, <span class="hlFld-ContribAuthor ">David  Bauer</span>, <span class="hlFld-ContribAuthor ">Michele  Kubryk</span>, <span class="hlFld-ContribAuthor ">Jinghui  Zhan</span>, <span class="hlFld-ContribAuthor ">Keegan  Cooke</span>, <span class="hlFld-ContribAuthor ">Petia  Mitchell</span>, <span class="hlFld-ContribAuthor ">Kristin L.  Andrews</span>, <span class="hlFld-ContribAuthor ">Faye  Hsieh</span>, <span class="hlFld-ContribAuthor ">Dean  Hickman</span>, <span class="hlFld-ContribAuthor ">Nataraj  Kalyanaraman</span>, <span class="hlFld-ContribAuthor ">Tian  Wu</span>, <span class="hlFld-ContribAuthor ">Darren L.  Reid</span>, <span class="hlFld-ContribAuthor ">Edward K.  Lobenhofer</span>, <span class="hlFld-ContribAuthor ">Dina A.  Andrews</span>, <span class="hlFld-ContribAuthor ">Nancy  Everds</span>, <span class="hlFld-ContribAuthor ">Roberto  Guzman</span>, <span class="hlFld-ContribAuthor ">Andrew T.  Parsons</span>, <span class="hlFld-ContribAuthor ">Simon J.  Hedley</span>, <span class="hlFld-ContribAuthor ">Jason  Tedrow</span>, <span class="hlFld-ContribAuthor ">Oliver R.  Thiel</span>, <span class="hlFld-ContribAuthor ">Matthew  Potter</span>, <span class="hlFld-ContribAuthor ">Robert  Radinsky</span>, <span class="hlFld-ContribAuthor ">Pedro J.  Beltran</span>, and <span class="hlFld-ContribAuthor ">Andrew S.  Tasker</span>  . </span><span class="cited-content_cbyCitation_article-title">Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (9)
                                     , 987-992. <a href="https://doi.org/10.1021/acsmedchemlett.5b00193" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00193%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DOxopyrido%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252BCovalent%252BL858R%25252FT790M%252BMutant%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%26aulast%3DWurz%26aufirst%3DRyan%2BP.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D08052015%26date%3D27072015%26date%3D31072015%26date%3D10092015%26date%3D27072015%26volume%3D6%26issue%3D9%26spage%3D987%26epage%3D992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shengping  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiani  Tan</span>, <span class="hlFld-ContribAuthor ">Zhonghui  Lai</span>, <span class="hlFld-ContribAuthor ">Ying  Li</span>, <span class="hlFld-ContribAuthor ">Junxia  Pang</span>, <span class="hlFld-ContribAuthor ">Jianhu  Xiao</span>, <span class="hlFld-ContribAuthor ">Zhangjian  Huang</span>, <span class="hlFld-ContribAuthor ">Yihua  Zhang</span>, <span class="hlFld-ContribAuthor ">Hui  Ji</span>, and <span class="hlFld-ContribAuthor ">Yisheng  Lai</span>  . </span><span class="cited-content_cbyCitation_article-title">Effective Virtual Screening Strategy toward Covalent Ligands: Identification of Novel NEDD8-Activating Enzyme Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2014,</strong> <em>54 </em>
                                    (6)
                                     , 1785-1797. <a href="https://doi.org/10.1021/ci5002058" title="DOI URL">https://doi.org/10.1021/ci5002058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci5002058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci5002058%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DEffective%252BVirtual%252BScreening%252BStrategy%252Btoward%252BCovalent%252BLigands%25253A%252BIdentification%252Bof%252BNovel%252BNEDD8-Activating%252BEnzyme%252BInhibitors%26aulast%3DZhang%26aufirst%3DShengping%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D02042014%26date%3D12062014%26date%3D23062014%26date%3D24052014%26volume%3D54%26issue%3D6%26spage%3D1785%26epage%3D1797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Fang  Xu</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of selective degraders of EGFRL858R/T790M mutant. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112199. <a href="https://doi.org/10.1016/j.ejmech.2020.112199" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112199</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112199%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bselective%252Bdegraders%252Bof%252BEGFRL858R%25252FT790M%252Bmutant%26aulast%3DZhang%26aufirst%3DXin%26date%3D2020%26volume%3D192%26spage%3D112199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pascale  Moreau</span>, <span class="hlFld-ContribAuthor ">Fabrice  Anizon</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 6-6 Systems: Other Four Heteroatoms 2/2. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1016/B978-0-12-409547-2.14956-X" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.14956-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.14956-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.14956-X%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B6-6%252BSystems%25253A%252BOther%252BFour%252BHeteroatoms%252B2%25252F2%26aulast%3DMoreau%26aufirst%3DPascale%26date%3D2020%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2020%26volume%3Dvol.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun M.  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Sanjay J.  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Current Approaches in the Development of Covalent Irreversible EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 45-128. <a href="https://doi.org/10.1016/B978-0-08-102661-8.00003-2" title="DOI URL">https://doi.org/10.1016/B978-0-08-102661-8.00003-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102661-8.00003-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102661-8.00003-2%26sid%3Dliteratum%253Aachs%26atitle%3DCurrent%252BApproaches%252Bin%252Bthe%252BDevelopment%252Bof%252BCovalent%252BIrreversible%252BEGFR%252BInhibitors%26aulast%3DPatel%26aufirst%3DHarun%2BM.%26date%3D2019%26spage%3D45%26epage%3D128%26pub%3DElsevier%26atitle%3DThird%252BGeneration%252BEGFR%252BInhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin  Wang</span>, <span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Xue-Yan  Yang</span>, <span class="hlFld-ContribAuthor ">Hao  Lei</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (12)
                                     , 3619-3633. <a href="https://doi.org/10.1016/j.bmc.2018.05.039" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.05.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.05.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.05.039%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Birreversible%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%252Bcontaining%252Bpyrido%25255B3%25252C4-d%25255Dpyrimidine%252Bscaffold%26aulast%3DZhang%26aufirst%3DHao%26date%3D2018%26volume%3D26%26issue%3D12%26spage%3D3619%26epage%3D3633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Shen</span>, <span class="hlFld-ContribAuthor ">Hui-Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Wei-Ming  Duan</span>, <span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Hei</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>148 </em>, 221-237. <a href="https://doi.org/10.1016/j.ejmech.2018.02.051" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.02.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.02.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.02.051%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2%25252C4%25252C6-trisubstitued%252Bpyrido%25255B3%25252C4-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bnew%252BEGFR-TKIs%26aulast%3DZhang%26aufirst%3DHao%26date%3D2018%26volume%3D148%26spage%3D221%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deheng  Chen</span>, <span class="hlFld-ContribAuthor ">Dexiang  Guo</span>, <span class="hlFld-ContribAuthor ">Ziqin  Yan</span>, <span class="hlFld-ContribAuthor ">Yujun  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Allenamide as a bioisostere of acrylamide in the design and synthesis of targeted covalent inhibitors. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2018,</strong> <em>9 </em>
                                    (2)
                                     , 244-253. <a href="https://doi.org/10.1039/C7MD00571G" title="DOI URL">https://doi.org/10.1039/C7MD00571G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7MD00571G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7MD00571G%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DAllenamide%252Bas%252Ba%252Bbioisostere%252Bof%252Bacrylamide%252Bin%252Bthe%252Bdesign%252Band%252Bsynthesis%252Bof%252Btargeted%252Bcovalent%252Binhibitors%26aulast%3DChen%26aufirst%3DDeheng%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D2%26spage%3D244%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haixing  Guan</span>, <span class="hlFld-ContribAuthor ">Yongli  Du</span>, <span class="hlFld-ContribAuthor ">Yang  Ning</span>, <span class="hlFld-ContribAuthor ">Xin  Cao</span>. </span><span class="cited-content_cbyCitation_article-title">A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2017,</strong> <em>9 </em>
                                    (7)
                                     , 693-704. <a href="https://doi.org/10.4155/fmc-2016-0222" title="DOI URL">https://doi.org/10.4155/fmc-2016-0222</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2016-0222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2016-0222%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DA%252Bbrief%252Bperspective%252Bof%252Bdrug%252Bresistance%252Btoward%252BEGFR%252Binhibitors%25253A%252Bthe%252Bcrystal%252Bstructures%252Bof%252BEGFRs%252Band%252Btheir%252Bvariants%26aulast%3DGuan%26aufirst%3DHaixing%26date%3D2017%26volume%3D9%26issue%3D7%26spage%3D693%26epage%3D704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Minhao  Huang</span>, <span class="hlFld-ContribAuthor ">Tianfeng  Xu</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Xiao-e  Yan</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Caihong  Yun</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>126 </em>, 1107-1117. <a href="https://doi.org/10.1016/j.ejmech.2016.12.006" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.12.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.12.006%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bstructure-guided%252Boptimization%252Bof%252Bpyrido%25255B2%25252C3-d%25255Dpyrimidin-7-ones%252Bas%252Bselective%252Binhibitors%252Bof%252BEGFRL858R%25252FT790M%252Bmutant%252Bwith%252Bimproved%252Bpharmacokinetic%252Bproperties%26aulast%3DYu%26aufirst%3DLei%26date%3D2017%26volume%3D126%26spage%3D1107%26epage%3D1117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weibo  Yang</span>, <span class="hlFld-ContribAuthor ">Shengqing  Ye</span>, <span class="hlFld-ContribAuthor ">Yvonne  Schmidt</span>, <span class="hlFld-ContribAuthor ">Dean  Stamos</span>, <span class="hlFld-ContribAuthor ">Jin-Quan  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Ligand-Promoted C(sp
              3
              )−H Olefination en Route to Multi-functionalized Pyrazoles. </span><span class="cited-content_cbyCitation_journal-name">Chemistry - A European Journal</span><span> <strong>2016,</strong> <em>22 </em>
                                    (21)
                                     , 7059-7062. <a href="https://doi.org/10.1002/chem.201600704" title="DOI URL">https://doi.org/10.1002/chem.201600704</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201600704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201600704%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520-%2520A%2520European%2520Journal%26atitle%3DLigand-Promoted%252BC%252528sp%252B3%252B%252529%2525E2%252588%252592H%252BOlefination%252Ben%252BRoute%252Bto%252BMulti-functionalized%252BPyrazoles%26aulast%3DYang%26aufirst%3DWeibo%26date%3D2016%26date%3D2016%26volume%3D22%26issue%3D21%26spage%3D7059%26epage%3D7062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sang Min  Lim</span>, <span class="hlFld-ContribAuthor ">Yujeong  Jeong</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2016,</strong> <em>8 </em>
                                    (8)
                                     , 853-878. <a href="https://doi.org/10.4155/fmc-2016-0019" title="DOI URL">https://doi.org/10.4155/fmc-2016-0019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2016-0019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2016-0019%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DStrategies%252Bto%252Bovercome%252Bacquired%252Bresistances%252Bconferred%252Bby%252Bmutations%252Bin%252Bthe%252Bkinase%252Bdomain%252Bof%252BEGFR%26aulast%3DLim%26aufirst%3DSang%2BMin%26date%3D2016%26volume%3D8%26issue%3D8%26spage%3D853%26epage%3D878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu-Jia  Ren</span>, <span class="hlFld-ContribAuthor ">Zhong-Chang  Wang</span>, <span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Han-Yue  Qiu</span>, <span class="hlFld-ContribAuthor ">Peng-Fei  Wang</span>, <span class="hlFld-ContribAuthor ">Hai-Bin  Gong</span>, <span class="hlFld-ContribAuthor ">Ai-Qin  Jiang</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">EGFR/HER-2 inhibitors: synthesis, biological evaluation and 3D-QSAR analysis of dihydropyridine-containing thiazolinone derivatives. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2015,</strong> <em>5 </em>
                                    (28)
                                     , 21445-21454. <a href="https://doi.org/10.1039/C4RA10606G" title="DOI URL">https://doi.org/10.1039/C4RA10606G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4RA10606G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4RA10606G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DEGFR%25252FHER-2%252Binhibitors%25253A%252Bsynthesis%25252C%252Bbiological%252Bevaluation%252Band%252B3D-QSAR%252Banalysis%252Bof%252Bdihydropyridine-containing%252Bthiazolinone%252Bderivatives%26aulast%3DRen%26aufirst%3DYu-Jia%26date%3D2015%26date%3D2015%26volume%3D5%26issue%3D28%26spage%3D21445%26epage%3D21454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tianfeng  Xu</span>, <span class="hlFld-ContribAuthor ">Ting  Peng</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Lianwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Zhaoru  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFR
              T790M
              mutant. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2015,</strong> <em>6 </em>
                                    (9)
                                     , 1693-1697. <a href="https://doi.org/10.1039/C5MD00208G" title="DOI URL">https://doi.org/10.1039/C5MD00208G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5MD00208G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5MD00208G%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DC5-substituted%252Bpyrido%25255B2%25252C3-d%25255Dpyrimidin-7-ones%252Bas%252Bhighly%252Bspecific%252Bkinase%252Binhibitors%252Btargeting%252Bthe%252Bclinical%252Bresistance-related%252BEGFR%252BT790M%252Bmutant%26aulast%3DXu%26aufirst%3DTianfeng%26date%3D2015%26date%3D2015%26volume%3D6%26issue%3D9%26spage%3D1693%26epage%3D1697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/medium/jm-2013-012388_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012388&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/medium/jm-2013-012388_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design of new EGFR<sup>T790M</sup> inhibitors with improved pharmacokinetics.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012388&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/medium/jm-2013-012388_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0004.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012388&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagent and conditions: (a) K<sub>2</sub>CO<sub>3</sub> (2 equiv), DMF, 60 °C, 85–97%; (b) LiAlH<sub>4</sub> (2 equiv), THF, −40 °C to 0 °C, 40–58%; (c) MnO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 84–93%; (d) R<sub>1</sub>NH<sub>2</sub>, AcOH, NaBH<sub>4</sub>, MeOH, 0 °C to rt, 72–90%; (e) triphosgene (0.34 equiv), Et<sub>3</sub>N (3.0 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 88–96%; (f) 3-chloroperbenzoic acid (3.0 equiv), CH<sub>2</sub>Cl<sub>2</sub>, rt, 80–92%; (g) RNH<sub>2</sub>, (1.2 equiv), trifluoroacetic acid (1.2 equiv), 2-BuOH, 110 °C; (h) trifluoroacetic acid (10 equiv), CH<sub>2</sub>Cl<sub>2</sub>, rt, 38–60% (for two steps); (i) acryloyl chloride (1.2 equiv), DIPEA (2 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 75–90%.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/medium/jm-2013-012388_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. <b>2v</b> dose-dependently decreases the phosphorylation of EGFR, AKT, and ERK. H1975 cells were treated with vehicle (DMSO) or 3 to 330 nM <b>2v</b> for 2 h. The cells were lysed, and the proteins were determined by a Western blot assay. The results are representative of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012388&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/medium/jm-2013-012388_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. In vivo effect of compound <b>2v</b> on tumor volume and body weight in xenograft model of H1975. (A) Antitumor efficacy of compound <b>2v</b> in a human NSCLC (H1975) xenograft nude mouse model. (B) Body weight of mice during treatment with <b>2v</b> for 2 weeks. Mice were orally dosed once daily (qd) for 14 days at 10 mg/kg or 30 mg/kg, and were monitored for signs of morbidity. Tumors and body weight were measured every other day (*<i>p</i> < 0.05, **<i>p</i> < 0.01).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm4012388/production/images/large/jm-2013-012388_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012388&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i51">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05604" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05604" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 22 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yarden, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Untangling the ErbB Signalling Network</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1038%2F35052073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=11252954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=127-137&author=Y.+Yardenauthor=M.+X.+Sliwkowski&title=Untangling+the+ErbB+Signalling+Network"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Untangling the ErbB signalling network</span></div><div class="casAuthors">Yarden, Yosef; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-137</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 112 refs.  When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signaling pathways, culminating in responses ranging from cell division to death, motility to adhesion.  The network is often dysregulated in cancer and lends credence to the mantra that mol. understanding yields clin. benefit: over 25,000 women with breast cancer have now been treated with Herceptin, a recombinant antibody designed to block the receptor ErbB2.  Likewise, small-mol. enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clin. testing.  What can this pathway teach us about translating basic science into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhWL1HObvNrVg90H21EOLACvtfcHk0lj5d3YHejt3LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D&md5=1561a9666f77fce888be821399870cd6</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2F35052073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35052073%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DUntangling%2520the%2520ErbB%2520Signalling%2520Network%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D127%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hynes, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span> </span><span class="NLM_article-title">ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&author=N.+E.+Hynesauthor=H.+A.+Lane&title=ERBB+Receptors+and+Cancer%3A+The+Complexity+of+Targeted+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0lhklujMKOCqyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DERBB%2520Receptors%2520and%2520Cancer%253A%2520The%2520Complexity%2520of%2520Targeted%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D341%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Cell Signaling by Receptor Tyrosine Kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1016%2FS0092-8674%2800%2900114-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=11057895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=211-225&author=J.+Schlessinger&title=Cell+Signaling+by+Receptor+Tyrosine+Kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-225</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review, with 109 refs.  The purpose of this review is to describe general concepts underlying the mechanism of action of RTKs and the signaling pathways that they regulate, while attempting to shed light on the question of how specificity is defined by the action of RTKs, and how a specific biol. response can be generated by the diverse array of signaling pathways activated by all RTKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0AvjN2PpaVbVg90H21EOLACvtfcHk0lhklujMKOCqyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D&md5=7b4cacd2513290f3b3e6120b58647654</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900114-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900114-8%26sid%3Dliteratum%253Aachs%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520Signaling%2520by%2520Receptor%2520Tyrosine%2520Kinases%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D211%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Blume-Jensen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span> </span><span class="NLM_article-title">Oncogenic Kinase Signalling</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">411</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1038%2F35077225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=11357143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktVSjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=411&publication_year=2001&pages=355-365&author=P.+Blume-Jensenauthor=T.+Hunter&title=Oncogenic+Kinase+Signalling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1dR"><div class="casContent"><span class="casTitleNuber">1d</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic kinase signaling</span></div><div class="casAuthors">Blume-Jensen, Peter; Hunter, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">411</span>
        (<span class="NLM_cas:issue">6835</span>),
    <span class="NLM_cas:pages">355-365</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 93 refs.  Protein-tyrosine kinases (PTKs) are important regulators of intracellular signal-transduction pathways mediating development and multicellular communication in metazoans.  Their activity is normally tightly controlled and regulated.  Perturbation of PTK signaling by mutations and other genetic alterations results in deregulated kinase activity and malignant transformation.  The lipid kinase phosphoinositide 3-OH kinase (PI(3)K) and some of its downstream targets, such as the protein-serine/threonine kinases Akt and p70 S6 kinase (p70S6K), are crucial effectors in oncogenic PTK signaling.  This review emphasizes how oncogenic conversion of protein kinases results from perturbation of the normal autoinhibitory constraints on kinase activity and provides an update on our knowledge about the role of deregulated PI(3)K/Akt and mammalian target of rapamycin/p70S6K signaling in human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJiBzQk4vjZbVg90H21EOLACvtfcHk0lhklujMKOCqyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktVSjsr0%253D&md5=cd1bce803c2daadb98cbdba8550be43b</span></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.1038%2F35077225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35077225%26sid%3Dliteratum%253Aachs%26aulast%3DBlume-Jensen%26aufirst%3DP.%26aulast%3DHunter%26aufirst%3DT.%26atitle%3DOncogenic%2520Kinase%2520Signalling%26jtitle%3DNature%26date%3D2001%26volume%3D411%26spage%3D355%26epage%3D365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henthorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, L.</span><span> </span><span class="NLM_article-title">Studies Leading to the Identification of ZD1839 (Iressa): An Orally Active, Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Targeted to the Treatment of Cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1016%2FS0960-894X%2801%2900344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=11459659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1911-1914&author=A.+J.+Barkerauthor=K.+H.+Gibsonauthor=W.+Grundyauthor=A.+A.+Godfreyauthor=J.+J.+Barlowauthor=M.+P.+Healyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=L.+Scarlettauthor=L.+Henthornauthor=L.+Richards&title=Studies+Leading+to+the+Identification+of+ZD1839+%28Iressa%29%3A+An+Orally+Active%2C+Selective+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitor+Targeted+to+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span></div><div class="casAuthors">Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1914</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compds.  ZD1839 has suitable properties for use as a clin. effective drug and shows activity against human tumors.  In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvsJ1FTqEwvbVg90H21EOLACvtfcHk0ljGLiQrFjES_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D&md5=ebb210453ade246e43de9fd07ae1d581</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900344-4%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26aulast%3DGrundy%26aufirst%3DW.%26aulast%3DGodfrey%26aufirst%3DA.%2BA.%26aulast%3DBarlow%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DScarlett%26aufirst%3DL.%26aulast%3DHenthorn%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DL.%26atitle%3DStudies%2520Leading%2520to%2520the%2520Identification%2520of%2520ZD1839%2520%2528Iressa%2529%253A%2520An%2520Orally%2520Active%252C%2520Selective%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitor%2520Targeted%2520to%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1911%26epage%3D1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacci, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiOrio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neveu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollack, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnik, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theleman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, P.</span><span> </span><span class="NLM_article-title">Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4838</span><span class="NLM_x">–</span> <span class="NLM_lpage">4848</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=9354447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADyaK2sXnt12nsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=4838-4848&author=J.+D.+Moyerauthor=E.+G.+Barbacciauthor=K.+K.+Iwataauthor=L.+Arnoldauthor=B.+Bomanauthor=A.+Cunninghamauthor=C.+DiOrioauthor=J.+Dotyauthor=M.+J.+Morinauthor=M.+P.+Moyerauthor=M.+Neveuauthor=V.+A.+Pollackauthor=L.+R.+Pustilnikauthor=M.+M.+Reynoldsauthor=D.+Sloanauthor=A.+Thelemanauthor=P.+Miller&title=Induction+of+Apoptosis+and+Cell+Cycle+Arrest+by+CP-358%2C774%2C+an+Inhibitor+of+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase</span></div><div class="casAuthors">Moyer, James D.; Barbacci, Elsa G.; Iwata, Kenneth K.; Arnold, Lee; Boman, Bruce; Cunningham, Ann; Diorio, Catherine; Doty, Jonathan; Morin, Michael J.; Moyer, Mikel P.; Neveu, Mark; Pollack, Vincent A.; Pustilnik, Leslie R.; Reynolds, Margaret M.; Sloan, Don; Theleman, April; Miller, Penny</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4838-4848</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of carcinomas and contributes to the malignant phenotype.  CP-358774 is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM and reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM.  This inhibition is selective for EGFR tyrosine kinase relative to other tyrosine kinases we have examd., both in assays of isolated kinases and whole cells.  At doses of 100 mg/kg, CP-358774 completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice.  CP-358774 inhibits the proliferation of DiFi human colon tumor cells at submicromolar concns. in cell culture and blocks cell cycle progression at the G1 phase.  This inhibitor produces a marked accumulation of retinoblastoma protein in its underphosphorylated form and accumulation of p27KIP1 in DiFi cells, which may contribute to the cell cycle block.  Inhibition of the EGFR also triggers apoptosis in these cells as detd. by formation of DNA fragments and other criteria.  These results indicate that CP-358774 has potential for the treatment of tumors that are dependent on the EGFR pathway for proliferation or survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpghArQOnGlkbVg90H21EOLACvtfcHk0ljGLiQrFjES_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt12nsr4%253D&md5=0a6e9697bf290d8e7c44cbe2a125e0b1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DBarbacci%26aufirst%3DE.%2BG.%26aulast%3DIwata%26aufirst%3DK.%2BK.%26aulast%3DArnold%26aufirst%3DL.%26aulast%3DBoman%26aufirst%3DB.%26aulast%3DCunningham%26aufirst%3DA.%26aulast%3DDiOrio%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%26aulast%3DMorin%26aufirst%3DM.%2BJ.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DNeveu%26aufirst%3DM.%26aulast%3DPollack%26aufirst%3DV.%2BA.%26aulast%3DPustilnik%26aufirst%3DL.%2BR.%26aulast%3DReynolds%26aufirst%3DM.%2BM.%26aulast%3DSloan%26aufirst%3DD.%26aulast%3DTheleman%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DP.%26atitle%3DInduction%2520of%2520Apoptosis%2520and%2520Cell%2520Cycle%2520Arrest%2520by%2520CP-358%252C774%252C%2520an%2520Inhibitor%2520of%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D4838%26epage%3D4848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Chan, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullick, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, M. E.</span><span> </span><span class="NLM_article-title">Mutations of the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer – Search and Destroy</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=17-23&author=S.+K.+Chanauthor=W.+J.+Gullickauthor=M.+E.+Hill&title=Mutations+of+the+Epidermal+Growth+Factor+Receptor+in+Non-Small+Cell+Lung+Cancer+%E2%80%93+Search+and+Destroy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DS.%2BK.%26aulast%3DGullick%26aufirst%3DW.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BE.%26atitle%3DMutations%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520%25E2%2580%2593%2520Search%2520and%2520Destroy%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2006%26volume%3D42%26spage%3D17%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.-H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+Lung+Cancer-Derived+EGFR+Mutants+and+Inhibitor+Complexes%3A+Mechanism+of+Activation+and+Insights+into+Differential+Inhibitor+Sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0ljGLiQrFjES_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520Lung%2520Cancer-Derived%2520EGFR%2520Mutants%2520and%2520Inhibitor%2520Complexes%253A%2520Mechanism%2520of%2520Activation%2520and%2520Insights%2520into%2520Differential%2520Inhibitor%2520Sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">235</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=225-235&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+Resistance+of+Lung+Adenocarcinomas+to+Gefitinib+or+Erlotinib+Is+Associated+with+a+Second+Mutation+in+the+EGFR+Kinase+Domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520Resistance%2520of%2520Lung%2520Adenocarcinomas%2520to%2520Gefitinib%2520or%2520Erlotinib%2520Is%2520Associated%2520with%2520a%2520Second%2520Mutation%2520in%2520the%2520EGFR%2520Kinase%2520Domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3D225%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib</span> <span class="citation_source-journal">New Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+J%C3%A4nneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+Mutation+and+Resistance+of+Non-Small-Cell+Lung+Cancer+to+Gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lgnuTYu8boKOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520Mutation%2520and%2520Resistance%2520of%2520Non-Small-Cell%2520Lung%2520Cancer%2520to%2520Gefitinib%26jtitle%3DNew%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer</span> <span class="citation_source-journal">Clin. Cancer. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2895</span><span class="NLM_x">–</span> <span class="NLM_lpage">2899</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1158%2F1078-0432.CCR-07-2248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=18483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A280%3ADC%252BD1czitVKjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=2895-2899&author=J.+A.+Engelmanauthor=P.+A.+J%C3%A4nne&title=Mechanisms+of+Acquired+Resistance+to+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitors+in+Non%E2%80%93Small+Cell+Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5dR"><div class="casContent"><span class="casTitleNuber">5d</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer</span></div><div class="casAuthors">Engelman Jeffrey A; Janne Pasi A</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2895-9</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective therapies for non-small cell lung cancer patients whose tumors harbor somatic mutations in EGFR.  All patients, however, ultimately develop resistance to these agents.  Thus, there is a great need to understand how patients become resistant to develop effective therapies for these cancers.  Studies over the last few years have identified two different EGFR tyrosine kinase inhibitor resistance mechanisms, a secondary mutation in EGFR, EGFR 790M, and amplification of the MET oncogene.  These findings have led to clinical trials using newly designed targeted therapies that can overcome these resistance mechanisms and have shown promise in laboratory studies.  Ongoing research efforts will likely continue to identify additional resistance mechanisms, and these findings will hopefully translate into effective therapies for non-small cell lung cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSwZmvJ4PNLtd-cVm4E2RlLfW6udTcc2ebINYTx5UrXxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czitVKjug%253D%253D&md5=a3ecf68a85a0ae413c451cf8f756a976</span></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-2248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-2248%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DMechanisms%2520of%2520Acquired%2520Resistance%2520to%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitors%2520in%2520Non%25E2%2580%2593Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer.%2520Res.%26date%3D2008%26volume%3D14%26spage%3D2895%26epage%3D2899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M Mutation in EGFR Kinase Causes Drug Resistance by Increasing the Affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+Mutation+in+EGFR+Kinase+Causes+Drug+Resistance+by+Increasing+the+Affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5eR"><div class="casContent"><span class="casTitleNuber">5e</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lgnuTYu8boKOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit5e&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520Mutation%2520in%2520EGFR%2520Kinase%2520Causes%2520Drug%2520Resistance%2520by%2520Increasing%2520the%2520Affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Slichenmyer, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">CI-1033, a Pan-erbB Tyrosine Kinase Inhibitor</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1016%2FS0093-7754%2801%2990285-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=11706399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1Wgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2001&pages=80-85&author=W.+J.+Slichenmyerauthor=W.+L.+Elliottauthor=D.+W.+Fry&title=CI-1033%2C+a+Pan-erbB+Tyrosine+Kinase+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">CI-1033, a pan-erbB tyrosine kinase inhibitor</span></div><div class="casAuthors">Slichenmyer, William J.; Elliott, William L.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5, Suppl. 16</span>),
    <span class="NLM_cas:pages">80-85</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  Overexpression of the erbB family of receptor tyrosine kinases has been implicated in a variety of tumors including breast, lung, prostate, and brain.  Most solid tumors express one or more of these receptors, which can often be related to tumor aggressiveness and poor patient prognosis.  CI-1033, a pan-erbB tyrosine kinase inhibitor, is a clin. promising agent that is active against all four members of the erbB receptor tyrosine kinase family.  In vitro studies of human cancer cell lines indicate that CI-1033 results in prompt, potent, and sustained inhibition of tyrosine kinase activity.  This inhibition is highly selective for erbBI (epidermal growth factor receptor), erbB2, erbB3, and erbB4 without inhibiting tyrosine kinase activity of receptors such as platelet-derived growth factor receptor, fibroblast growth factor receptor, and insulin receptor, even at high concns.  Treatment of athymic nude mice bearing xenografts of human A431 epidermoid carcinoma, H125 non-small cell lung carcinoma, and SF-767 glioblastoma results in highly significant suppression of tumor growth.  The major toxicity in animals is diarrhea, which is more severe at higher doses.  In animal models, all side effects are reversible on cessation of treatment.  Thus, CI-1033, which is currently undergoing phase I clin. trials, holds significant potential for use in a broad range of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWblWCZGMLQLVg90H21EOLACvtfcHk0lj-wfR6eg4_vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1Wgu7c%253D&md5=cc0507480a4182c3e52314750347b4c2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0093-7754%2801%2990285-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0093-7754%252801%252990285-4%26sid%3Dliteratum%253Aachs%26aulast%3DSlichenmyer%26aufirst%3DW.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DCI-1033%252C%2520a%2520Pan-erbB%2520Tyrosine%2520Kinase%2520Inhibitor%26jtitle%3DSemin.%2520Oncol.%26date%3D2001%26volume%3D28%26spage%3D80%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">3958</span><span class="NLM_x">–</span> <span class="NLM_lpage">3965</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1158%2F0008-5472.CAN-03-2868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=15173008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=3958-3965&author=S.+K.+Rabindranauthor=C.+M.+Discafaniauthor=E.+C.+Rosfjordauthor=M.+Baxterauthor=M.+B.+Floydauthor=J.+Golasauthor=W.+A.+Hallettauthor=B.+D.+Johnsonauthor=R.+Nilakantanauthor=E.+Overbeekauthor=M.+F.+Reichauthor=R.+Shenauthor=X.+Shiauthor=H.-R.+Tsouauthor=Y.-F.+Wangauthor=A.+Wissner&title=Antitumor+Activity+of+HKI-272%2C+an+Orally+Active%2C+Irreversible+Inhibitor+of+the+HER-2+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase</span></div><div class="casAuthors">Rabindran, Sridhar K.; Discafani, Carolyn M.; Rosfjord, Edward C.; Baxter, Michelle; Floyd, M. Brawner; Golas, Jonathan; Hallett, William A.; Johnson, Bernard D.; Nilakantan, Ramaswamy; Overbeek, Elsebe; Reich, Marvin F.; Shen, Ru; Shi, Xiaoqing; Tsou, Hwei-Ru; Wang, Yu-Fen; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3958-3965</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER-2 belongs to the ErbB family of receptor tyrosine kinases, which has been implicated in a variety of cancers.  Overexpression of HER-2 is seen in 25-30% of breast cancer patients and predicts a poor outcome in patients with primary disease.  Trastuzumab (Herceptin), a monoclonal antibody to HER-2, is specifically approved for HER-2-pos. breast cancer but is active only in a subset of these tumors.  Blocking HER-2 function by a small mol. kinase inhibitor, therefore, represents an attractive alternate strategy to inhibit the growth of HER-2-pos. tumors.  HKI-272 is a potent inhibitor of HER-2 and is highly active against HER-2-overexpressing human breast cancer cell lines in vitro.  It also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.  HKI-272 reduces HER-2 receptor autophosphorylation in cells at doses consistent with inhibition of cell proliferation and functions as an irreversible binding inhibitor, most likely by targeting a cysteine residue in the ATP-binding pocket of the receptor.  In agreement with the predicted effects of HER-2 inactivation, HKI-272 treatment of cells results in inhibition of downstream signal transduction events and cell cycle regulatory pathways.  This leads to arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle, ultimately resulting in decreased cell proliferation.  In vivo, HKI-272 is active in HER-2- and EGFR-dependent tumor xenograft models when dosed orally on a once daily schedule.  On the basis of its favorable preclin. pharmacol. profile, HKI-272 has been selected as a candidate for addnl. development as an antitumor agent in breast and other HER-2-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2xeLXlAwWvbVg90H21EOLACvtfcHk0lj-wfR6eg4_vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D&md5=60accd0599b7c489e4c3753d4f39cab4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-2868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-2868%26sid%3Dliteratum%253Aachs%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DBaxter%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DAntitumor%2520Activity%2520of%2520HKI-272%252C%2520an%2520Orally%2520Active%252C%2520Irreversible%2520Inhibitor%2520of%2520the%2520HER-2%2520Tyrosine%2520Kinase%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D3958%26epage%3D3965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations That Are Resistant to Gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">11924</span><span class="NLM_x">–</span> <span class="NLM_lpage">11932</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-11932&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=C.-M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.-K.+Wongauthor=P.+A.+J%C3%A4nne&title=PF00299804%2C+an+Irreversible+Pan-ERBB+Inhibitor%2C+Is+Effective+in+Lung+Cancer+Models+with+EGFR+and+ERBB2+Mutations+That+Are+Resistant+to+Gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DGale%26aufirst%3DC.-M.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPF00299804%252C%2520an%2520Irreversible%2520Pan-ERBB%2520Inhibitor%252C%2520Is%2520Effective%2520in%2520Lung%2520Cancer%2520Models%2520with%2520EGFR%2520and%2520ERBB2%2520Mutations%2520That%2520Are%2520Resistant%2520to%2520Gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11924%26epage%3D11932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Barf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span> </span><span class="NLM_article-title">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6243</span><span class="NLM_x">–</span> <span class="NLM_lpage">6262</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+Protein+Kinase+Inhibitors%3A+Balancing+the+Benefits+and+Risks"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0ljMom8bXudDdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520Protein%2520Kinase%2520Inhibitors%253A%2520Balancing%2520the%2520Benefits%2520and%2520Risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6243%26epage%3D6262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm360499.htm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm360499.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm360499.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacharchuk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freyman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ananthakrishnan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J.-C.</span><span> </span><span class="NLM_article-title">Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients with Advanced Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">3076</span><span class="NLM_x">–</span> <span class="NLM_lpage">3083</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1200%2FJCO.2009.27.9414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=20479403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=3076-3083&author=L.+V.+Sequistauthor=B.+Besseauthor=T.+J.+Lynchauthor=V.+A.+Millerauthor=K.+K.+Wongauthor=B.+Gitlitzauthor=K.+Eatonauthor=C.+Zacharchukauthor=A.+Freymanauthor=C.+Powellauthor=R.+Ananthakrishnanauthor=S.+Quinnauthor=J.-C.+Soria&title=Neratinib%2C+an+Irreversible+Pan-ErbB+Receptor+Tyrosine+Kinase+Inhibitor%3A+Results+of+a+Phase+II+Trial+in+Patients+with+Advanced+Non-Small-Cell+Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Neratinib, an irreversible Pan-ErbB, receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Sequist, Lecia V.; Besse, Benjamin; Lynch, Thomas J.; Miller, Vincent A.; Wong, Kwok K.; Gitlitz, Barbara; Eaton, Keith; Zacharchuk, Charles; Freyman, Amy; Powell, Christine; Ananthakrishnan, Revathi; Quinn, Susan; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3076-3083</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non-small-cell lung cancer (NSCLC) outcomes, particularly for patients with EGFR mutations.  Resistance emerges after 9 to 12 mo, primarily mediated by the T790M resistance mutation.  We studied neratinib, an irreversible pan-ErbB TKI that may overcome T790M.  Patients with advanced NSCLC underwent EGFR sequencing of available tumor tissue at enrollment.  Those with ≥ 12 wk of prior TKI therapy were placed in arm A if they were EGFR mutation pos. or arm B if they were wild-type.  Arm C included TKI-naive patients with adenocarcinoma and light smoking histories (≤ 20 pack-years).  All patients received daily oral neratinib, initially at 320 mg but subsequently reduced to 240 mg because of excessive diarrhea.  The primary end point was objective response rate (RR).  167 Patients were treated: 91 in arm A, 48 in arm B, and 28 in arm C.  Diarrhea was the most common toxicity; grade 3 incidence was 50% at 320 mg but improved to 25% after dose redn.  The RR was 3% in arm A and zero in arms B and C.  No patients with known T790M responded.  Notably, three of four patients with an exon 18 G719X EGFR mutation had a partial response and the fourth had stable disease lasting 40 wk.  Neratinib had low activity in patients with prior benefit from TKIs and in TKI-naive patients, potentially because of insufficient bioavailability from diarrhea-imposed dose limitation.  Responses were seen in patients with the rare G719X EGFR mutation, highlighting the importance of obtaining comprehensive genetic information on trials of targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Z3gsvbWbOrVg90H21EOLACvtfcHk0ljMom8bXudDdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D&md5=460e088e58919bbfcf8c153772f157b0</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.27.9414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.27.9414%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DGitlitz%26aufirst%3DB.%26aulast%3DEaton%26aufirst%3DK.%26aulast%3DZacharchuk%26aufirst%3DC.%26aulast%3DFreyman%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DC.%26aulast%3DAnanthakrishnan%26aufirst%3DR.%26aulast%3DQuinn%26aufirst%3DS.%26aulast%3DSoria%26aufirst%3DJ.-C.%26atitle%3DNeratinib%252C%2520an%2520Irreversible%2520Pan-ErbB%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitor%253A%2520Results%2520of%2520a%2520Phase%2520II%2520Trial%2520in%2520Patients%2520with%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D3076%26epage%3D3083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddigkeit, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">868</span><span class="NLM_x">–</span> <span class="NLM_lpage">874</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1158%2F0008-5472.CAN-09-3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=20103621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=868-874&author=M.+L.+Sosauthor=H.+B.+Rodeauthor=S.+Heynckauthor=M.+Peiferauthor=F.+Fischerauthor=S.+Kl%C3%BCterauthor=V.+G.+Pawarauthor=C.+Reuterauthor=J.+M.+Heuckmannauthor=J.+Weissauthor=L.+Ruddigkeitauthor=M.+Rabillerauthor=M.+Kokerauthor=J.+R.+Simardauthor=M.+Getlikauthor=Y.+Yuzaauthor=T.-H.+Chenauthor=H.+Greulichauthor=R.+K.+Thomasauthor=D.+Rauh&title=Chemogenomic+Profiling+Provides+Insights+into+the+Limited+Activity+of+Irreversible+EGFR+Inhibitors+in+Tumor+Cells+Expressing+the+T790M+EGFR+Resistance+Mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span></div><div class="casAuthors">Sos, Martin L.; Rode, Haridas B.; Heynck, Stefanie; Peifer, Martin; Fischer, Florian; Klueter, Sabine; Pawar, Vijaykumar G.; Reuter, Cecile; Heuckmann, Johannes M.; Weiss, Jonathan; Ruddigkeit, Lars; Rabiller, Matthias; Koker, Mirjam; Simard, Jeffrey R.; Getlik, Matthaeus; Yuza, Yuki; Chen, Tzu-Hsiu; Greulich, Heidi; Thomas, Roman K.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">868-874</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small mols. to improve progression-free survival of patients with EGFR-mutated lung cancers.  Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clin. activity in patients with T790M-mutant tumors.  In this study, we systematically analyzed the determinants of the activity and selectivity of the second-generation EGFR inhibitors.  A focused library of irreversible as well as structurally corresponding reversible EGFR-inhibitors was synthesized for chemogenomic profiling involving over 79 genetically defined NSCLC and 19 EGFR-dependent cell lines.  Overall, our results show that the growth-inhibitory potency of all irreversible inhibitors against the EGFRT790M resistance mutation was limited by reduced target inhibition, linked to decreased binding velocity to the mutant kinase.  Combined treatment of T790M-mutant tumor cells with BIBW-2992 and the phosphoinositide-3-kinase/mammalian target of rapamycin inhibitor PI-103 led to synergistic induction of apoptosis.  Our findings offer a mechanistic explanation for the limited efficacy of irreversible EGFR inhibitors in EGFRT790M gatekeeper-mutant tumors, and they prompt combination treatment strategies involving inhibitors that target signaling downstream of the EGFR.  Cancer Res; 70(3); 868-74.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjzYq32JnJ7Vg90H21EOLACvtfcHk0ljMom8bXudDdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D&md5=db40fb75245450e8f79fca7e37bad588</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3106%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DPawar%26aufirst%3DV.%2BG.%26aulast%3DReuter%26aufirst%3DC.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DRuddigkeit%26aufirst%3DL.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.-H.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DChemogenomic%2520Profiling%2520Provides%2520Insights%2520into%2520the%2520Limited%2520Activity%2520of%2520Irreversible%2520EGFR%2520Inhibitors%2520in%2520Tumor%2520Cells%2520Expressing%2520the%2520T790M%2520EGFR%2520Resistance%2520Mutation%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D868%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulkus, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheswaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">The T790M “Gatekeeper” Mutation in EGFR Mediates Resistance to Low Concentrations of an Irreversible EGFR Inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">874</span><span class="NLM_x">–</span> <span class="NLM_lpage">879</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1158%2F1535-7163.MCT-07-2387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=18413800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1GmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=874-879&author=N.+Godin-Heymannauthor=L.+Ulkusauthor=B.+W.+Branniganauthor=U.+McDermottauthor=J.+Lambauthor=S.+Maheswaranauthor=J.+Settlemanauthor=D.+A.+Haber&title=The+T790M+%E2%80%9CGatekeeper%E2%80%9D+Mutation+in+EGFR+Mediates+Resistance+to+Low+Concentrations+of+an+Irreversible+EGFR+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor</span></div><div class="casAuthors">Godin-Heymann, Nadia; Ulkus, Lindsey; Brannigan, Brian W.; McDermott, Ultan; Lamb, Jennifer; Maheswaran, Shyamala; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">874-879</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal growth factor receptor (EGFR) kinase domain tend to respond well to the tyrosine kinase inhibitors, gefitinib and erlotinib.  However, following clin. response, these patients typically relapse within a year of treatment.  In many cases, resistance is caused by an acquired secondary EGFR kinase domain mutation, T790M.  In vitro studies have shown that a new class of EGFR-irreversible inhibitors could overcome the resistance conferred by T790M.  Clin. trials are under way to examine the efficacy of one of these inhibitors, HKI-272, in patients with NSCLC who initially responded to gefitinib/erlotinib and subsequently relapsed.  To anticipate the possibility that patients who respond to irreversible inhibitors will develop secondary resistance to such inhibitors, as has been seen in other similar settings, we modeled acquired resistance to the dual EGFR/HER2-irreversible tyrosine kinase inhibitor HKI-272 in a NSCLC cell culture model.  We found that HKI-272-resistant clones fall into two biochem. groups based on the retention of EGFR phosphorylation in the presence of the drug.  Cells that retain phosphorylated EGFR have acquired the secondary mutation T790M.  Moreover, HKI-272 can overcome T790M resistance only at suprapharmacol. concns.  We further model mutations at EGFR C797 as a mechanism of resistance to irreversible EGFR inhibitors and show that although these mutants are resistant to the irreversible inhibitor, they retain erlotinib sensitivity.  Our findings suggest that HKI-272 treatment at maximally tolerated dosing may lead to the emergence of T790M-mediated resistance, whereas treatment with a more potent irreversible inhibitor could yield a resistance mutation at EGFR C797.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra5FtRNHnlNLVg90H21EOLACvtfcHk0lh_ffWcEqpRYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1GmsLo%253D&md5=f71cd83bfabef2d7b2c5d8b6e5cfac6a</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2387%26sid%3Dliteratum%253Aachs%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DUlkus%26aufirst%3DL.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DThe%2520T790M%2520%25E2%2580%259CGatekeeper%25E2%2580%259D%2520Mutation%2520in%2520EGFR%2520Mediates%2520Resistance%2520to%2520Low%2520Concentrations%2520of%2520an%2520Irreversible%2520EGFR%2520Inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D874%26epage%3D879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel Mutant-Selective EGFR Kinase Inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">4</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-4&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+Mutant-Selective+EGFR+Kinase+Inhibitors+against+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lh_ffWcEqpRYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520Mutant-Selective%2520EGFR%2520Kinase%2520Inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of Selective Irreversible Inhibitors for EGFR-T790M</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">638</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1016%2Fj.bmcl.2010.12.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=21208802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=638-643&author=W.+Zhouauthor=D.+Ercanauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Discovery+of+Selective+Irreversible+Inhibitors+for+EGFR-T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for EGFR-T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">638-643</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer.  A series of novel covalent EGFR kinase inhibitors with selectivity for the clin. relevant T790M gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening.  A representative compd. 3i (I) was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB2Qq3f78-wLVg90H21EOLACvtfcHk0lh_ffWcEqpRYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D&md5=c19f3f288ab99aaaab0a23bcf5273daf</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520Selective%2520Irreversible%2520Inhibitors%2520for%2520EGFR-T790M%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D638%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tjin Tham Sjin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T.,  St</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kalken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-mediated Resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=A.+O.+Walterauthor=R.+Tjin+Tham+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+Mutant-Selective+Covalent+Inhibitor+of+EGFR+That+Overcomes+T790M-mediated+Resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DTjin%2BTham%2BSjin%26aufirst%3DR.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520Mutant-Selective%2520Covalent%2520Inhibitor%2520of%2520EGFR%2520That%2520Overcomes%2520T790M-mediated%2520Resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span>Clinical Trials. <a href="http://clinicaltrials.gov/" class="extLink">http://clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+Trials.+http%3A%2F%2Fclinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine<sup>790</sup> → Methionine<sup>790</sup> Mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2711</span><span class="NLM_x">–</span> <span class="NLM_lpage">2723</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Novel+Conformationally+Constrained+Inhibitors+Targeting+Epidermal+Growth+Factor+Receptor+Threonine790+%E2%86%92+Methionine790+Mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Novel%2520Conformationally%2520Constrained%2520Inhibitors%2520Targeting%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Threonine790%2520%25E2%2586%2592%2520Methionine790%2520Mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2711%26epage%3D2723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of New Molecules Inhibiting Epidermal Growth Factor Receptor Threonine<sup>790</sup> → Methionine<sup>790</sup> Mutant</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1155</span><span class="NLM_x">–</span> <span class="NLM_lpage">1159</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1155-1159&author=S.+Xuauthor=L.+Zhangauthor=S.+Changauthor=J.+Luoauthor=X.+Luauthor=Z.+Tuauthor=Y.+Liuauthor=Z.+zhangauthor=Y.+Xuauthor=X.+Renauthor=K.+Ding&title=Design%2C+Synthesis+and+Biological+Evaluation+of+New+Molecules+Inhibiting+Epidermal+Growth+Factor+Receptor+Threonine790+%E2%86%92+Methionine790+Mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3Dzhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520New%2520Molecules%2520Inhibiting%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Threonine790%2520%25E2%2586%2592%2520Methionine790%2520Mutant%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D1155%26epage%3D1159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Pyrimido[4,5-<i>d</i>]pyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine<sup>790</sup> to Methionine<sup>790</sup> (T790M) Mutants</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">8387</span><span class="NLM_x">–</span> <span class="NLM_lpage">8390</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=8387-8390&author=T.+Xuauthor=L.+Zhangauthor=S.+Xuauthor=C.-Y.+Yangauthor=J.+Luoauthor=F.+Dingauthor=X.+Luauthor=Y.+Liuauthor=Z.+Tuauthor=S.+Liauthor=D.+Peiauthor=Q.+Caiauthor=H.+Liauthor=X.+Renauthor=S.+Wangauthor=K.+Ding&title=Pyrimido%5B4%2C5-d%5Dpyrimidin-4%281H%29-one+Derivatives+as+Selective+Inhibitors+of+EGFR+Threonine790+to+Methionine790+%28T790M%29+Mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DPyrimido%255B4%252C5-d%255Dpyrimidin-4%25281H%2529-one%2520Derivatives%2520as%2520Selective%2520Inhibitors%2520of%2520EGFR%2520Threonine790%2520to%2520Methionine790%2520%2528T790M%2529%2520Mutants%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D8387%26epage%3D8390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ishikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, Y.</span><span> </span><span class="NLM_article-title">Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1539</span><span class="NLM_x">–</span> <span class="NLM_lpage">1554</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101356p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1539-1554&author=M.+Ishikawaauthor=Y.+Hashimoto&title=Improvement+in+Aqueous+Solubility+in+Small+Molecule+Drug+Discovery+Programs+by+Disruption+of+Molecular+Planarity+and+Symmetry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry</span></div><div class="casAuthors">Ishikawa, Minoru; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1539-1554</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKbtbfvqKZjrVg90H21EOLACvtfcHk0lgTeSpS_eH0pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D&md5=a88804b3850625ef9c3f7424366acb91</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1021%2Fjm101356p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101356p%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DImprovement%2520in%2520Aqueous%2520Solubility%2520in%2520Small%2520Molecule%2520Drug%2520Discovery%2520Programs%2520by%2520Disruption%2520of%2520Molecular%2520Planarity%2520and%2520Symmetry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1539%26epage%3D1554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kerns, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span> </span><span class="NLM_article-title">Pharmaceutical Profiling in Drug Discovery</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">323</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1016%2FS1359-6446%2803%2902649-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=12654544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1Kls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=316-323&author=E.+H.+Kernsauthor=L.+Di&title=Pharmaceutical+Profiling+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmaceutical profiling in drug discovery</span></div><div class="casAuthors">Kerns, Edward H.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">316-323</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug discovery research organizations are building capability for measuring an ensemble of crucial drug-like' properties.  These structure-property relationship (SPR) data complement current SAR information.  This pharmaceutical profiling strategy enables research teams to better plan and interpret discovery expts., be alerted to potential 'show stoppers', improve property liabilities, and select the best candidates for advancement.  High throughput property assays for physicochem. properties - soly., permeability, lipophilicity, stability, and pKa - in vitro ADME - metab., transporters, protein binding and CYP inhibition - and in vivo PK/exposure provide a wealth of data for teams to make informed decisions.  The measurement of crucial 'druglike' properties involves correlating SAR and SPR data and enables research teams to better plan and interpret drug discovery expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbKmN9rLPo3bVg90H21EOLACvtfcHk0li_5Hg4Q40Uig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1Kls7g%253D&md5=4260212023cf21edd518ae9ceea601b0</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2803%2902649-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252803%252902649-7%26sid%3Dliteratum%253Aachs%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DPharmaceutical%2520Profiling%2520in%2520Drug%2520Discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2003%26volume%3D8%26spage%3D316%26epage%3D323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Vignaroli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamperini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreassi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelucci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanita, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crespan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kissova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maga, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schenone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musumeci, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, M.</span><span> </span><span class="NLM_article-title">Pyrazolo[3,4-<i>d</i>]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">622</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml4000782" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=622-626&author=G.+Vignaroliauthor=C.+Zamperiniauthor=E.+Dreassiauthor=M.+Radiauthor=A.+Angelucciauthor=P.+Sanitaauthor=E.+Crespanauthor=M.+Kissovaauthor=G.+Magaauthor=S.+Schenoneauthor=F.+Musumeciauthor=M.+Botta&title=Pyrazolo%5B3%2C4-d%5Dpyrimidine+Prodrugs%3A+Strategic+Optimization+of+the+Aqueous+Solubility+of+Dual+Src%2FAbl+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1021%2Fml4000782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4000782%26sid%3Dliteratum%253Aachs%26aulast%3DVignaroli%26aufirst%3DG.%26aulast%3DZamperini%26aufirst%3DC.%26aulast%3DDreassi%26aufirst%3DE.%26aulast%3DRadi%26aufirst%3DM.%26aulast%3DAngelucci%26aufirst%3DA.%26aulast%3DSanita%26aufirst%3DP.%26aulast%3DCrespan%26aufirst%3DE.%26aulast%3DKissova%26aufirst%3DM.%26aulast%3DMaga%26aufirst%3DG.%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DPyrazolo%255B3%252C4-d%255Dpyrimidine%2520Prodrugs%253A%2520Strategic%2520Optimization%2520of%2520the%2520Aqueous%2520Solubility%2520of%2520Dual%2520Src%252FAbl%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D622%26epage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Press, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fullerton, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tranter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denholm, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haberthuer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatto, J. D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keenan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercer, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oakman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahri, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuffnell, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tweed, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyler, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fozard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trifilieff, A.</span><span> </span><span class="NLM_article-title">Solubility-Driven Optimization of Phosphodiesterase-4 Inhibitors Leading to a Clinical Candidate</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7472</span><span class="NLM_x">–</span> <span class="NLM_lpage">7479</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300459a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOrurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7472-7479&author=N.+J.+Pressauthor=R.+J.+Taylorauthor=J.+D.+Fullertonauthor=P.+Tranterauthor=C.+McCarthyauthor=T.+H.+Kellerauthor=N.+Arnoldauthor=D.+Beerauthor=L.+Brownauthor=R.+Cheungauthor=J.+Christieauthor=A.+Denholmauthor=S.+Haberthuerauthor=J.+D.+I.+Hattoauthor=M.+Keenanauthor=M.+K.+Mercerauthor=H.+Oakmanauthor=H.+Sahriauthor=A.+R.+Tuffnellauthor=M.+Tweedauthor=J.+W.+Tylerauthor=T.+Wagnerauthor=J.+R.+Fozardauthor=A.+Trifilieff&title=Solubility-Driven+Optimization+of+Phosphodiesterase-4+Inhibitors+Leading+to+a+Clinical+Candidate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Solubility-Driven Optimization of Phosphodiesterase-4 Inhibitors Leading to a Clinical Candidate</span></div><div class="casAuthors">Press, Neil J.; Taylor, Roger J.; Fullerton, Joseph D.; Tranter, Pamela; McCarthy, Clive; Keller, Thomas H.; Arnold, Nicola; Beer, David; Brown, Lyndon; Cheung, Robert; Christie, Julie; Denholm, Alastair; Haberthuer, Sandra; Hatto, Julia D. I.; Keenan, Mark; Mercer, Mark K.; Oakman, Helen; Sahri, Helene; Tuffnell, Andrew R.; Tweed, Morris; Tyler, John W.; Wagner, Trixie; Fozard, John R.; Trifilieff, Alexandre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7472-7479</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The soly.-driven optimization of a series of 1,7-naphthyridine phosphodiesterase-4 inhibitors is described.  Directed structural changes resulted in increased aq. soly., enabling superior pharmacokinetic properties with retention of PDE4 inhibition.  A range of potent and orally bioavailable compds. with good in vivo efficacy in animal models of inflammation and reduced emetic potential compared to previously described drugs were synthesized.  Compd. 2d (I) was taken forward as a clin. candidate for the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL0BzBNQVqnrVg90H21EOLACvtfcHk0li_5Hg4Q40Uig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOrurnO&md5=deee9ca074de0b531a130d9a6ce530b2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm300459a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300459a%26sid%3Dliteratum%253Aachs%26aulast%3DPress%26aufirst%3DN.%2BJ.%26aulast%3DTaylor%26aufirst%3DR.%2BJ.%26aulast%3DFullerton%26aufirst%3DJ.%2BD.%26aulast%3DTranter%26aufirst%3DP.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DArnold%26aufirst%3DN.%26aulast%3DBeer%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DL.%26aulast%3DCheung%26aufirst%3DR.%26aulast%3DChristie%26aufirst%3DJ.%26aulast%3DDenholm%26aufirst%3DA.%26aulast%3DHaberthuer%26aufirst%3DS.%26aulast%3DHatto%26aufirst%3DJ.%2BD.%2BI.%26aulast%3DKeenan%26aufirst%3DM.%26aulast%3DMercer%26aufirst%3DM.%2BK.%26aulast%3DOakman%26aufirst%3DH.%26aulast%3DSahri%26aufirst%3DH.%26aulast%3DTuffnell%26aufirst%3DA.%2BR.%26aulast%3DTweed%26aufirst%3DM.%26aulast%3DTyler%26aufirst%3DJ.%2BW.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DFozard%26aufirst%3DJ.%2BR.%26aulast%3DTrifilieff%26aufirst%3DA.%26atitle%3DSolubility-Driven%2520Optimization%2520of%2520Phosphodiesterase-4%2520Inhibitors%2520Leading%2520to%2520a%2520Clinical%2520Candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7472%26epage%3D7479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Wells-Knecht, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesaros, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yazdanian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeigler, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">2,7-Disubstituted-Pyrrolotriazine Kinase Inhibitors with an Unusually High Degree of Reactive Metabolite Formation</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1994</span><span class="NLM_x">–</span> <span class="NLM_lpage">2003</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx200304r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1994-2003&author=K.+J.+Wells-Knechtauthor=G.+R.+Ottauthor=M.+Chengauthor=G.+J.+Wellsauthor=H.+J.+Breslinauthor=D.+E.+Gingrichauthor=L.+Weinbergauthor=E.+F.+Mesarosauthor=Z.+Huangauthor=M.+Yazdanianauthor=M.+A.+Atorauthor=L.+D.+Aimoneauthor=K.+Zeiglerauthor=B.+D.+Dorsey&title=2%2C7-Disubstituted-Pyrrolotriazine+Kinase+Inhibitors+with+an+Unusually+High+Degree+of+Reactive+Metabolite+Formation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Ftx200304r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200304r%26sid%3Dliteratum%253Aachs%26aulast%3DWells-Knecht%26aufirst%3DK.%2BJ.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DWells%26aufirst%3DG.%2BJ.%26aulast%3DBreslin%26aufirst%3DH.%2BJ.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DWeinberg%26aufirst%3DL.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DYazdanian%26aufirst%3DM.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DZeigler%26aufirst%3DK.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3D2%252C7-Disubstituted-Pyrrolotriazine%2520Kinase%2520Inhibitors%2520with%2520an%2520Unusually%2520High%2520Degree%2520of%2520Reactive%2520Metabolite%2520Formation%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1994%26epage%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mesaros, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thieu, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zificsak, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diebold, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wohler, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells-Knecht, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Strategies to Mitigate the Bioactivation of 2-Anilino-7-arylpyrrolo[2,1-<i>f</i>][1,2,4]triazines: Identification of Orally Bioavailable, Efficacious ALK Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=115-125&author=E.+F.+Mesarosauthor=T.+V.+Thieuauthor=G.+J.+Wellsauthor=C.+A.+Zificsakauthor=J.+C.+Wagnerauthor=H.+J.+Breslinauthor=R.+Tripathyauthor=J.+L.+Dieboldauthor=R.+J.+McHughauthor=A.+T.+Wohlerauthor=M.+R.+Quailauthor=W.+Wanauthor=L.+Luauthor=Z.+Huangauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=K.+J.+Wells-Knechtauthor=L.+D.+Aimoneauthor=M.+Chengauthor=M.+A.+Atorauthor=G.+R.+Ottauthor=B.+D.+Dorsey&title=Strategies+to+Mitigate+the+Bioactivation+of+2-Anilino-7-arylpyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazines%3A+Identification+of+Orally+Bioavailable%2C+Efficacious+ALK+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DThieu%26aufirst%3DT.%2BV.%26aulast%3DWells%26aufirst%3DG.%2BJ.%26aulast%3DZificsak%26aufirst%3DC.%2BA.%26aulast%3DWagner%26aufirst%3DJ.%2BC.%26aulast%3DBreslin%26aufirst%3DH.%2BJ.%26aulast%3DTripathy%26aufirst%3DR.%26aulast%3DDiebold%26aufirst%3DJ.%2BL.%26aulast%3DMcHugh%26aufirst%3DR.%2BJ.%26aulast%3DWohler%26aufirst%3DA.%2BT.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DWells-Knecht%26aufirst%3DK.%2BJ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DStrategies%2520to%2520Mitigate%2520the%2520Bioactivation%2520of%25202-Anilino-7-arylpyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazines%253A%2520Identification%2520of%2520Orally%2520Bioavailable%252C%2520Efficacious%2520ALK%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D55%26spage%3D115%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Huang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutta, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rinker, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donatelli, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurkow, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span> </span><span class="NLM_article-title">Pyrido[2,3-<i>d</i>]pyrimidin-5-ones: A Novel Class of Antiinflammatory Macrophage Colony-Stimulating Factor-1 Receptor Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1081</span><span class="NLM_x">–</span> <span class="NLM_lpage">1099</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801406h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1081-1099&author=H.+Huangauthor=D.+A.+Huttaauthor=J.+M.+Rinkerauthor=H.+Huauthor=W.+H.+Parsonsauthor=C.+Schubertauthor=R.+L.+DesJarlaisauthor=C.+S.+Cryslerauthor=M.+A.+Chaikinauthor=R.+R.+Donatelliauthor=Y.+Chenauthor=D.+Chengauthor=Z.+Zhouauthor=E.+Yurkowauthor=C.+L.+Mantheyauthor=M.+R.+Player&title=Pyrido%5B2%2C3-d%5Dpyrimidin-5-ones%3A+A+Novel+Class+of+Antiinflammatory+Macrophage+Colony-Stimulating+Factor-1+Receptor+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1021%2Fjm801406h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801406h%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHutta%26aufirst%3DD.%2BA.%26aulast%3DRinker%26aufirst%3DJ.%2BM.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DParsons%26aufirst%3DW.%2BH.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DCrysler%26aufirst%3DC.%2BS.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DDonatelli%26aufirst%3DR.%2BR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DYurkow%26aufirst%3DE.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26atitle%3DPyrido%255B2%252C3-d%255Dpyrimidin-5-ones%253A%2520A%2520Novel%2520Class%2520of%2520Antiinflammatory%2520Macrophage%2520Colony-Stimulating%2520Factor-1%2520Receptor%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1081%26epage%3D1099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hagmann, W. K.</span><span> </span><span class="NLM_article-title">The Many Roles for Fluorine in Medicinal Chemistry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4359</span><span class="NLM_x">–</span> <span class="NLM_lpage">4369</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800219f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1WjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4359-4369&author=W.+K.+Hagmann&title=The+Many+Roles+for+Fluorine+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">The Many Roles for Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Hagmann, William K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4359-4369</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkZV7sio8RhbVg90H21EOLACvtfcHk0lgvn-W_81T6CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1WjtLo%253D&md5=821f8076bb0f632f687b1c90b05dd382</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1021%2Fjm800219f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800219f%26sid%3Dliteratum%253Aachs%26aulast%3DHagmann%26aufirst%3DW.%2BK.%26atitle%3DThe%2520Many%2520Roles%2520for%2520Fluorine%2520in%2520Medicinal%2520Chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4359%26epage%3D4369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2529</span><span class="NLM_x">–</span> <span class="NLM_lpage">2591</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+Some+Recent+Tactical+Application+of+Bioisosteres+in+Drug+Design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0lgvn-W_81T6CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520Some%2520Recent%2520Tactical%2520Application%2520of%2520Bioisosteres%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Jares-Erijman, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jovin, T. M.</span><span> </span><span class="NLM_article-title">FRET Imaging</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1387</span><span class="NLM_x">–</span> <span class="NLM_lpage">1395</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm4012388&amp;key=10.1038%2Fnbt896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm4012388&amp;key=14595367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm4012388&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosFOksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=1387-1395&author=E.+A.+Jares-Erijmanauthor=T.+M.+Jovin&title=FRET+Imaging"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">FRET imaging</span></div><div class="casAuthors">Jares-Erijman, Elizabeth A.; Jovin, Thomas M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1387-1395</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Foerster (or Fluorescence) Resonance Energy Transfer (FRET) is unique in generating fluorescence signals sensitive to mol. conformation, assocn., and sepn. in the 1-10 nm range.  We introduce a revised photophys. framework for the phenomenon and provide a systematic catalog of FRET techniques adapted to imaging systems, including new approaches proposed as suitable prospects for implementation.  Applications extending from a single mol. to live cells will benefit from multidimensional microscopy techniques, particularly those adapted for optical sectioning and incorporating new algorithms for resolving the component contributions to images of complex mol. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTN4i2irXbCLVg90H21EOLACvtfcHk0liex5cyh_IU1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosFOksbo%253D&md5=01814592b10786fdb8f660c4a23dfa78</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnbt896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt896%26sid%3Dliteratum%253Aachs%26aulast%3DJares-Erijman%26aufirst%3DE.%2BA.%26aulast%3DJovin%26aufirst%3DT.%2BM.%26atitle%3DFRET%2520Imaging%26jtitle%3DNat.%2520Biotechnol.%26date%3D2003%26volume%3D21%26spage%3D1387%26epage%3D1395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i47"><a href="/doi/suppl/10.1021/jm4012388">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_60230"></div></div></div></div></div><hr /></hr><p class="last"><sup>1</sup>H NMR, <sup>13</sup>C NMR, and purity determination for compounds <b>2a</b>–<b>v</b>, and biological assay details and results. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm4012388/suppl_file/jm4012388_si_001.pdf">jm4012388_si_001.pdf (14.13 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm4012388&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Fjm4012388%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-21%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm4012388" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a69d21909d1c3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
